1. Diseases
1.1. Disease across categories
1.1.1. Type 1 diabetes and autoimmune thyroid diseases
1.1.2. Obesity and osteoporosis
1.1.3. Coarse facial features, scoliosis, pectus excavatum, skin laxity, hypotonia, GERD, hyperactive airways, undescended testes
1.1.4. Colobomas, heart defects, ichthyosiform dermatosis, mental retardation & ear anomalies
1.1.5. Craniofacial and anterior segment developmental abnormalities
1.1.6. Developmental delay, epilepsy & brain abnormalities
1.1.7. Developmental delay, failure to thrive, infantile spasms & cardiac features
1.1.8. Diabetic eye and kidney complications, association with
1.1.9. DNA damage in coke oven workers, association with
1.1.10. Dyslipidaemia and insulin resistance, association
1.1.11. Heart defects with mtDNA depletion
1.1.12. Hyperphagia and obesity, early onset
1.1.13. Inflammatory diseases, association with
1.1.14. Lipid and glucose homeostasis, blood pressure and coronary artery disease, pleiotropic effects
1.1.15. Meier-Gorlin syndrome & craniosynostosis
1.1.16. Multiorgan involvement (liver, kidney, hemopoethic system), skeletal dysplasia, growth failure, and complex I deficiency
1.1.17. Polycythaemia with paraganglioma
1.1.18. Respiratory/pancreatic disease, association with
1.1.19. Systemic inflamation, association with
1.1.20. Systemic sclerosis with autoimmune thyroiditis
1.1.21. Systemic sclerosis with end-stage lung disease, assoc with
1.1.22. T cell deficiency, CD4 lymphopaenia, and interstitial lung disease
1.2. Disease by infectious agent
1.2.1. AIDS & pneumocystis pneumonia, association with
1.2.2. Bacteraemia, malaria, and tuberculosis, susceptibility to, association with
1.2.3. Bacterial infectious disease
1.2.3.1. Anthrax
1.2.3.1.1. Anthrax toxin sensitivity, association with
1.2.3.2. Bacterial infection, association with
1.2.3.3. BCG infection
1.2.3.4. Borrelia seropositivity, association with
1.2.3.5. Commensal bacterial infectious disease
1.2.3.5.1. Sepsis
1.2.3.5.1.1. Sepsis and multiple organ dysfunction in major trauma, association with
1.2.3.5.1.2. Sepsis, severe, association with
1.2.3.5.1.3. Septic shock, modifier of
1.2.3.5.1.4. Severe sepsis, susceptibility to
1.2.3.5.2. Trachoma
1.2.3.5.2.1. Trachomatous trichiasis infection, association with
1.2.3.6. Enterobacteriacea bacteremia severity, association with
1.2.3.7. Gram-positive infection, increased risk
1.2.3.8. Helicobacter pylori infection, association with
1.2.3.9. Primary bacterial infectious disease
1.2.3.9.1. Legionellosis
1.2.3.9.1.1. Legionnaires disease, association with
1.2.3.9.2. Leprosy
1.2.3.9.2.1. Leprosy, altered susceptibility to
1.2.3.9.2.2. Leprosy, association with
1.2.3.9.2.3. Leprosy, susceptibility to, association with
1.2.3.9.2.4. Tuberculoid leprosy, association with
1.2.3.9.3. Pulmonary nontuberculosis mycobacterial infection, susceptibility to
1.2.3.9.4. Tuberculosis
1.2.3.9.4.1. Meningeal tuberculosis, susceptibility, association with
1.2.3.9.4.2. Pulmonary tuberculosis, association  with
1.2.3.9.4.3. Pulmonary tuberculosis, association with
1.2.3.9.4.4. Pulmonary tuberculosis, increased risk, association with
1.2.3.9.4.5. Tuberculosis, association with
1.2.3.9.4.6. Tuberculosis, susceptibility to
1.2.3.9.4.7. Tuberculosis, susceptibility to, association with
1.2.3.9.4.8. Tuberculosis, young-onset, association with
1.2.3.10. Pseudomonas aeruginosa infection in cystic fibrosis, increased risk
1.2.3.11. Staphylococcus aureus infection
1.2.3.12. Yesternosis
1.2.3.12.1. Chronic yersiniosis susceptibility
1.2.4. Fungal infectious diseases
1.2.4.1. Systemic mycosis
1.2.4.1.1. Opportunistic mycosis
1.2.4.1.1.1. Aspergillosis
1.2.4.1.1.1.1. Aspergillosis in stem cell transplant recipients, association with
1.2.4.1.1.1.2. Invasive aspergillosis, susceptibility
1.2.4.1.1.2. Candidiasis
1.2.4.1.1.2.1. Candida colonisation in hematopoietic stem cell transplantees
1.2.5. Parasitic infectious disease
1.2.5.1. Parasitic helminthiasis infectious disease
1.2.5.1.1. Schistosomiasis
1.2.5.1.1.1. Schistosomiasis infection, association with
1.2.5.2. Parasitic protozoa infectious disease
1.2.5.2.1. Malaria
1.2.5.2.1.1. Cerebral malaria, association with
1.2.5.2.1.2. Malaria, association with
1.2.5.2.1.3. Malaria, severe, association with
1.2.5.2.1.4. Malaria, severity, association with
1.2.5.2.1.5. Malaria, susceptibility, association with
1.2.5.2.1.6. Mild malaria, increased risk, association with
1.2.5.2.1.7. Severe malaria, increased risk
1.2.5.2.1.8. Severe malaria, increased risk, association with
1.2.5.2.2. Leishmaniasis visceral
1.2.5.2.3. Trypanosomiasis
1.2.5.2.3.1. Chagas disease
1.2.5.2.3.1.1. Chronic Chagas cardiomyopathy, increased risk
1.2.6. Viral infectious disease
1.2.6.1. Herpes simplex
1.2.6.1.1. Genital HSV-2 infection, association with
1.2.6.1.2. Herpes simplex encephalitis
1.2.6.1.3. Herpes simplex labialis, frequency, association with
1.2.6.2. Hepatitis
1.2.6.2.1. Hepatitis B
1.2.6.2.2. Hepatitis B viral clearance
1.2.6.2.3. Chronic hepatitis B infection
1.2.6.2.4. Chronic hepatitis C infection
1.2.6.2.5. Hepatitis B infection outcome, association with
1.2.6.2.6. Hepatitis B persistence, association with
1.2.6.2.7. Hepatitis B, chronic, association with
1.2.6.2.8. Hepatitis C clearance, association with
1.2.6.2.9. Susceptibility to disease progression in male HBV
1.2.6.3. H1N1 influenza A virus infection, 2009 pandemic, increased severity, association with
1.2.6.4. Human immunodeficiency virus infectious disease
1.2.6.4.1. AIDS
1.2.6.4.1.1. Delayed onset of AIDS, association with
1.2.6.4.2. AIDS progression
1.2.6.4.2.1. AIDS, progression, association with
1.2.6.4.3. HIV-1 control
1.2.6.4.4. HIV-1 progression
1.2.6.4.5. HIV-1 susceptibility
1.2.6.4.6. HIV-1 viral setpoint
1.2.6.4.7. HIV 1, delayed disease progression, association
1.2.6.4.8. HIV 1, rapid disease progression, association
1.2.6.4.9. HIV 1, susceptibility to, association with
1.2.6.4.10. HIV infection, susceptibility to, association
1.2.6.4.11. HIV progression to AIDS, association with
1.2.6.4.12. HIV-1 infection, association with
1.2.6.4.13. HIV-1 replication in monocyte-derived macrophages, association with
1.2.6.4.14. HIV-1 suscept, association with
1.2.6.4.15. HIV-1, mother-to-child-transmission, association with
1.2.6.4.16. Intrauterine HIV-1 infection, increased risk
1.2.6.4.17. Progression to AIDS, association with
1.2.6.5. Influenza, severe, increased risk
1.2.6.6. Panencephalitis, sclerosing, association with
1.2.6.7. Poliomyelitis
1.2.6.7.1. Paralytic poliomyelitis, association with
1.2.6.8. Severe RSV infection, association with
1.2.6.9. Subacute sclerosing panencephalitis, incr suscept, association
1.2.6.10. Viral infection, susceptibility, association with
1.2.7. Recurrent respiratory tract infection, association
1.3. Disease of anatomical entity
1.3.1. Cardiovascular system disease
1.3.1.1. Acanthocytosis
1.3.1.2. Attenuated cardiomyocyte response to stimulation
1.3.1.3. Cadiovascular disease, increased risk, association with
1.3.1.4. Cardiovascular death, association with
1.3.1.5. Cardiovascular defects
1.3.1.6. Cardiovascular disease, accelerated course, association
1.3.1.7. Epistaxis and telangiectasia
1.3.1.8. Heart disease
1.3.1.8.1. Adverse cardiovascular outcome in hypertension
1.3.1.8.2. Atrial and ventricular arrhythmia
1.3.1.8.3. Cardiac arrhythmia
1.3.1.8.4. Cardiac dysrhythmia
1.3.1.8.5. Cardiac disease
1.3.1.8.6. Cardiomyopathy
1.3.1.8.6.1. Cardiomyopathy, arrhythmogenic right ventricular
1.3.1.8.6.2. Cardiomyopathy, dilated
1.3.1.8.6.3. Cardiomyopathy, dilated / hypertrophic
1.3.1.8.6.4. Cardiomyopathy, dilated, association with
1.3.1.8.6.5. Cardiomyopathy, dilated, increased risk
1.3.1.8.6.6. Cardiomyopathy, hypertrophic
1.3.1.8.6.7. Cardiomyopathy, hypertrophic, association with
1.3.1.8.6.8. Cardiomyopathy, hypertrophic, modifier of, association with
1.3.1.8.6.9. Cardiomyopathy, hypertropic
1.3.1.8.6.10. Cardiomyopathy, left ventricular noncompaction
1.3.1.8.6.11. Cardiomyopathy, mitochondrial, and sudden cardiac death
1.3.1.8.6.12. Cardiomyopathy, modifier of
1.3.1.8.6.13. Cardiomyopathy, tako-tsubo, increased risk
1.3.1.8.6.14. Heart dilation, association with
1.3.1.8.6.15. Intrinsic cardiomyopathy
1.3.1.8.6.15.1. Hypertrophic cardiomyopathy
1.3.1.8.6.15.2. Hypertrophic cardiomyopathy, early onset
1.3.1.8.6.15.3. Long QT syndrome
1.3.1.8.6.15.4. Long QT syndrome, drug-associated
1.3.1.8.6.15.5. Long QT syndrome, drug-induced, increased risk
1.3.1.8.6.15.6. Long QT syndrome, modifier of
1.3.1.8.6.15.7. Longer QT interval, association with
1.3.1.8.6.15.8. QT interval prolongation, association with
1.3.1.8.6.16. Ischaemic cardiomyopathy, infarct size, association with
1.3.1.8.7. Cardiac hypertrophy
1.3.1.8.7.1. Intrinsic cardiomyopathy
1.3.1.8.7.1.1. Arrhythmogenic cardiomyopathy
1.3.1.8.7.1.2. Arrhythmogenic right ventricular cardiomyopathy
1.3.1.8.7.1.2.1. Arrhythmogenic right ventricular dysplasia
1.3.1.8.7.1.2.2. Arrhythmogenic right ventricular dysplasia/cardiomyopathy
1.3.1.8.7.1.3. Long QT syndrome
1.3.1.8.7.2. Restrictive cardiomyopathy
1.3.1.8.7.2.1. Atrial standstill, association with
1.3.1.8.8. Acute coronary syndrome, association with
1.3.1.8.9. Congenital heart defects
1.3.1.8.10. Congenital heart disease
1.3.1.8.10.1. Congenital heart disease, increased risk
1.3.1.8.10.2. Congenital heart malformation
1.3.1.8.10.3. Heart septal defect
1.3.1.8.10.3.1. Atrial septal defect
1.3.1.8.10.3.2. Atrial septal defects & postaxial hexodactyly
1.3.1.8.10.3.3. Atrioventricular septal defect
1.3.1.8.10.3.3.1. Cardiac atrioventricular septal defect
1.3.1.8.10.3.4. Atrioventricular septal defect, Down-syndrome-associated
1.3.1.8.10.3.5. Ventricular septal defect
1.3.1.8.10.3.5.1. Ventricular septal defect, association with
1.3.1.8.10.4. Hypoplastic left heart syndrome
1.3.1.8.10.5. Left ventricular hypertrophy, association with
1.3.1.8.10.6. Left ventricular hypertrophy, lower risk, association
1.3.1.8.10.7. Tetralogy of Fallot
1.3.1.8.10.7.1. Tetralogy of Fallot, association with
1.3.1.8.10.7.2. Tetralogy of Fallot, predisposition to
1.3.1.8.10.8. Total anomalous pulmonary venous return
1.3.1.8.11. Cardiovascular heart disease in diabetics
1.3.1.8.12. Aortic-valve calcification
1.3.1.8.13. Heart failure, increased mortality in, association with
1.3.1.8.14. Heart failure, increased risk
1.3.1.8.15. Heart malformations
1.3.1.8.16. Increased risk of ischemic heart disease
1.3.1.8.17. Infrarenal abdominal aortic calcified plaque, association with
1.3.1.8.18. Ischaemic heart disease, increased risk, association with
1.3.1.8.19. Life threatening arrhythmia
1.3.1.8.20. Mortality in heart failure
1.3.1.8.21. Sudden arrhythmic death syndrome
1.3.1.8.22. Sudden cardiac arrest
1.3.1.8.22.1. Sudden cardiac arrest, in coronary artery disease, association with
1.3.1.8.23. Unexplained cardiac arrest, association with
1.3.1.8.24. Heart conduction disease
1.3.1.8.24.1. Cardiac conduction disease, isolated
1.3.1.8.24.2. Catecholaminergic polymorphic ventricular tachycardia
1.3.1.8.24.3. Cathecholaminergic polymorphic ventricular tachycardia
1.3.1.8.24.3.1. Ventricular tachycardia, polymorphic
1.3.1.8.24.4. Brugada syndrome
1.3.1.8.24.5. Atrial fibrillation
1.3.1.8.24.5.1. Atrial fibrillation & slow ventricular rates
1.3.1.8.24.5.2. Atrial fibrillation, early-onset, association with
1.3.1.8.24.5.3. Postoperative atrial fibrillation in coronary artery bypass grafting surgery
1.3.1.8.24.5.4. Atrial fibrillationatrial flutter
1.3.1.8.24.6. Primary VF during acute MI, association
1.3.1.8.24.7. Ventricular fibrillation, recurrent
1.3.1.8.25. Heart valve disease
1.3.1.8.25.1. Aortic valve disease
1.3.1.8.25.1.1. Bicuspid aortic valve
1.3.1.8.25.1.2. Coarctation of the aorta
1.3.1.8.25.2. Heart valve defect
1.3.1.8.25.3. Mitral valve prolapse
1.3.1.8.26. Ventricular arrhythmias, association with
1.3.1.9. Ischemic cerebrovascular events, association with
1.3.1.10. Vascular disease
1.3.1.10.1. Vascular brain injury
1.3.1.10.2. Cervical artery dissection
1.3.1.10.3. Artery disease
1.3.1.10.3.1. Abdominal aortic aneurysm
1.3.1.10.3.1.1. Abdominal aortic aneurysm, female, association
1.3.1.10.3.1.2. Abdominal aortic aneurysm, increased risk
1.3.1.10.3.1.3. Abdominal aortic aneurysm, male, association
1.3.1.10.3.1.4. Abdominal aortic aneurysm, male, association
1.3.1.10.3.2. Aortic disease
1.3.1.10.3.2.1. Aortic aneurysm
1.3.1.10.3.2.1.1. Thoracic aortic aneurysm or dissection
1.3.1.10.3.2.1.2. Thoracic aortic aneurysm, smaller diameter
1.3.1.10.3.2.1.3. Thoracic aortic aneurysms & dissections, association with
1.3.1.10.3.3. Arteriosclerosis
1.3.1.10.3.3.1. Arteriosclerotic cardiovascular disease
1.3.1.10.3.3.1.1. Atherosclerosis
1.3.1.10.3.3.1.1.1. Atherosclerotic stenosis, increased severity, association with
1.3.1.10.3.3.1.1.2. Atherothrombotic stroke, increased risk, association with
1.3.1.10.3.3.1.1.3. Reduced HDL level in atherosclerosis, association
1.3.1.10.3.4. Hypertension
1.3.1.10.3.4.1. Essential hypertension
1.3.1.10.3.4.1.1. Esential hypertension, association with
1.3.1.10.3.4.1.2. Essential hypertension in Han Chinese, association with
1.3.1.10.3.4.1.3. Essential hypertension, association with
1.3.1.10.3.4.1.4. Essential hypertension, increased risk
1.3.1.10.3.4.1.5. Essential hypertension, susceptibility to
1.3.1.10.3.4.2. Hypertension in men, association with
1.3.1.10.3.4.3. Hypertension in women, association with
1.3.1.10.3.4.4. Hypertension, association with
1.3.1.10.3.4.5. Hypertension, female, association with
1.3.1.10.3.4.6. Hypertension, in Caucasians, association with
1.3.1.10.3.4.7. Hypertension, in men, association with
1.3.1.10.3.4.8. Hypertension, increased risk, association with
1.3.1.10.3.4.9. Hypertension, response to verapamil, association with
1.3.1.10.3.4.10. Hypertension, severity, association with
1.3.1.10.3.4.11. Hypertension, susceptibility to, association
1.3.1.10.3.4.12. Pre-eclampsia
1.3.1.10.3.4.12.1. Preeclampsia and essential hypertension, association with
1.3.1.10.3.4.12.2. Preeclampsia in multigravid pregnancies, association with
1.3.1.10.3.4.12.3. Preeclampsia, association with
1.3.1.10.3.4.12.4. Preeclampsia, increased risk, association with
1.3.1.10.3.4.12.5. Preeclampsia, susceptibility to
1.3.1.10.3.4.13. Pulmonary hypertension
1.3.1.10.3.4.14. Raised blood pressure, association with
1.3.1.10.3.4.15. Reduced anteroseptal wall thickness of the left ventricle, in hypertension, association with
1.3.1.10.3.5. Peripheral artery disease
1.3.1.10.3.6. Cerebrovascular disease
1.3.1.10.3.6.1. Brain infarction
1.3.1.10.3.6.1.1. Brain infarction, association with
1.3.1.10.3.6.1.2. Cerebral infarction, association with
1.3.1.10.3.6.2. Carotid artery disease
1.3.1.10.3.6.2.1. Carotid artery disease, association with
1.3.1.10.3.6.2.2. Carotid stenosis, association with
1.3.1.10.3.6.3. Carotid atherosclerosis in HIV infection
1.3.1.10.3.6.4. Intracerebral hemorrhage
1.3.1.10.3.6.5. Pulmonary arterial hypertension
1.3.1.10.3.6.5.1. Pulmonary arterial hypertension without BMPR2 mutations
1.3.1.10.3.6.5.2. Pulmonary arterial hypertension, association with
1.3.1.10.3.6.5.3. Pulmonary arterial hypertension, idiopathic, association with
1.3.1.10.3.6.5.4. Pulmonary arterial hypertension, increased risk
1.3.1.10.3.6.6. Stroke
1.3.1.10.3.6.6.1. Haemorrhagic stroke
1.3.1.10.3.6.6.2. Intracerebral haemorrhage, association with
1.3.1.10.3.6.6.3. Intracerebral haemorrhage, increased risk
1.3.1.10.3.6.6.4. Intracerebral haemorrhage, late-onset
1.3.1.10.3.6.6.5. Intracerebral hemorrhage, association with
1.3.1.10.3.6.6.6. Ischemic stroke
1.3.1.10.3.6.6.7. Ischaemic stroke, association with
1.3.1.10.3.6.6.8. Ischaemic stroke, increased risk
1.3.1.10.3.6.6.9. Ischemic stroke, association with
1.3.1.10.3.6.6.10. Large artery stroke
1.3.1.10.3.6.6.11. Progressing stroke, increased risk, association with
1.3.1.10.3.6.6.12. Stroke ischemic
1.3.1.10.3.6.6.13. Stroke pediatric
1.3.1.10.3.6.6.14. Stroke recurrence, association with
1.3.1.10.3.6.6.15. Stroke, association with
1.3.1.10.3.6.6.16. Stroke, increased risk, association with
1.3.1.10.3.6.7. Intracranial arterial disease
1.3.1.10.3.6.7.1. Cerebral arterial disease
1.3.1.10.3.6.7.1.1. Intracranial aneurysm
1.3.1.10.3.6.7.1.2. Intracranial aneurysm, association with
1.3.1.10.3.6.7.1.3. Intracranial aneurysm, increased risk, association with
1.3.1.10.3.6.7.1.4. Intracranial aneurysm, susceptibility, association with
1.3.1.10.3.6.7.1.5. Moyamoya disease, association with
1.3.1.10.3.6.7.1.6. Moyamoya disease
1.3.1.10.3.6.7.1.7. Saccular intracranial aneurysm, association with
1.3.1.10.3.7. Coronary artery disease
1.3.1.10.3.7.1. Coronary heart disease
1.3.1.10.3.7.1.1. Coronary heart disease in SLE, association with
1.3.1.10.3.7.1.2. Coronary heart disease, in Caucasians, association with
1.3.1.10.3.7.1.3. Coronary heart disease, increased risk
1.3.1.10.3.7.1.4. Coronary heart disease, increased risk in smokers, association
1.3.1.10.3.7.1.5. Coronary heart disease, premature, association with
1.3.1.10.3.7.2. Coronary artery disease
1.3.1.10.3.7.2.1. Coronary artery disease in smokers, association
1.3.1.10.3.7.2.2. Coronary artery disease, increased risk
1.3.1.10.3.7.2.3. Coronary artery disease, severity, in Japanese men, association with
1.3.1.10.3.7.2.4. Coronary artery disease, susceptibility to
1.3.1.10.3.7.3. Coronary atherosclerosis, severe, association with
1.3.1.10.3.7.4. Coronary spasm
1.3.1.10.3.7.4.1. Coronary spasm, association with
1.3.1.10.3.7.4.2. Coronary spastic angina, association with
1.3.1.10.3.7.5. Coronary stenosis
1.3.1.10.3.7.5.1. Coronary in-stent restenosis, increased risk
1.3.1.10.3.7.5.2. Coronary restenosis
1.3.1.10.3.7.6. Coronary thrombosis, association with
1.3.1.10.3.7.7. Increased risk of coronary artery disease, association with
1.3.1.10.3.7.8. Increased risk of death in CAD, association with
1.3.1.10.3.7.9. Myocardial infarction
1.3.1.10.3.7.9.1. Acute myocardial infarction
1.3.1.10.3.7.9.2. Myocardial infarction in Japanese, increased risk, association with
1.3.1.10.3.7.9.3. Myocardial infarction, age related, association
1.3.1.10.3.7.9.4. Myocardial infarction, association with
1.3.1.10.3.7.9.5. Myocardial infarction, increased risk, association
1.3.1.10.3.7.9.6. Myocardial infarction, increased risk, association with
1.3.1.10.3.7.9.7. Myocardial infarction, risk, association with
1.3.1.10.3.7.9.8. Myocardial infarction, susceptibility, association
1.3.1.10.3.7.9.9. Myocardial infarction
1.3.1.10.3.7.9.10. Myocardial infarction early onset
1.3.1.10.3.7.9.11. Premature myocardial infarction, association with
1.3.1.10.3.7.10. Severe coronary artery disease, association with
1.3.1.10.4. Peripheral vascular disease
1.3.1.10.4.1. Microangiopathy in type 2 diabetes, association
1.3.1.10.4.2. Priapism
1.3.1.10.4.2.1. Priapism in sickle cell anaemia, association with
1.3.1.10.5. Vasculitis
1.3.1.10.5.1. Behcets disease
1.3.1.10.5.1.1. BehÃ§et disease, association with
1.3.1.10.5.1.2. BehÃ§et's uveitis, association with
1.3.1.10.5.2. Churg-Strauss syndrome
1.3.1.10.5.2.1. ANCA-negative Churg-Strauss syndrome, association
1.3.1.10.5.3. Polyarteritis nodosa, systemic & cutaneous
1.3.1.10.5.4. Systemic vasculitis, association with
1.3.1.10.6. Vein disease
1.3.1.10.6.1. Deep venous thrombosis, increased risk, association with
1.3.1.10.6.2. Venous thromboembolic disease
1.3.1.10.6.3. Venous thromboembolism
1.3.1.10.6.4. Venous thromboembolism, association with
1.3.1.10.6.5. Venous thromboembolism, susceptibility, association with
1.3.1.10.6.6. Venous thrombosis, increased risk, association
1.3.1.11. Orthostatic hypotension
1.3.2. Endocrine system disease
1.3.2.1. Adrenal disease (or adrenal gland disease)
1.3.2.1.1. Adrenal cortex disease
1.3.2.1.1.1. Adrenal gland hyperfunction
1.3.2.1.1.1.1. Aldosteronism, primary
1.3.2.1.2. Adrenal hyperplasia
1.3.2.1.3. Adrenal insufficiency
1.3.2.1.4. Adrenocortical hyperplasia
1.3.2.1.5. Androgen secretion, association with
1.3.2.2. Cortisone reductase deficiency
1.3.2.3. Dysalbuminaemic hyperthyroxinaemia, familial
1.3.2.4. Gonadal disease
1.3.2.4.1. Hypogonadism
1.3.2.4.1.1. Hypogonadotropic hypogonadism
1.3.2.4.1.1.1. Kallmann syndrome
1.3.2.4.2. Sex differentiation disease
1.3.2.4.2.1. Pseudohermaphroditism
1.3.2.4.2.1.1. Persistent Mullerian ducts syndrome
1.3.2.5. Pancreas disease
1.3.2.5.1. Exocrine pancreatic insufficiency and calvarial hyperostosis
1.3.2.5.2. Endocrine pancreas disease
1.3.2.5.2.1. Hyperinsulinaemia, association with
1.3.2.5.2.2. Hyperinsulinism
1.3.2.5.2.3. Hypoglycaemia, association with
1.3.2.5.2.4. Hypoglycaemia, persistent hyperinsulinaemic
1.3.2.5.3. Hyperlipidemic pancreatitis, association with
1.3.2.5.4. Pancreatitis
1.3.2.5.4.1. Pancreatitis, acute
1.3.2.5.4.2. Pancreatitis, chronic
1.3.2.5.4.3. Pancreatitis, chronic, association with
1.3.2.5.4.4. Pancreatitis, tropical
1.3.2.5.4.5. Pancreatitis, tropical, association with
1.3.2.5.4.6. Tropical calcific pancreatitis, association with
1.3.2.6. Parathyroid gland disease
1.3.2.6.1. Hyperparathyroidism, association with
1.3.2.7. Pituitary gland disease
1.3.2.7.1. Hypopituitarism
1.3.2.7.1.1. Combined growth hormone deficiency, increased risk
1.3.2.7.1.2. Growth hormone deficiency
1.3.2.8. Thyroid gland disease
1.3.2.8.1. Hyperthyroidism
1.3.2.8.1.1. Hyperthyroidism, autoimmune, association with
1.3.2.8.1.2. Toxic multinodular goitre, association with
1.3.2.8.2. Hypothyroidism
1.3.2.8.2.1. Hypothyroidism, association with
1.3.2.8.2.2. Hypothyroidism, subclinical
1.3.2.8.2.3. Hypothyroidism, transient
1.3.2.8.2.4. Thyroid-stimulating hormone resistance
1.3.2.8.3. Goitre
1.3.2.8.3.1. Goitre, dyshormonogenetic
1.3.2.8.3.2. Goitre, multinodular
1.3.2.8.3.3. Goitre, multinodular, non-toxic
1.3.2.8.3.4. Goitre, simple
1.3.2.8.3.5. Goitre with hypothyroidism
1.3.2.8.3.6. Goitre, adenomatous
1.3.2.8.3.7. Goitre, congenital
1.3.3. Gastrointestinal system disease
1.3.3.1. Acetaldehyde dehydrogenase deficiency
1.3.3.2. Adenomatous polyposis coli
1.3.3.3. Adenomatous polyposis coli, association with
1.3.3.4. Diarrhea
1.3.3.4.1. Diarrhoea, congenital chloride
1.3.3.5. Digestive system disease Barretts esophagus and esophageal adenocarcinoma combined
1.3.3.6. Sclerosing cholangitis and ulcerative colitis combined
1.3.3.7. Esophageal disease
1.3.3.7.1. Barretts esophagus
1.3.3.7.2. Barrett oesophagus/oesophageal adenocarcinoma
1.3.3.7.3. Achalasia, association with
1.3.3.8. Gastroduodenal ulcer, increased risk, association with
1.3.3.9. Gallbladder disease
1.3.3.9.1. Cholelithiasis
1.3.3.9.1.1. Cholestasis, drug-induced, association with
1.3.3.9.1.2. Low phospholipid associated cholelithiasis
1.3.3.9.2. Cholelithiasis-related traits in sickle cell anemia
1.3.3.9.3. Gallstones
1.3.3.9.4. Gallstone disease, association with
1.3.3.10. Hepatobiliary disease
1.3.3.10.1. Biliary tract disease
1.3.3.10.1.1. Bile duct disease
1.3.3.10.1.1.1. Cholestasis
1.3.3.10.1.1.1.1. Biliary atresia, association with
1.3.3.10.1.1.1.2. Biliary atresia
1.3.3.10.2. Liver disease
1.3.3.10.2.1. Advanced liver disease in drinkers
1.3.3.10.2.2. Alagille syndrome
1.3.3.10.2.3. Cryptogenic liver disease
1.3.3.10.2.4. Early dysfunction in vascular access in haemodialysis, association
1.3.3.10.2.5. End-stage liver disease, early onset, association with
1.3.3.10.2.6. HCV-related liver disease, severity, association
1.3.3.10.2.7. Hepatitis
1.3.3.10.2.8. Hepatitis C induced liver fibrosis
1.3.3.10.2.9. Hepatic fibrosis, association with
1.3.3.10.2.10. Infantile hepatopathy
1.3.3.10.2.11. Intrahepatic cholestasis of pregnancy
1.3.3.10.2.12. Intrahepatic cholestasis of pregnancy, association
1.3.3.10.2.13. Intrahepatic cholestasis of pregnancy, association with
1.3.3.10.2.14. Intrahepatic cholestasis, familial progressive
1.3.3.10.2.15. Intrahepatic cholestasis, familial progressive 2
1.3.3.10.2.16. Liver cirrhosis
1.3.3.10.2.16.1. Cirrhosis
1.3.3.10.2.16.2. Hepatitis C induced liver cirrhosis
1.3.3.10.2.16.3. Liver cirrhosis, association with
1.3.3.10.2.16.4. North American Indian childhood cirrhosis
1.3.3.10.2.16.5. Primary biliary cirrhosis
1.3.3.10.2.16.6. Primary biliary cirrhosis, association with
1.3.3.10.2.16.7. Primary biliary cirrhosis, susceptibility to
1.3.3.10.2.17. Liver disease, susceptibility to
1.3.3.11. Intestinal disease
1.3.3.11.1. Colonic disease
1.3.3.11.1.1. Hirschsprung disease
1.3.3.11.1.1.1. Aganglionosis, in Hirschsprung disease
1.3.3.11.1.2. Accelerated colonic transit in irritable bowel syndrome, association
1.3.3.11.1.3. Colonic disease in CARD15 mutation positive individuals, association
1.3.3.11.1.4. Megacolon
1.3.3.11.1.4.1. Hirschsprung disease
1.3.3.11.1.4.2. Hirschsprung disease, association with
1.3.3.11.2. Indirect inguinal hernia
1.3.3.11.3. Indirect inguinal hernia, association with
1.3.3.11.4. Inflammatory bowel disease
1.3.3.11.4.1. Inflammatory bowel disease
1.3.3.11.4.2. Inflammatory bowel disease early onset
1.3.3.11.4.3. Inflammatory bowel disease, association with
1.3.3.11.4.4. Inflammatory bowel disease, risk, association with
1.3.3.11.4.5. Crohns disease
1.3.3.11.4.6. Crohn disease
1.3.3.11.4.6.1. Crohn's disease risk, association with
1.3.3.11.4.6.2. Crohn's disease, association with
1.3.3.11.4.6.3. Crohn's disease, childhood onset, association with
1.3.3.11.4.6.4. Crohn's disease, ileal, association with
1.3.3.11.4.6.5. Crohn's disease, increased risk
1.3.3.11.4.6.6. Crohn's disease, increased risk, association with
1.3.3.11.4.6.7. Crohn's disease, modifier of
1.3.3.11.4.6.8. Crohn's disease, susceptibility to
1.3.3.11.4.6.9. Crohn's disease, susceptibility to, association
1.3.3.11.4.6.10. Crohn's disease, susceptibility to, association with
1.3.3.11.4.6.11. Crohn's disease, susceptibility, association with
1.3.3.11.4.7. Crohns disease need for surgery
1.3.3.11.4.8. Crohns disease-related phenotypes
1.3.3.11.4.9. Crohns disease time to surgery
1.3.3.11.4.10. Ulcerative colitis or Crohns disease
1.3.3.11.4.11. Ulcerative colitis
1.3.3.11.4.11.1. Ulcerative colitis, association with
1.3.3.11.4.11.2. Ulcerative colitis, increased risk, association with
1.3.3.11.4.11.3. Ulcerative colitis, susceptibility to
1.3.3.11.5. Inguinal hernia, association with
1.3.3.11.6. Sitosterolaemia
1.3.3.12. Mouth disease
1.3.3.12.1. Tooth disease
1.3.3.12.1.1. Dental decay, association with
1.3.3.12.1.2. Molar-incisor hypomineralization
1.3.3.12.1.3. Periodontal disease
1.3.3.12.1.3.1. Periodontitis
1.3.3.12.1.3.1.1. Periodontitis, aggressive, association with
1.3.3.12.1.3.1.2. Periodontitis, association with
1.3.3.12.1.3.1.3. Periodontitis, increased risk, association with
1.3.3.12.1.4. Periodontal disease
1.3.3.12.1.4.1. Periodontitis
1.3.3.12.1.4.1.1. Periapical periodontitis
1.3.3.12.1.4.1.1.1. Chronic periodontitis, severity, association with
1.3.3.12.1.4.2. Periodontitis CDCAAP
1.3.3.12.1.4.3. Periodontitis DPAL
1.3.3.12.1.4.4. Periodontitis Mean PAL
1.3.3.12.1.4.5. Periodontitis PAL4Q3
1.3.3.12.1.4.6. Periodontal microbiota
1.3.3.12.1.5. Oligodontia
1.3.3.12.1.6. Teeth hard tissue disease
1.3.3.12.1.6.1. Dental caries
1.3.3.12.1.6.1.1. Pit-and-Fissure caries
1.3.3.12.1.6.1.2. Smooth-surface caries
1.3.3.12.1.6.2. Dental enamel hypoplasia
1.3.3.12.1.6.2.1. Amelogenesis imperefecta
1.3.3.12.1.6.2.1.1. Pigmented hypomaturation amelogenesis imperfecta
1.3.3.12.1.7. Tooth agenesis
1.3.3.12.1.7.1. Selective tooth agenesis, association with
1.3.3.12.1.7.2. Tooth agenesis, non-syndromic, association with
1.3.3.12.1.7.3. Tooth agenesis third molar
1.3.3.12.1.7.4. Tooth agenesis mandibular third molar
1.3.3.13. Peptic ulcer disease
1.3.3.13.1. Duodenal ulcer
1.3.3.14. Stomach disease
1.3.3.14.1. Functional gastric disease
1.3.3.14.1.1. Functional dyspepsia, association with
1.3.3.14.2. Gastritis
1.3.3.14.3. Gastritis, association with
1.3.3.14.4. Gastric outlet obstruction
1.3.3.14.4.1. Infantile hypertrophic pyloric stenosis
1.3.3.14.4.2. Pyloric stenosis, infantile hypertrophic, association with
1.3.4. Hematopoietic system disease
1.3.4.1. Anemia
1.3.4.1.1. Aplastic anaemia
1.3.4.1.1.1. Congenital hypoplastic anemia
1.3.4.1.1.1.1. Fanconi anaemia
1.3.4.1.2. Iron-refractory iron deficiency anaemia (IRIDA)
1.3.4.1.3. Macrocytic anemia
1.3.4.1.3.1. Megaloblastic anaemia
1.3.4.1.3.2. Megaloblastic anaemia 1
1.3.4.1.4. Malarial anaemia, increased risk, association with
1.3.4.1.5. Microcytic anemia
1.3.4.1.5.1. Iron deficiency anaemia, susceptibility association with
1.3.4.1.6. Normocytic anemia
1.3.4.1.6.1. Hemolytic anemia
1.3.4.1.6.1.1. Congenital hemolytic anemia
1.3.4.1.6.1.1.1. Anaemia, dyserythropoietic congenital, type II
1.3.4.1.6.1.1.2. Congenital nonspherocytic hemolytic anemia
1.3.4.1.6.1.1.2.1. Pyruvate kinase deficiency
1.3.4.1.6.1.1.3. Hemoglobinopathy
1.3.4.1.6.1.1.3.1. Methaemoglobinaemia
1.3.4.1.6.1.1.3.2. Methaemoglobinaemia 1
1.3.4.1.6.1.1.4. Hereditary spherocytosis
1.3.4.1.6.1.1.4.1. Spherocytosis
1.3.4.1.6.1.1.4.2. Spherocytosis, association with
1.3.4.1.6.1.2. Haemolytic uraemic syndrome
1.3.4.1.6.1.3. Haemolytic uraemic syndrome, association with
1.3.4.1.6.1.4. Haemolytic uraemic syndrome, atypical
1.3.4.1.6.1.5. Haemolytic uraemic syndrome, atypical, association with
1.3.4.1.6.1.6. Hemolysis, mild chronic
1.3.4.1.6.1.7. Pyropoikilocytosis
1.3.4.2. Blood coagulation disease
1.3.4.2.1. Thrombophilia, association with
1.3.4.2.2. Chronic bleeding disorder
1.3.4.2.3. Hemorrhagic disease
1.3.4.2.3.1. Blood platelet disease
1.3.4.2.3.1.1. Thrombocytopenia
1.3.4.2.3.1.1.1. Amegakaryocytic thrombocytopaenia, congenital
1.3.4.2.3.1.1.2. Immune thrombocytopaenia, treatment response
1.3.4.2.3.1.1.3. Macrothrombocytopaenia
1.3.4.2.3.1.1.4. Thrombocytopaenia 2
1.3.4.2.3.1.2. Thrombocytosis, association with
1.3.4.3. Bone marrow disease
1.3.4.3.1. Polycythemia
1.3.4.3.1.1.1. Erythrocytosis with megakaryocytic atypia
1.3.4.3.1.1.2. Polycythaemia
1.3.4.4. Blood protein disease
1.3.4.4.1. Protein S deficiency
1.3.4.5. Inherited blood coagulation disease
1.3.4.5.1. Afibrinogenaemia
1.3.4.5.2. Antithrombin deficiency
1.3.4.5.3. Bernard-Soulier syndrome
1.3.4.5.4. Dysfibrinogenaemia
1.3.4.5.5. Factor H deficiency
1.3.4.5.6. Factor V and factor VIII deficiency, combined
1.3.4.5.7. Factor V deficiency
1.3.4.5.8. Factor VII deficiency
1.3.4.5.9. Factor VII deficiency, association with
1.3.4.5.10. Factor X deficiency
1.3.4.5.11. Factor XIII deficiency
1.3.4.5.12. Glanzmann thrombasthenia
1.3.4.5.13. Protein C deficiency
1.3.4.5.14. Protein C deficiency, type I
1.3.4.5.15. Von Willebrand disease
1.3.4.5.15.1. Von Willebrand disease 1
1.3.4.5.15.2. Von Willebrand disease 2b
1.3.4.5.15.3. Von Willebrand disease 2m
1.3.4.5.15.4. Von Willebrand, Normandy variant
1.3.4.5.15.5. Von Willebrand disease 3
1.3.4.5.15.6. Von Willebrand disease, quantitative type, association with
1.3.4.5.15.7. CD36 deficiency
1.3.4.5.16. Scott syndrome
1.3.4.6. Leukocyte disease
1.3.4.6.1. Leukopenia
1.3.4.6.1.1. Agranulocytosis
1.3.4.6.1.1.1. Neutropaenia
1.3.4.6.1.1.2. Neutropaenia, congenital
1.3.4.6.1.1.3. Neutropaenia, cyclic
1.3.4.6.1.1.4. Neutropaenia, severe chronic
1.3.4.6.1.2. CD4 lymphopaenia, idiopathic
1.3.4.6.2. Mastocytosis
1.3.4.6.2.1. Mastocytosis predisposition
1.3.4.6.3. Neutrophil antigen 2 deficiency
1.3.4.7. Neonatal alloimmune thrombocytopenic purpura, association with
1.3.5. Immune system disease
1.3.5.1. Acute graft versus host disease, association with
1.3.5.2. Altered antiviral signalling
1.3.5.3. Antibodies to double-stranded DNA, presence of
1.3.5.4. Autoimmune disease predisposition, association with
1.3.5.5. Autoimmune disease, association with
1.3.5.6. Autoimmune diseases, association with
1.3.5.7. Hypersensitivity reaction disease
1.3.5.7.1. Atopy
1.3.5.7.1.1. Atopy, association with
1.3.5.7.1.2. Atopy, increased risk, association with
1.3.5.7.1.3. Atopy, maternally inherited, association with
1.3.5.7.2. Allergic hypersensitivity disease
1.3.5.7.2.1. Respiratory allergy
1.3.5.7.2.1.1. Allergy to pollen and mites, association with
1.3.5.7.3. Allergic disease
1.3.5.7.4. Allergic disorders, association with
1.3.5.7.5. Anaphylaxis, food-induced, association with
1.3.5.7.6. Anaphylaxis, in hypogammaglobulinaemia, association with
1.3.5.7.6.1. Nut allergy
1.3.5.7.6.1.1. Peanut allergy
1.3.5.7.6.2. Self-reported allergy
1.3.5.7.6.2.1. Allergy, self-reported, association with
1.3.5.7.7. Hypersensitivity reaction type II disease
1.3.5.7.7.1. Autoimmune disease of the nervous system
1.3.5.7.7.1.1. Autoimmune disease of the peripheral nervous system
1.3.5.7.7.1.1.1. Guillain-Barre syndrome
1.3.5.7.7.1.1.1.1. Miller syndrome
1.3.5.7.7.1.2. Juvenile myasthenia gravis, ophthalmoplegic complication, association with
1.3.5.7.7.2. Myasthenia gravis
1.3.5.7.7.2.1. Myasthenia gravis, association with
1.3.5.7.7.2.2. Myasthenia gravis, early onset, association with
1.3.5.7.7.3. Autoimmune disease of the blood
1.3.5.7.7.3.1. Haemolytic anaemia
1.3.5.7.7.4. Autoimmune disease of the endocrine system
1.3.5.7.7.4.1. Hashimoto disease, severity, association with
1.3.5.7.7.5. Cryopyrin-associated periodic syndrome, atypical
1.3.5.7.7.6. Lupus erythematosus
1.3.5.7.7.6.1. Cutaneous lupus erythematosus
1.3.5.7.7.6.1.1. Subacute cutaneous lupus erythematosus, association with
1.3.5.7.7.7. Systemic lupus erythematosus
1.3.5.7.7.8. Mediterranean fever, familial
1.3.5.7.7.9. Mediterranean fever, familial, association with
1.3.5.7.7.10. Periodic fever, autosomal dominant
1.3.5.7.7.11. Vogt-Koyanagi-Harada syndrome, susceptibility to
1.3.5.7.7.12. Vitiligo
1.3.5.7.7.12.1. Vitiligo susceptibility, association with
1.3.5.7.7.12.2. Vitiligo, association with
1.3.5.7.7.12.3. Vitiligo, autosomal dominant, association with
1.3.5.7.7.12.4. Vitiligo, susceptibility to
1.3.5.7.7.12.5. Vitiligo, susceptibility to, association with
1.3.5.7.7.12.6. Vitiligo-association multiple autoimmune disease susceptibility
1.3.5.7.8. Hypersensitivity reaction type IV disease
1.3.5.7.8.1. Autoimmune lymphoproliferative syndrome
1.3.5.7.8.1.1. Autoimmune lymphoproliferative syndrome II
1.3.5.7.8.2. Cryoglobulinemia
1.3.5.7.8.2.1. Cryoglobulinemia, predisposition, association with
1.3.5.7.8.3. Alopecia areata
1.3.5.7.8.3.1. Alopecia areata, association with
1.3.5.7.8.4. Antiphospholipid syndrome, association with
1.3.5.7.8.5. Sjögrens syndrome
1.3.5.7.8.6. Vogt-Koyanagi-Harada syndrome
1.3.5.7.8.7. Vitiligo
1.3.5.7.8.8. Vitiligo non-segmental
1.3.5.7.8.9. Wegeners granulomatosis
1.3.5.7.8.10. Mixed cryoglobulinemia vasculitis in chronic hepatitis C infection
1.3.5.7.8.11. Autoimmune disease of endocrine system
1.3.5.7.8.11.1. Autoimmune thyroid disease
1.3.5.7.8.11.2. Graves' disease
1.3.5.7.8.11.3. Graves disease, association with
1.3.5.7.8.11.4. Graves' disease, association with
1.3.5.7.8.11.5. Graves disease, earlier age of onset, association
1.3.5.7.8.11.6. Graves disease, susceptibility to, association
1.3.5.7.8.11.7. Hashimoto thyroiditis versus Graves' disease
1.3.5.7.8.12. Autoimmune disease of the nervous system
1.3.5.7.8.12.1. Myasthenia gravis
1.3.5.7.8.12.1.1. Extraocular muscle pareses in myasthenia gravis
1.3.5.7.8.13. Autoimmune disease of gastrointestinal tract
1.3.5.7.8.13.1. Autoimmune pancreatitis, association with
1.3.5.7.8.13.2. Celiac disease
1.3.5.7.8.13.2.1. Celiac disease, association with
1.3.5.7.8.13.2.2. Celiac disease, increased risk, association with
1.3.5.7.8.14. Sarcoidosis
1.3.5.7.8.14.1. Sarcoidosis, susceptibility, association with
1.3.5.8. Lymphatic system disease
1.3.5.8.1. Haemophagocytic lymphohistiocytosis
1.3.5.8.2. Haemophagocytic lymphohistiocytosis, familial
1.3.5.8.3. Histiocytosis
1.3.5.8.3.1. Non-Langerhans-cell histiocytosis
1.3.5.8.3.1.1. Niemann-Pick disease
1.3.5.8.3.1.1.1. Niemann-Pick disease C
1.3.5.8.3.1.1.2. Niemann-Pick type II disease
1.3.5.8.4. Lymph node disease
1.3.5.8.4.1. Kawasaki disease
1.3.5.8.4.2. Kawasaki disease with left ventricular non-compaction
1.3.5.8.4.3. Kawasaki disease, association with
1.3.5.8.5. Lymphoedema
1.3.5.8.5.1. Lymphoedema, primary
1.3.5.8.5.2. Secondary lymphoedema
1.3.5.9. Primary immunodeficiency disease
1.3.5.9.1. Antibody deficiency
1.3.5.9.2. B cell deficiency
1.3.5.9.2.1. Agammaglobulinemia
1.3.5.9.2.1.1. Immunodeficiency, common variable
1.3.5.9.2.2. Hyperimmunoglobulin D and periodic fever syndrome
1.3.5.9.2.3. Hyperimmunoglobulin D syndrome
1.3.5.9.3. Combined T cell and B cell immunodeficiency
1.3.5.9.3.1. Immunodeficiency, combined
1.3.5.9.3.2. Immunodeficiency, combined, with intestinal atresias
1.3.5.9.3.3. Immunodeficiency, severe combined
1.3.5.9.3.4. Immunodeficiency, severe combined, atypical
1.3.5.9.3.5. Immunodeficiency, severe combined, T & B cell -ve
1.3.5.9.3.6. Severe combined immunodeficiency
1.3.5.9.4. Complement deficiency
1.3.5.9.4.1. Complement C2 deficiency
1.3.5.9.4.2. Complement C5 deficiency
1.3.5.9.4.3. Complement C6 deficiency, subtotal
1.3.5.9.4.4. Complement C7 deficiency
1.3.5.9.4.5. Complement factor I deficiency
1.3.5.9.5. Phagocyte bactericidal dysfunction
1.3.5.9.5.1. Chronic granulomatous disease
1.3.5.9.6. Immunodeficiency, primary
1.3.6. Integumentary system disease
1.3.6.1. Hair disease
1.3.6.1.1. Hypotrichosis
1.3.6.1.1.1. Alopecia
1.3.6.1.1.1.1. Alopecia areata, association with
1.3.6.1.1.1.2. Alopecia universalis, association with
1.3.6.1.2. Male-pattern baldness
1.3.6.2. Skin disease
1.3.6.2.1. Acne severe
1.3.6.2.2. Acral peeling skin syndrome
1.3.6.2.3. Angioedema
1.3.6.2.3.1. Angioedema, hereditary
1.3.6.2.4. Cutis laxa
1.3.6.2.4.1. Cutis laxa, autosomal recessive
1.3.6.2.5. Keloid
1.3.6.2.6. Keloid formation, association with
1.3.6.2.7. Keratoderma, palmoplantar, punctate, Buschke-Fischer-Brauer type
1.3.6.2.8. Peeling skin syndrome, type A
1.3.6.2.9. Psoriasis
1.3.6.2.9.1. Psoriasis, association with
1.3.6.2.9.2. Psoriasis, generalised pustular
1.3.6.2.9.3. Psoriasis, increased risk, association with
1.3.6.2.9.4. Psoriasis, juvenile onset, association with
1.3.6.2.9.5. Psoriasis, predisposition to
1.3.6.2.9.6. Psoriasis, susceptibility, association with
1.3.6.2.9.7. Psoriasis susceptibility, association with
1.3.6.2.9.8. Psoriasis vulgaris, susceptibility to, assoc with
1.3.6.2.9.9. Pustular psoriasis
1.3.6.2.10. Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis SJSTEN
1.3.6.2.11. Lipodystrophy
1.3.6.2.11.1. Congenital generalized lipodystrophy
1.3.6.2.11.1.1. Berardinelli-Seip lipodystrophy
1.3.6.2.11.2. Lipodystrophy, partial, acquired, susceptibility to
1.3.6.2.11.3. Partial lipodystrophy, Dunnigan
1.3.6.2.12. Sunburns
1.3.6.2.13. Skin sensitivity to sun
1.3.6.2.14. Pruritis in biliary cirrhosis patients, association with
1.3.6.2.15. Pseudofolliculitis Barbae, increased risk, association
1.3.6.2.16. Dermatitis
1.3.6.2.16.1. Atopic dermatitis
1.3.6.2.16.1.1. Atopic dermatitis and psoriasis vulgaris, susceptibility, association
1.3.6.2.16.1.2. Atopic dermatitis, association with
1.3.6.2.16.1.3. Atopic dermatitis, childhood, association with
1.3.6.2.16.1.4. Atopic dermatitis, increased susceptibility, assoc with
1.3.6.2.16.1.5. Atopic dermatitis, severity, association with
1.3.6.2.16.1.6. Bullous skin disease
1.3.6.2.16.1.6.1. Pemphigus
1.3.6.2.16.1.6.1.1. Hailey-Hailey disease, modifier of
1.3.6.2.16.1.6.1.2. Pemphigus foliaceus, association with
1.3.6.2.16.1.6.1.3. Pemphigus vulgaris, increased risk, association with
1.3.6.2.16.1.7. Eczema, association with
1.3.6.2.16.1.8. Eczema, atopic, association with
1.3.6.2.16.1.9. Elevated IgE level in atopic dermatitis patients, association
1.3.6.2.16.1.10. Recalcitrant atopic dermatitis
1.3.6.2.16.1.11. Allergic dermatitis nickel
1.3.6.2.16.1.12. Pyoderma gangrenosum in inflammatory bowel disease
1.3.6.2.16.1.13. Reduced serum IgE levels in atopic dermatitis
1.3.6.2.16.1.14. Symptoms of atopic dermatitis, in  African Americans, association with
1.3.6.2.17. UV-induced skin damage, vulnerability to
1.3.6.2.18. Vesticulobullous skin disease
1.3.6.2.18.1. Epidermolysis bullosa
1.3.6.2.18.1.1. Epidermolysis bullosa dystrophica
1.3.6.2.18.1.2. Epidermolysis bullosa simplex
1.3.6.2.18.1.3. Epidermolysis bullosa with pyloric atresia
1.3.6.2.18.1.4. Epidermolysis bullosa, junctional
1.3.6.2.18.1.5. Epidermolysis bullosa, junctional with prurigo-like lesions
1.3.6.2.18.1.6. Epidermolysis bullosa, recessive dystrophic
1.3.7. Musculoskeletal system disease
1.3.7.1. Connective tissue disease
1.3.7.1.1. Bone disease
1.3.7.1.1.1. Bone development disease
1.3.7.1.1.1.1. Developmental dysplasia of the hip
1.3.7.1.1.1.2. Dysostosis
1.3.7.1.1.1.2.1. Synostosis
1.3.7.1.1.1.2.1.1. Greig cephalopolysyndactyly syndrome
1.3.7.1.1.1.3. Osteochondrodysplasia
1.3.7.1.1.1.3.1. Atelosteogenesis 2
1.3.7.1.1.1.3.2. Catel-Manzke syndrome
1.3.7.1.1.1.3.3. Osteogenesis imperfecta
1.3.7.1.1.1.3.4. Osteogenesis imperfecta I
1.3.7.1.1.1.3.5. Osteogenesis imperfecta, autosomal recessive
1.3.7.1.1.1.3.6. Microcephalic osteodysplastic primordial dwarfism type 2
1.3.7.1.1.1.3.7. Microcephalic primordial dwarfism
1.3.7.1.1.1.3.8. Multiple epiphyseal dysplasia
1.3.7.1.1.1.3.9. Pseudoachondroplasia
1.3.7.1.1.1.3.10. Spondyloepimetaphyseal dysplasia
1.3.7.1.1.1.3.10.1. Spondyloepiphyseal dysplasia
1.3.7.1.1.1.3.10.2. Spondyloepimetaphyseal dysplasia, Strudwick
1.3.7.1.1.1.3.11. Steel syndrome
1.3.7.1.1.1.4. Split hand/foot malformation
1.3.7.1.1.1.5. Talipes equinovarus, congential idiopathic, association with
1.3.7.1.1.2. Bone structure disease
1.3.7.1.1.2.1. Bone deterioration disease
1.3.7.1.1.2.1.1. Decreased bone mineral density, association
1.3.7.1.1.2.1.2. Disc degeneration lumbar
1.3.7.1.1.2.1.3. Lumbar disc degeneration, association with
1.3.7.1.1.2.1.4. Lumbar disc degeneration, susceptibility to
1.3.7.1.1.2.1.5. Lumbar disc disease, association with
1.3.7.1.1.2.1.6. Lumbar disc herniation, association with
1.3.7.1.1.2.1.7. Lumbar-disc herniation, association with
1.3.7.1.1.2.2. Sagittal craniosynostosis
1.3.7.1.1.3. Bone inflammation disease
1.3.7.1.1.3.1. Ankylosing spondylitis
1.3.7.1.1.3.2. Arthritis
1.3.7.1.1.3.2.1. Chondrocalcinosis
1.3.7.1.1.3.2.2. Gout
1.3.7.1.1.3.2.3. Gout, association with
1.3.7.1.1.3.2.4. Hip osteoarthritis, association with
1.3.7.1.1.3.2.5. Juvenile idiopathic arthritis
1.3.7.1.1.3.2.6. Juvenile idiopathic arthritis, association with
1.3.7.1.1.3.2.7. Juvenile rheumatoid arthritis, association with
1.3.7.1.1.3.2.8. Osteoarthritis
1.3.7.1.1.3.2.9. Osteoarthritis hand, severe
1.3.7.1.1.3.2.10. Osteoarthritis biomarkers
1.3.7.1.1.3.2.11. Osteoarthritis hip
1.3.7.1.1.3.2.12. Osteoarthritis in males, association with
1.3.7.1.1.3.2.13. Osteoarthritis, association with
1.3.7.1.1.3.2.14. Osteoarthritis, early-onset
1.3.7.1.1.3.2.15. Osteoarthritis, knee, association with
1.3.7.1.1.3.2.16. Osteoarthritis, susceptibility to, association with
1.3.7.1.1.3.2.17. Osteoarthritis, susceptibility, association with
1.3.7.1.1.3.2.18. Knee osteoarthritis
1.3.7.1.1.3.2.19. Knee osteoarthritis, susceptibility to, association
1.3.7.1.1.3.2.20. Rheumatoid arthritis
1.3.7.1.1.3.2.20.1. Arthritis juvenile idiopathic
1.3.7.1.1.3.2.20.2. Arthritis, systemic juvenile idiopathic
1.3.7.1.1.3.2.20.3. Rheumatoid arthritis, association with
1.3.7.1.1.3.2.20.4. Rheumatoid arthritis, earlier onset, association with
1.3.7.1.1.3.2.20.5. Rheumatoid arthritis, increased risk, association with
1.3.7.1.1.3.2.20.6. Rheumatoid arthritis, joint destruction, slower progression
1.3.7.1.1.3.2.20.7. Rheumatoid arthritis, juvenile, association with
1.3.7.1.1.3.2.20.8. Rheumatoid arthritis, severity, & response to infliximab, association with
1.3.7.1.1.3.2.20.9. Rheumatoid arthritis, shorter duration, association with
1.3.7.1.1.3.2.20.10. Rheumatoid arthritis, susceptibility to
1.3.7.1.1.3.2.20.11. Rheumatoid arthritis, susceptibility to, association with
1.3.7.1.1.3.2.20.12. Rheumatoid arthritis, susceptibility, association
1.3.7.1.1.3.3. Arthropathy
1.3.7.1.1.3.3.1. Arthropathy unspecified, involving lower leg
1.3.7.1.1.3.3.2. Bursitis
1.3.7.1.1.3.3.2.1. Chronic achilles tendinopathy, association with
1.3.7.1.1.4. Bone remodeling disease
1.3.7.1.1.4.1. Bone resorption disease
1.3.7.1.1.4.1.1. Bone mineral density in osteoporosis, association with
1.3.7.1.1.4.1.2. Osteoporosis
1.3.7.1.1.4.1.2.1. Carbonic anhydrase deficiency
1.3.7.1.1.4.1.3. Osteoporosis-related phenotypes
1.3.7.1.1.4.2. Hyperostosis
1.3.7.1.1.4.2.1. Exostosis
1.3.7.1.1.4.2.1.1. Multiple exostoses
1.3.7.1.1.4.2.1.2. Osteochondroma
1.3.7.1.1.4.2.2. Paget’s disease of bone
1.3.7.1.1.4.2.2.1. Pagets disease
1.3.7.1.1.4.2.2.2. Paget disease of bone
1.3.7.1.1.4.2.2.3. Paget disease of bone, association with
1.3.7.1.1.4.3. Osteosclerosis
1.3.7.1.1.4.3.1. Osteopetrosis, autosomal recessive
1.3.7.1.1.4.3.2. Osteoporosis, association with
1.3.7.1.1.4.3.3. Osteoporosis, primary
1.3.7.1.1.4.3.4. Osteoporosis, susceptibility to, association
1.3.7.1.1.4.3.5. Osteoporotic fractures, association with
1.3.7.1.1.4.4. Rickets
1.3.7.1.1.4.4.1. Hereditary hypophosphataemic rickets with hypercalciuria, modifier of
1.3.7.1.1.4.5. Scoliosis
1.3.7.1.1.4.5.1. Adolescent idiopathic scoliosis severe
1.3.7.1.1.4.5.2. Adolescent idiopathic scoliosis
1.3.7.1.1.4.5.3. Scoliosis, idiopathic, association with
1.3.7.1.1.5. Collagen disease
1.3.7.1.1.5.1. Ehlers-Danlos syndrome
1.3.7.1.1.5.1.1. Brittle cornea syndrome
1.3.7.1.1.5.1.2. Ehlers-Danlos syndrome, autosomal recessive
1.3.7.1.1.5.1.3. Ehlers-Danlos syndrome, vascular-type
1.3.7.1.1.5.2. Scleroderma
1.3.7.1.1.5.2.1. Systemic sclerosis
1.3.7.1.1.5.2.1.1. Anticentromere antibody positive systemic sclerosis, association
1.3.7.1.1.5.2.1.2. Limited cutaneous systemic sclerosis, association with
1.3.7.1.1.5.2.1.3. Systemic sclerosis, association with
1.3.7.1.1.5.2.1.4. Systemic sclerosis, susceptibility association with
1.3.7.1.1.5.2.1.5. Systemic sclerosis, susceptibility to, association with
1.3.7.1.1.6. Fractures
1.3.7.1.1.6.1. Bone mineral density and vertebral fracture, association with
1.3.7.1.1.6.2. Fracture, increased risk, association with
1.3.7.1.1.6.3. Fragility fractures, increased risk, association with
1.3.7.1.1.6.4. Stress fracture, association with
1.3.7.1.1.7. Ischemic bone disease
1.3.7.1.1.7.1. Osteonecrosis of the jaw
1.3.7.1.1.8. Stuve-Wiedemann syndrome
1.3.7.1.2. Collagen VI deficiency
1.3.7.1.3. Dupuytrens disease
1.3.7.1.4. Marfan syndrome
1.3.7.1.5. Marfan syndrome, atypical
1.3.7.1.6. Myelopathy (OPLL), association with
1.3.7.1.7. Ossification of posterior longitudinal ligament, association with
1.3.7.1.8. Ossification of the posterior longitudinal ligament of the spine, association with
1.3.7.1.9. Ossification of the posterior longitudinal ligament of the spine, predisposition to
1.3.7.1.10. Ossification of the posterior longitudinal ligament of the spine
1.3.7.1.11. Systemic lupus erythematosus
1.3.7.1.11.1. Systemic lupus erythematosus, association with
1.3.7.1.11.2. Systemic lupus erythematosus, increased risk, association with
1.3.7.1.11.3. Systemic lupus erythematosus, risk, association with
1.3.7.1.11.4. Systemic lupus erythematosus, susceptibility association with
1.3.7.1.11.5. Systemic lupus erythematosus, susceptibility to
1.3.7.2. Muscular disease
1.3.7.2.1. Diaphragm disease
1.3.7.2.1.1. Diaphragmatic hernia, congenital
1.3.7.2.2. Dysferlinopathy
1.3.7.2.3. Muscular tissue disease
1.3.7.2.3.1. Alpha actin 3 deficiency
1.3.7.2.3.2. Myopathy
1.3.7.2.3.2.1. Congenital structural myopathy
1.3.7.2.3.2.1.1. Nemaline myopathy
1.3.7.2.3.2.2. Hereditary myopathy with early respiratory failure
1.3.7.2.3.2.3. Mitochondrial myopathy
1.3.7.2.3.2.3.1. Progressive external ophthalmoplegia
1.3.7.2.3.2.4. Muscular dystrophy
1.3.7.2.3.2.4.1. Congenital muscular dystrophy
1.3.7.2.3.2.4.1.1. Bethlem myopathy
1.3.7.2.3.2.4.1.2. Walker-Warburg syndrome
1.3.7.2.3.2.4.1.3. Ullrich congenital muscular dystrophy
1.3.7.2.3.2.4.1.4. Ullrich congenital muscular dystrophy, intermediate
1.3.7.2.3.2.4.2. Distal muscular dystrophy
1.3.7.2.3.2.4.2.1. Miyoshi myopathy
1.3.7.2.3.2.4.3. Emery-Dreifuss muscular dystrophy
1.3.7.2.3.2.4.4. Emery-Dreifuss muscular dystrophy, modifier of
1.3.7.2.3.2.4.5. Facioscapulohumeral dystrophy-like phenotype
1.3.7.2.3.2.4.6. Muscular dystrophy with epidermolysis bullosa
1.3.7.2.3.2.4.7. Muscular dystrophy with mental retardation
1.3.7.2.3.2.4.8. Muscular dystrophy, Duchenne-like
1.3.7.2.3.2.4.9. Muscular dystrophy, Emery-Dreifuss
1.3.7.2.3.2.4.10. Muscular dystrophy, limb girdle
1.3.7.2.3.2.4.11. Muscular dystrophy, limb girdle / Miyoshi myopathy
1.3.7.2.3.2.4.12. Muscular dystrophy, limb girdle 2B
1.3.7.2.3.2.4.13. Muscular dystrophy, limb girdle 2L
1.3.7.2.3.2.4.14. Muscular dystrophy, limb-girdle
1.3.7.2.3.2.4.15. Muscular dystrophy, merosin deficient
1.3.7.2.3.2.4.16. Myotonic disease
1.3.7.2.3.2.4.16.1. Myotonic dystrophy, type 1, association with
1.3.7.2.3.2.4.16.2. Myotonic dystrophy, type 1, modifier of
1.3.7.2.3.2.5. Myofibrillar myopathy
1.3.7.2.3.2.6. Myositis
1.3.7.2.3.2.6.1. Fibromyalgia syndrome, association with
1.3.7.2.3.2.7. Congenital myopathy
1.3.7.2.3.2.7.1. Congenital fibre type disproportion
1.3.7.2.3.2.8. Myopathy / muscular dystrophy
1.3.7.2.3.2.9. Myopathy, congenital
1.3.7.2.3.2.10. Myopathy, late-onset
1.3.7.2.3.2.11. Myopathy, progressive axial with cataracts
1.3.7.2.3.3. Myotonia congenita
1.3.7.2.3.4. Myotonia, Becker
1.3.7.2.3.5. Rhabdomyolysis, exercise-induced
1.3.7.2.4. Thyrotoxic hypokalemic periodic paralysis
1.3.7.3. Joint disease
1.3.7.3.1. Temporomandibular joint disorders
1.3.8. Nervous system disease
1.3.8.1. Central nervous system disease
1.3.8.1.1. Central nervous system malformation
1.3.8.1.1.1. Non-syndromic central nervous system malformation
1.3.8.1.1.1.1. Neural tube defects
1.3.8.1.1.1.1.1. Neural tube defect, association with
1.3.8.1.1.1.1.2. Neural tube defect, increased risk, association with
1.3.8.1.1.1.1.3. Neural tube defects, increased risk, association with
1.3.8.1.1.1.1.4. Spina bifida
1.3.8.1.1.1.1.5. Craniorachischisis
1.3.8.1.1.1.1.6. Craniosynostosis, isolated metopic
1.3.8.1.2. Restless legs syndrome
1.3.8.1.2.1. Restless legs syndrome, association with
1.3.8.1.2.2. Restless legs syndrome, increased risk
1.3.8.1.3. Brain disease
1.3.8.1.3.1. Basal ganglia disease
1.3.8.1.3.1.1. Frontotemporal dementia
1.3.8.1.3.1.1.1. Frontotemporal dementia / amyotrophic lateral sclerosis
1.3.8.1.3.1.1.2. Frontotemporal dementia, association with
1.3.8.1.3.1.1.3. Frontotemporal dementia, in GRN mutation carriers, association with
1.3.8.1.3.2. Cerebral degeneration
1.3.8.1.3.2.1. Alpers syndrome
1.3.8.1.3.2.2. Hippocampal volume loss, association with
1.3.8.1.3.2.3. Leukodystrophy
1.3.8.1.3.2.3.1. Alexander disease
1.3.8.1.3.2.3.2. Canavan disease
1.3.8.1.3.2.3.3. Hypomyelinating leukodystrophy
1.3.8.1.3.2.3.3.1. Hypomyelination with brain stem and spinal cord involvement and leg spasticity
1.3.8.1.3.2.3.3.2. Hypomyelination, hypodontia & hypogonadotropic hypogonadism
1.3.8.1.3.2.3.3.3. Hypomyelination, hypodontia & hypogonadotropic hypogonadism with late-onset growth hormone deficiency
1.3.8.1.3.2.3.3.4. Pelizaeus-Merzbacher-like disease
1.3.8.1.3.2.3.4. Leukodystrophy, POLR3-related
1.3.8.1.3.2.3.5. Leukoencephalopathy with calcifications & cysts
1.3.8.1.3.2.3.6. Leukoencephalopathy with thalamus & brainstem involvement & high lactate
1.3.8.1.3.2.3.7. Leukoencephalopathy with vanishing white matter
1.3.8.1.3.2.3.8. Leukoencephalopathy, infantile
1.3.8.1.3.3. Cerebellar disease
1.3.8.1.3.3.1. Cerebellar ataxia
1.3.8.1.3.3.2. Cortical myoclonus with cerebellar ataxia
1.3.8.1.3.4. Cerebral palsy
1.3.8.1.3.4.1. Cerebral palsy/hypoxic-ischemic encephalopathy, association with
1.3.8.1.3.5. Encephalopathy, severe infantile syndromic
1.3.8.1.3.6. Epileptic encephalopathy
1.3.8.1.3.7. Epilepsy
1.3.8.1.3.7.1. Epilepsy, pyridoxine-dependent
1.3.8.1.3.7.2. Epilepsy, susceptibility to
1.3.8.1.3.7.3. Infantile epilepsy with severe cystic degeneration of the brain
1.3.8.1.3.7.4. Intractable seizures
1.3.8.1.3.7.5. Electroclinical syndrome
1.3.8.1.3.7.5.1. Adolecent-adult electroclinical syndrome
1.3.8.1.3.7.5.1.1. Myoclonic epilepsy, juvenile, association with
1.3.8.1.3.7.5.2. Childhood electroclinical syndrome
1.3.8.1.3.7.5.2.1. Childhood absence epilepsy, association with
1.3.8.1.3.7.5.2.2. Epilepsy, childhood absence
1.3.8.1.3.7.5.2.3. Epilepsy, childhood absence, association with
1.3.8.1.3.7.5.2.4. Epilepsy, rolandic without neonatal seizures
1.3.8.1.3.7.5.2.5. Rolandic epilepsy
1.3.8.1.3.7.5.3. Infancy electroclinical syndrome
1.3.8.1.3.7.5.3.1. Dravet syndrome
1.3.8.1.3.7.5.3.2. Myoclonic epilepsy of infancy
1.3.8.1.3.7.6. Generalized convulsive epilepsy, without mention of intractable epilepsy
1.3.8.1.3.7.7. Focal epilepsy
1.3.8.1.3.7.7.1. Epilepsy, familial focal with variable foci
1.3.8.1.3.7.7.2. Temporal lobe epilepsy
1.3.8.1.3.7.7.3. Temporal lobe epilepsy, association with
1.3.8.1.3.7.7.4. Mesial temporal lobe epilepsy with hippocampal sclerosis
1.3.8.1.3.7.8. Idiopathic generalized epilepsy
1.3.8.1.3.7.8.1. Epilepsy, idiopathic
1.3.8.1.3.7.8.2. Epilepsy, idiopathic generalised, association with
1.3.8.1.3.7.8.3. Idiopathic epilepsy, generalised
1.3.8.1.3.7.9. Partial epilepsies
1.3.8.1.3.7.10. Sudden unexpected death in epilepsy
1.3.8.1.3.8. Hippocampal sclerosis
1.3.8.1.3.8.1. Hippocampal sclerosis of aging
1.3.8.1.3.9. Infuenza infection-associated encephalopathy
1.3.8.1.3.10. Kernicterus, acute
1.3.8.1.3.11. Migraine
1.3.8.1.3.11.1. Migraine
1.3.8.1.3.11.2. Migraine with aura
1.3.8.1.3.11.2.1. Hemiplegic migraine
1.3.8.1.3.11.3. Migraine without aura
1.3.8.1.3.11.4. Migraine - clinic-based
1.3.8.1.3.11.5. Migraine duration, association with
1.3.8.1.3.11.6. Migraine severity, association with
1.3.8.1.3.11.7. Migraine, association with
1.3.8.1.3.12. Movement disease
1.3.8.1.3.12.1. Dystonia
1.3.8.1.3.12.1.1. Dystonia, dopa-responsive
1.3.8.1.3.12.1.2. Dystonia, primary torsion, adult-onset
1.3.8.1.3.12.1.3. Focal dystonia
1.3.8.1.3.12.1.3.1. Primary blepharospasm, spread, association with
1.3.8.1.3.12.1.4. Myoclonus dystonia
1.3.8.1.3.12.1.5. Torsion dystonia, phenotype modifier, association with
1.3.8.1.3.12.1.6. Writer's cramp, increased risk
1.3.8.1.3.12.2. Essential tremor
1.3.8.1.3.12.3. Marked hypotonia with waddling gait
1.3.8.1.3.12.4. Mirror movements, congenital
1.3.8.1.3.12.5. Progressive supranuclear palsy, association with
1.3.8.1.3.12.6. Supranuclear palsy, progressive, association with
1.3.8.1.3.12.7. Tardive dyskinesia in schizophrenia, association
1.3.8.1.3.13. Polymicrogyria, bilateral frontoparietal
1.3.8.1.3.14. Prion disease
1.3.8.1.3.14.1. Creutzfeldt-Jakob disease
1.3.8.1.3.14.2. Creutzfeldt-Jakob disease, association with
1.3.8.1.3.14.3. Creutzfeldt-Jakob disease sporadic
1.3.8.1.3.14.4. Creutzfeldt-Jakob disease, sporadic, increased risk
1.3.8.1.3.14.5. Creutzfeldt-Jakob syndrome
1.3.8.1.3.14.6. Creutzfeldt-Jakob syndrome, sporadic, association
1.3.8.1.3.14.7. Gerstmann-Straeussler syndrome, association with
1.3.8.1.4. Neurodegenerative disease
1.3.8.1.4.1. Alzheimer and Parkinson disease
1.3.8.1.4.2. Boucher-NeuhÃ¤user syndrome
1.3.8.1.4.3. Demyelinating disease
1.3.8.1.4.3.1. Multiple sclerosis
1.3.8.1.4.3.2. Multiple sclerosis severity
1.3.8.1.4.3.3. Multiple sclerosis susceptibility, association with
1.3.8.1.4.3.4. Multiple sclerosis, age of onset, association with
1.3.8.1.4.3.5. Multiple sclerosis, association with
1.3.8.1.4.3.6. Multiple sclerosis, increased risk, association with
1.3.8.1.4.3.7. Multiple sclerosis, predisposition to
1.3.8.1.4.3.8. Multiple sclerosis, susceptibility in men, association
1.3.8.1.4.3.9. Multiple sclerosis, susceptibility to
1.3.8.1.4.3.10. Multiple sclerosis, susceptibility to, association with
1.3.8.1.4.3.11. Multiple sclerosis, susceptibility, association with
1.3.8.1.4.3.12. Brain atrophy in multiple sclerosis, association with
1.3.8.1.4.4. Hereditary ataxia
1.3.8.1.4.4.1. Autosomal dominant cerebellar ataxia
1.3.8.1.4.4.1.1. Spinocerebellar ataxia 23
1.3.8.1.4.4.1.2. Spinocerebellar ataxia type 5
1.3.8.1.4.4.2. Autosomal recessive cerebellar ataxia
1.3.8.1.4.4.2.1. Ataxia telangiectasia
1.3.8.1.4.4.2.2. Ataxia-ocular apraxia 1
1.3.8.1.4.4.2.3. Ataxia-ocular apraxia 2
1.3.8.1.4.4.3. Episodic ataxia
1.3.8.1.4.4.3.1. Episodic ataxia 2
1.3.8.1.4.5. Earlier onset in Huntington disease, association with
1.3.8.1.4.6. Huntington disease, age at onset, association with
1.3.8.1.4.7. Huntington disease, delayed age-at-onset
1.3.8.1.4.8. Huntington disease, earlier onset in females, association with
1.3.8.1.4.9. Motor neuron disease
1.3.8.1.4.9.1. Amyotrophic lateral sclerosis
1.3.8.1.4.9.2. Amyotrophic lateral sclerosis sporadic
1.3.8.1.4.9.3. Amyotrophic lateral sclerosis age of onset
1.3.8.1.4.9.4. Monomelic amyotrophy, association with
1.3.8.1.4.9.5. Spinal muscular atrophy
1.3.8.1.4.9.5.1. Spinal muscular atrophy with respiratory distress 1
1.3.8.1.4.9.6. Upper motor neuron syndrome
1.3.8.1.4.9.7. Upper motor neuron syndrome, adult onset
1.3.8.1.4.10. Neuroacanthosytosis
1.3.8.1.4.10.1. Chorea-acanthocytosis
1.3.8.1.4.11. Synucleinopathy
1.3.8.1.4.11.1. Multiple system atrophy
1.3.8.1.4.11.1.1. Multiple system atrophy, increased risk, association with
1.3.8.1.4.11.2. Parkinson’s disease
1.3.8.1.4.11.2.1. Parkinsons disease
1.3.8.1.4.11.2.2. Parkinsons disease familial
1.3.8.1.4.11.2.3. Parkinsons disease age of onset
1.3.8.1.4.11.2.4. Parkinson disease and lewy body pathology
1.3.8.1.4.11.2.5. Parkinson disease
1.3.8.1.4.11.2.6. Parkinson disease, association with
1.3.8.1.4.11.2.7. Parkinson disease, autosomal recessive
1.3.8.1.4.11.2.8. Parkinson disease, early-onset
1.3.8.1.4.11.2.9. Parkinson disease, familial, association with
1.3.8.1.4.11.2.10. Parkinson disease, GBA-associated, modifier of
1.3.8.1.4.11.2.11. Parkinson disease, in heterozygosity, association
1.3.8.1.4.11.2.12. Parkinson disease, increased risk, assoc
1.3.8.1.4.11.2.13. Parkinson disease, increased risk, association with
1.3.8.1.4.11.2.14. Parkinson disease, late-onset, assoc with
1.3.8.1.4.11.2.15. Parkinsonism, late-onset, association with
1.3.8.1.4.11.2.16. Parkinson disease, risk, association with
1.3.8.1.4.11.2.17. Parkinson disease, susceptibility to, association
1.3.8.1.4.11.2.18. Parkinson's disease, risk, association with
1.3.8.1.4.11.2.19. Parkinsonism, association with
1.3.8.1.4.11.2.20. Parkinsonism, juvenile, autosomal recessive
1.3.8.1.4.12. Tauopathy
1.3.8.1.4.12.1. Alzheimers disease
1.3.8.1.4.12.2. Alzheimers disease in APOE e4- carriers
1.3.8.1.4.12.3. Alzheimers disease in APOE e4+ carriers
1.3.8.1.4.12.4. Alzheimers disease late onset
1.3.8.1.4.12.5. Alzheimers disease APOE e4 interaction
1.3.8.1.4.12.6. Alzheimer disease in e4 carriers, association
1.3.8.1.4.12.7. Alzheimer disease risk, association with
1.3.8.1.4.12.8. Alzheimer disease, association with
1.3.8.1.4.12.9. Alzheimer disease, delayed onset, association with
1.3.8.1.4.12.10. Alzheimer disease, early onset
1.3.8.1.4.12.11. Alzheimer disease, in Amish, association with
1.3.8.1.4.12.12. Alzheimer disease, increased risk
1.3.8.1.4.12.13. Alzheimer disease, increased risk, association
1.3.8.1.4.12.14. Alzheimer disease, increased risk, association with
1.3.8.1.4.12.15. Alzheimer disease, late onset
1.3.8.1.4.12.16. Alzheimer disease, late onset, association with
1.3.8.1.4.12.17. Alzheimer disease, late-onset
1.3.8.1.4.12.18. Alzheimer disease, late-onset, association with
1.3.8.1.4.12.19. Alzheimer disease, susceptibility to, association with
1.3.8.1.4.12.20. Alzheimers disease, association with
1.3.8.1.4.12.21. Alzheimer's disease, association with
1.3.8.1.4.12.22. Alzheimer's disease, increased risk, association with
1.3.8.1.4.12.23. Alzheimer's, in APOE4 carriers, increased risk, association
1.3.8.1.4.12.24. Faster cognitive decline in alzheimer disease, association with
1.3.8.1.4.12.25. Neuropathology and cognition in Alzheimer disease, association
1.3.8.1.5. Paraplegia
1.3.8.1.5.1. Spastic paraplegia
1.3.8.1.5.2. Spastic paraplegia with thin corpus callosum
1.3.8.1.5.3. Spastic paraplegia, modifier of
1.3.8.1.5.4. Spastic paresis, progressive
1.3.8.2. Hyperekplexia
1.3.8.3. Neurodegeneration
1.3.8.4. Neuromuscular disorder
1.3.8.5. Peripheral nervous system disease
1.3.8.5.1. Neuropathy
1.3.8.5.1.1. Axonal neuropathy
1.3.8.5.1.1.1. Giant axonal neuropathy
1.3.8.5.1.2. Cranial nerve disease
1.3.8.5.1.2.1. Optic nerve disease
1.3.8.5.1.2.1.1. Optic atrophy
1.3.8.5.1.2.1.1.1. Optic atrophy
1.3.8.5.1.2.1.1.2. Optic atrophy 1
1.3.8.5.1.3. Erythermalgia, primary
1.3.8.5.1.4. Mutilating sensory neuropathy with spastic paraplegia
1.3.8.5.1.5. Neuromuscular disease
1.3.8.5.1.5.1. Charcot-Marie-Tooth disease
1.3.8.5.1.5.1.1. Charcot-Marie-Tooth disease, autosomal recessive
1.3.8.5.1.5.1.2. Charcot-Marie-Tooth disease, intermediate
1.3.8.5.1.5.1.3. Charcot-Marie-Tooth disease, modifier of
1.3.8.5.1.5.1.4. Charcot-Marie-Tooth disease 1
1.3.8.5.1.5.1.4.1. Charcot-Marie-Tooth disease 1a
1.3.8.5.1.5.1.4.2. Charcot-Marie-Tooth disease 1a/Neuropathy with liability to pressure palsies, earlier onset, association with
1.3.8.5.1.5.1.4.3. Charcot-Marie-Tooth disease 1b
1.3.8.5.1.5.1.4.4. Charcot-Marie-Tooth disease 1c
1.3.8.5.1.5.1.4.5. Charcot-Marie-Tooth disease 1e
1.3.8.5.1.5.1.5. Charcot-Marie-Tooth disease 2
1.3.8.5.1.5.1.5.1. Charcot-Marie-Tooth disease 2 with deafness
1.3.8.5.1.5.1.5.2. Charcot-Marie-Tooth disease 2, association with
1.3.8.5.1.5.1.5.3. Charcot-Marie-Tooth disease 2a
1.3.8.5.1.5.1.6. Charcot-Marie-Tooth disease 4
1.3.8.5.1.5.1.6.1. Charcot-Marie-Tooth disease 4A
1.3.8.5.1.5.1.6.2. Charcot-Marie-Tooth disease 4C
1.3.8.5.1.5.1.6.3. Charcot-Marie-Tooth disease 4J
1.3.8.5.1.5.2. Neuromuscular junction disease
1.3.8.5.1.5.2.1. Congenital myasthenic syndrome
1.3.8.5.1.5.2.1.1. Congenital myasthenic syndrome with episodic apnea
1.3.8.5.1.5.2.1.2. Congenital myasthenic syndrome with vocal cord paralysis
1.3.8.5.1.5.2.1.3. Congenital myasthenic syndromes
1.3.8.5.1.5.2.1.4. Endplate acetylcholinesterase deficiency
1.3.8.5.1.6. Peripheral neuropathy
1.3.8.5.1.7. Small fibre neuropathy
1.3.8.6. Polyglucosan body disease, adult
1.3.8.7. Sensory system disease
1.3.8.7.1. Auditory system disease
1.3.8.7.1.1. Hearing impairment
1.3.8.7.1.1.1. Deafness
1.3.8.7.1.1.1.1. Deafness, autosomal recessive 1
1.3.8.7.1.1.1.2. Deafness, autosomal recessive 12, modifier of
1.3.8.7.1.1.1.3. Deafness, childhood onset
1.3.8.7.1.1.1.4. Deafness, non-syndromic
1.3.8.7.1.1.1.5. Deafness, non-syndromic, autosomal recessive
1.3.8.7.1.1.1.6. Mitochondrial deafness, modifier of
1.3.8.7.1.1.2. Hearing impairment, nonsyndromic
1.3.8.7.1.1.3. Hearing loss
1.3.8.7.1.1.4. Hearing loss, age-related, association with
1.3.8.7.1.1.5. Hearing loss, non-syndromic
1.3.8.7.1.1.6. Hearing loss, progressive
1.3.8.7.1.1.7. Hearing loss, progressive, non-syndromic
1.3.8.7.1.1.8. Noise-induced hearing loss, susceptibility to, association
1.3.8.7.1.1.9. Non-syndromic hearing impairment, association with
1.3.8.7.1.2. Inner ear disease
1.3.8.7.1.2.1. Otosclerosis
1.3.8.7.1.2.2. Sensorineural hearing loss
1.3.8.7.1.2.3. Sensorineural hearing loss with poor cochlear implantation outcomes
1.3.8.7.1.2.4. Sensorineural hearing loss, association with
1.3.8.7.1.2.5. Sensorineural hearing loss, nonsyndromic
1.3.8.7.1.2.6. Vestibular disease
1.3.8.7.1.2.6.1. Enlarged vestibular aqueduct
1.3.8.7.1.2.6.2. Peripheral vertigo
1.3.8.7.1.2.6.2.1. Meniere's disease, association with
1.3.8.7.1.2.6.2.2. Meniere's disease, autosomal dominant
1.3.8.7.1.3. Middle eat disease
1.3.8.7.1.3.1. Otitis media
1.3.8.7.1.3.1.1. Otitis media, susceptibility to
1.3.8.7.1.4. Motion sickness
1.3.8.7.1.5. Otitis media chronicrecurrent
1.3.8.7.2. Eye and adnexa disease
1.3.8.7.2.1. Eye disease
1.3.8.7.2.1.1. Corneal Disease
1.3.8.7.2.1.1.1. Corneal dystrophy
1.3.8.7.2.1.1.1.1. Corneal dystrophy, epithelial basement membrane
1.3.8.7.2.1.1.1.2. Corneal dystrophy, Fuchs endothelial
1.3.8.7.2.1.1.1.3. Corneal dystrophy, Fuchs late-onset
1.3.8.7.2.1.1.1.4. Corneal dystrophy, gelatinous drop-like
1.3.8.7.2.1.1.1.5. Corneal dystrophy, lattice type
1.3.8.7.2.1.1.1.6. Corneal dystrophy, Meesmann
1.3.8.7.2.1.1.1.7. Fuch's corneal dystrophy, association with
1.3.8.7.2.1.1.1.8. Fuchs corneal dystrophy, late-onset
1.3.8.7.2.1.1.1.9. Fuchs corneal dystrophy
1.3.8.7.2.1.1.2. Keratoconus
1.3.8.7.2.1.1.3. Peters' anomaly
1.3.8.7.2.1.1.4. Pterygium
1.3.8.7.2.1.1.4.1. Pterygium, association with
1.3.8.7.2.1.1.4.2. Pterygium formation, association with
1.3.8.7.2.1.2. Eye developmental anomalies, autosomal dominant
1.3.8.7.2.1.3. Eye malformations, increased risk
1.3.8.7.2.1.4. Fundus dystrophy
1.3.8.7.2.1.4.1. Fundus albipunctatus
1.3.8.7.2.1.4.2. Retinitis punctata albescens
1.3.8.7.2.1.5. Glaucoma
1.3.8.7.2.1.5.1. Attenuated phenotype in glaucoma
1.3.8.7.2.1.5.2. Glaucoma primary angle closure
1.3.8.7.2.1.5.3. Glaucoma primary open-angle
1.3.8.7.2.1.5.4. Glaucoma high intraocular pressure
1.3.8.7.2.1.5.5. Glaucoma exfoliation
1.3.8.7.2.1.5.6. Glaucoma 1, open angle
1.3.8.7.2.1.5.7. Glaucoma 1, open angle, association with
1.3.8.7.2.1.5.8. Glaucoma 1, open angle, severity, association with
1.3.8.7.2.1.5.9. Glaucoma, open angle, association with
1.3.8.7.2.1.5.10. Glaucoma, primary congenital
1.3.8.7.2.1.5.11. Glaucoma, primary congenital, association with
1.3.8.7.2.1.5.12. Glaucoma, primary open angle
1.3.8.7.2.1.5.13. Glaucoma, primary open angle, association with
1.3.8.7.2.1.5.14. Normal tension glaucoma, association with
1.3.8.7.2.1.6. Intraocular pressure, association with
1.3.8.7.2.1.7. Lens disease
1.3.8.7.2.1.7.1. Cataract
1.3.8.7.2.1.7.1.1. Cataract, age-related, increased risk
1.3.8.7.2.1.7.1.2. Congenital cataract type, association with
1.3.8.7.2.1.7.1.3. Paediatric cataract, association with
1.3.8.7.2.1.7.2. Age-related cataracts
1.3.8.7.2.1.7.3. Age-related nuclear cataracts
1.3.8.7.2.1.7.4. Age-related cataracts age at onset
1.3.8.7.2.1.7.5. Cataracts in type 2 diabetes
1.3.8.7.2.1.8. Microphthalmia
1.3.8.7.2.1.8.1. Nanophthalmos
1.3.8.7.2.1.9. Pigmented paravenous chorioretinal atrophy
1.3.8.7.2.1.10. Poor visual field score, association with
1.3.8.7.2.1.11. Refractive error
1.3.8.7.2.1.11.1. Extreme myopia, increased risk
1.3.8.7.2.1.11.2. High myopia, association with
1.3.8.7.2.1.11.3. High myopia, increased risk, association with
1.3.8.7.2.1.11.4. Myopia severe
1.3.8.7.2.1.11.5. Myopia pathological
1.3.8.7.2.1.11.6. Myopia, high-grade
1.3.8.7.2.1.11.7. Myopia, high-grade, association with
1.3.8.7.2.1.11.8. Astigmatism
1.3.8.7.2.1.11.8.1. Corneal astigmatism
1.3.8.7.2.1.11.8.2. Refractive astigmatism
1.3.8.7.2.1.12. Retinal disease
1.3.8.7.2.1.12.1. Angioid streaks, increased risk, association with
1.3.8.7.2.1.12.2. Blindness
1.3.8.7.2.1.12.2.1. Colour-blindness, total
1.3.8.7.2.1.12.2.2. Achromatopsia
1.3.8.7.2.1.12.2.3. Achromatopsia, incomplete
1.3.8.7.2.1.12.3. Leber congenital amaurosis
1.3.8.7.2.1.12.3.1. Leber congenital amaurosis IV
1.3.8.7.2.1.12.4. Retinal degeneration
1.3.8.7.2.1.12.4.1. Age-related macular degeneration
1.3.8.7.2.1.12.4.2. Age-related macular degeneration CNV
1.3.8.7.2.1.12.4.3. Age-related macular degeneration CNV vs. GA
1.3.8.7.2.1.12.4.4. Age-related macular degeneration GA
1.3.8.7.2.1.12.4.5. Age-related macular degeneration extreme sampling
1.3.8.7.2.1.12.4.6. Age-related macular degeneration wet
1.3.8.7.2.1.12.4.7. Age-related macular degeneration smoking status interaction
1.3.8.7.2.1.12.4.8. Age related macular degeneration, association with
1.3.8.7.2.1.12.4.9. Age-related macular degeneration, association with
1.3.8.7.2.1.12.4.10. Age-related maculopathy, association with
1.3.8.7.2.1.12.4.11. Adult vitelliform macular dystrophy
1.3.8.7.2.1.12.4.12. Bietti crystalline corneoretinal dystrophy
1.3.8.7.2.1.12.4.13. Cone-rod dystrophy
1.3.8.7.2.1.12.4.14. Macular degeneration, age related
1.3.8.7.2.1.12.4.15. Macular degeneration, age related, association with
1.3.8.7.2.1.12.4.16. Macular degeneration, age related, increased risk
1.3.8.7.2.1.12.4.17. Macular degeneration, age related, neovascular, association with
1.3.8.7.2.1.12.4.18. Macular degeneration, age related, susceptibility to
1.3.8.7.2.1.12.4.19. Macular degeneration, age-related, association with
1.3.8.7.2.1.12.4.20. Macular degeneration, age-related, in smokers, association with
1.3.8.7.2.1.12.4.21. Macular degeneration, association with
1.3.8.7.2.1.12.4.22. Macular degeneration, juvenile
1.3.8.7.2.1.12.4.23. Macular degeneration, risk, association with
1.3.8.7.2.1.12.4.24. Macular dystrophy, occult
1.3.8.7.2.1.12.4.25. Multi-minicore disease
1.3.8.7.2.1.12.4.26. Multiminicore/minicore/multicore disease
1.3.8.7.2.1.12.4.27. Retinal degeneration in ciliopathies, association with
1.3.8.7.2.1.12.4.28. Retinal degeneration, association with
1.3.8.7.2.1.12.4.29. Retinitis pigmentosa
1.3.8.7.2.1.12.4.30. Retinitis pigmentosa & rod cone dystrophy
1.3.8.7.2.1.12.4.31. Retinitis pigmentosa, association with
1.3.8.7.2.1.12.4.32. Retinitis pigmentosa, autosomal recessive
1.3.8.7.2.1.12.4.33. Retinitis pigmentosa, modifier of
1.3.8.7.2.1.12.4.34. Retinitis pigmentosa, recessive, no hearing loss
1.3.8.7.2.1.12.4.35. Rod-cone dystrophy
1.3.8.7.2.1.12.4.36. Stargardt disease
1.3.8.7.2.1.12.4.37. Stargardt disease, association with
1.3.8.7.2.1.12.4.38. Wet age-related macular degeneration, association with
1.3.8.7.2.1.12.5. Rhegmatogenous retinal detachment
1.3.8.7.2.1.12.6. Retinal dystrophy
1.3.8.7.2.1.12.7. Retinal vascular disease
1.3.8.7.2.1.12.7.1. Diabetic retinopathy
1.3.8.7.2.1.12.7.2. Diabetic retinopathy in type 2 diabetes
1.3.8.7.2.1.12.7.3. Diabetic retinopathy, association with
1.3.8.7.2.1.12.7.4. Exudative vitreoretinopathy
1.3.8.7.2.1.12.7.5. Retinopathy in diabetic patients, association with
1.3.8.7.2.1.12.7.6. Retinopathy in non-diabetics
1.3.8.7.2.1.12.7.7. Sight-threatening diabetic retinopathy in type 2 diabetes
1.3.8.7.2.1.13. Birdshot chorioretinopathy
1.3.8.7.2.1.14. Uveal disease
1.3.8.7.2.1.14.1. Iris disease
1.3.8.7.2.1.14.1.1. Exfoliation glaucoma, association with
1.3.8.7.2.2. Paroxysmal extreme pain disorder
1.3.8.7.3. Olfactory
1.3.8.7.3.1. Olfactory receptor deficiency
1.3.9. Pelvic organ prolapse, association with
1.3.10. Reproductive system disease
1.3.10.1. Infertility, increased risk
1.3.10.2. Female reproductive system disease
1.3.10.2.1. Miscarriage, association with
1.3.10.2.2. Miscarriage, increased risk, association with
1.3.10.2.3. Ovarian disease
1.3.10.2.3.1. Ovarian insufficiency
1.3.10.2.3.2. Ovarian insufficiency, primary
1.3.10.2.3.3. Premature ovarian failure
1.3.10.2.3.4. Premature ovarian failure, association with
1.3.10.2.3.5. Premature ovarian failure, increased risk, association with
1.3.10.2.4. Ovulatory defects, association with
1.3.10.2.5. Poor pregnancy outcome in IVF
1.3.10.2.6. Preterm premature rupture of membranes, association
1.3.10.2.7. Recurrent miscarriage, association with
1.3.10.2.8. Uterine disease
1.3.10.2.8.1. Placenta disease
1.3.10.2.8.1.1. Placental abruption, association with
1.3.10.3. Male reproductive system disease
1.3.10.3.1. Male infertility
1.3.10.3.1.1. Azoospermia
1.3.10.3.1.1.1. Azoospermia by meiotic arrest, association with
1.3.10.3.1.1.2. Azoospermia, non-obstructive
1.3.10.3.1.1.3. Azoospermia, non-obstructive, increased risk
1.3.10.3.1.1.4. Non-obstructive azoospermia
1.3.10.3.1.2. Congenital absence of vas deferens
1.3.10.3.1.3. D-bifunctional protein deficiency with male infertility
1.3.10.3.1.4. Globozoospermia
1.3.10.3.1.5. Infertility, male
1.3.10.3.1.6. Infertility, male, association with
1.3.10.3.1.7. Male factor infertility, association with
1.3.10.3.1.8. Male infertility, association with
1.3.10.3.1.9. Oligoasthenozoospermia, increased risk
1.3.10.3.1.10. Oligozoospermia
1.3.10.3.1.11. Spermatogenic failure, association with
1.3.11. Respiratory system disease
1.3.11.1. Acute respiratory distress syndrome, association with
1.3.11.2. Asthma and hay fever
1.3.11.3. Lower respiratory tract disease
1.3.11.3.1. Asthma or chronic obstructive pulmonary disease
1.3.11.3.2. Chronic bronchitis and chronic obstructive pulmonary disease
1.3.11.3.3. Bronchial disease
1.3.11.3.3.1. Asthma
1.3.11.3.3.1.1. Asthma and atopy, association with
1.3.11.3.3.1.2. Asthma severity in males, association with
1.3.11.3.3.1.3. Asthma, aspirin-induced, association with
1.3.11.3.3.1.4. Asthma, aspirin-intolerant
1.3.11.3.3.1.5. Asthma, aspirin-intolerant, association with
1.3.11.3.3.1.6. Asthma, asprin-intolerant, association with
1.3.11.3.3.1.7. Asthma, association with
1.3.11.3.3.1.8. Asthma, atopic, association with
1.3.11.3.3.1.9. Asthma, bronchial, association with
1.3.11.3.3.1.10. Asthma, in European Americans, association with
1.3.11.3.3.1.11. Asthma, increased risk, association with
1.3.11.3.3.1.12. Asthma, nocturnal, association with
1.3.11.3.3.1.13. Asthma, non-allergic, association with
1.3.11.3.3.1.14. Asthma, severe
1.3.11.3.3.1.15. Asthma, severe, association with
1.3.11.3.3.1.16. Asthma, severe, in African Americans, association with
1.3.11.3.3.1.17. Asthma, susceptibility to, association with
1.3.11.3.3.1.18. Asthma childhood onset
1.3.11.3.3.1.19. Asthma toluene diisocyanate-induced
1.3.11.3.3.1.20. Atopic asthma, association with
1.3.11.3.3.1.21. Diisocyanate-induced asthma
1.3.11.3.3.1.22. Asthma sex interaction
1.3.11.3.3.1.23. Adult asthma, association with
1.3.11.3.3.1.24. Bronchial asthma, association with
1.3.11.3.3.1.25. Bronchial asthma, severity, association with
1.3.11.3.3.1.26. Bronchiectasis
1.3.11.3.3.1.27. Childhood asthma, association with
1.3.11.3.3.1.28. Reduced serum total IgE in atopic asthma, association with
1.3.11.3.3.2. Chronic bronchitis in chronic obstructive pulmonary disease
1.3.11.3.4. Lung disease
1.3.11.3.4.1. Acute lung injury
1.3.11.3.4.1.1. Acute lung injury, in major trauma, association with
1.3.11.3.4.1.2. Acute lung injury, in sepsis, association with
1.3.11.3.4.1.3. Transfusion-related acute lung injury
1.3.11.3.4.2. Bronchopulmonary dysplasia
1.3.11.3.4.3. Diffuse parenchymal lung disease
1.3.11.3.4.4. Inflammatory lung disease, association with
1.3.11.3.4.5. Fatal surfactant deficiency
1.3.11.3.4.6. Interstitial lung disease
1.3.11.3.4.6.1. Lung disease, interstitial
1.3.11.3.4.6.2. Pneumoconiosis
1.3.11.3.4.6.2.1. Beryllium disease, chronic
1.3.11.3.4.6.3. Pulmonary fibrosis
1.3.11.3.4.6.3.1. Pulmonary fibrosis, association with
1.3.11.3.4.7. Lung disease severity, in cystic fibrosis, association with
1.3.11.3.4.8. Obstructive lung disease
1.3.11.3.4.8.1. Chronic obstructive pulmonary disease
1.3.11.3.4.8.1.1. Chronic obstructive pulmonary disease severe
1.3.11.3.4.8.1.2. Chronic obstructive pulmonary disease moderate to severe
1.3.11.3.4.8.1.3. Chronic obstructive pulmonary disease, in smokers, association with
1.3.11.3.4.8.1.4. Pulmonary emphysema
1.3.11.3.4.8.1.4.1. Pulmonary emphysema, association with
1.3.11.3.4.9. Pneumonia
1.3.11.3.4.9.1. Idiopathic pulmonary fibrosis
1.3.11.3.4.9.2. Idiopathic pulmonary fibrosis, association with
1.3.11.3.4.10. Increased risk of relapsing pneumonia, association with
1.3.11.3.4.11. Reduced pulmonary function, in cystic fibrosis, association with
1.3.11.3.4.12. Respiratory failure
1.3.11.3.4.12.1. Neonatal respiratory distress syndrome, assoc with
1.3.11.4. Perinatal respiratory disease, association with
1.3.11.5. Respiratory disease, aspirin-exacerbated
1.3.11.6. Respiratory disease, aspirin-exacerbated, association with
1.3.11.7. Upper respiratory tract disease
1.3.11.7.1. Congenital high airways obstruction syndrome
1.3.11.7.2. Nose disease
1.3.11.7.2.1. Rhinitis
1.3.11.7.2.1.1. Allergic rhinitis
1.3.11.7.2.1.2. Allergic rhinitis in non-asthmatics
1.3.11.7.2.1.3. IgE grass sensitization
1.3.12. Thoracic disease
1.3.12.1. Breast disease
1.3.12.1.1. Benign breast disease, association with
1.3.13. Urinary system disease
1.3.13.1. Bladder disease, non-syndromic
1.3.13.2. Congenital anomalies of the kidney and urinary tract/CAKUT in VACTERL
1.3.13.3. Corticosterone methyl oxidase deficiency
1.3.13.4. Kidney and urinary tract abnormalities (CAKUT)
1.3.13.5. Kidney disease
1.3.13.5.1. Albuminuria
1.3.13.5.2. Aldosterone synthase deficiency, type 1
1.3.13.5.3. Chronic kidney disease
1.3.13.5.4. Kidney failure
1.3.13.5.4.1.1. Chronic kidney disease, in individuals with low triglycerides, association
1.3.13.5.5. Haematuria
1.3.13.5.5.1. Benign haematuria
1.3.13.5.5.2. Macroscopic haematuria with microhaematuria
1.3.13.5.6. Hyperoxaluria
1.3.13.5.7. Hyperoxaluria, association with
1.3.13.5.8. Hyperoxaluria, primary type III
1.3.13.5.9. Impaired renal function disease
1.3.13.5.9.1. Hypophosphataemic nephrolithiasis/osteoporosis 1/Fanconi syndrome
1.3.13.5.10. Kidney stones
1.3.13.5.11. Nephrotic syndrome acquired
1.3.13.5.12. Calcium nephrolithiasis with renal phosphate leak, association with
1.3.13.5.13. Calcium nephrolithiasis, association with
1.3.13.5.14. CFHR5 nephropathy, modifier of
1.3.13.5.15. Diabetic kidney disease
1.3.13.5.15.1. Diabetic nephropathy, association with
1.3.13.5.15.2. Diabetic nephropathy in type 1 diabetes
1.3.13.5.15.3. Type 1 diabetes nephropathy
1.3.13.5.15.4. Type 2 diabetes nephropathy
1.3.13.5.16. Nephritis
1.3.13.5.16.1. Idiopathic membranous nephropathy
1.3.13.5.16.2. Glomerulonephritis
1.3.13.5.16.2.1. IgA nephropathy
1.3.13.5.16.2.2. IgA nephropathy, association with
1.3.13.5.16.2.3. Immunoglobulin A nephropathy, association with
1.3.13.5.16.2.4. Immunoglobulin A nephropathy, increased risk, association
1.3.13.5.16.2.5. Glomerulosclerosis
1.3.13.5.16.2.5.1. Glomerulosclerosis, focal segmental
1.3.13.5.16.2.5.2. Focal segmental glomerulosclerosis
1.3.13.5.16.2.5.3. Focal segmental glomerulosclerosis, association with
1.3.13.5.16.2.6. Lupus nephritis in systemic lupus erythematosus
1.3.13.5.16.2.7. Membranous nephropathy, association with
1.3.13.5.16.2.8. Refractory lupus nephritis
1.3.13.5.16.3. Membranoproliferative glomerulonephritis
1.3.13.5.16.4. Membranoproliferative glomerulonephritis, association
1.3.13.5.16.5. Membranoproliferative glomerulonephritis, association with
1.3.13.5.17. Nephrolithiasis, association with
1.3.13.5.18. Nephrosis
1.3.13.5.18.1. Nephrotic syndrome
1.3.13.5.18.1.1. Nephrotic syndrome, steroid resistant
1.3.13.5.18.1.2. Nephrotic syndrome, tubular ectasia and haematuria
1.3.13.5.19. Proteinuria
1.3.13.5.19.1. Proteinuria in type 2 diabetes, association with
1.3.13.5.20. Pyelitis
1.3.13.5.20.1. Pyelonephritis
1.3.13.5.20.1.1. Acute pyelonephritis, association with
1.3.13.5.20.1.2. Acute pyelonephritis, in children, association with
1.3.13.5.21. Reduced newborn kidney size and function, association
1.3.13.5.22. Renal agenesis
1.3.13.5.23. Renal function in diabetes, association with
1.3.13.5.24. Renal hypodysplasia
1.3.13.5.25. Renal hypodysplasia, ureteropelvic junction obstruction & vesicoureteral reflux
1.3.13.5.26. Renal hypouricaemia
1.3.13.5.27. Renal tubular transport disease
1.3.13.5.27.1. Bartter syndrome
1.3.13.5.27.2. Distal renal tubular acidosis, autosomal recessive
1.3.13.5.27.3. Gitelman syndrome
1.3.13.5.27.4. Hyperkalaemic hypertension
1.3.13.5.27.5. Renal glucosuria
1.3.13.5.28. Uric acid nephrolithiasis, association with
1.3.13.5.29. Uromodulin-associated kidney disease
1.3.13.6. Ureteral disease
1.3.13.6.1. Vesicoureteral reflux
1.3.13.7. Urinary tract obstruction
1.3.13.7.1. Ureteropelvic junction obstruction / renal hypodysplasia
1.3.14. Disease across anatomical entity
1.3.14.1. Celiac disease or Rheumatoid arthritis
1.3.14.2. Crohns disease and celiac disease
1.3.14.3. Crohns disease and psoriasis
1.3.14.4. Crohns disease and sarcoidosis combined
1.4. Disease of cellular proliferation
1.4.1. Benign neoplasm
1.4.1.1. Cell type benign neoplasm
1.4.1.1.1. Fibrosis progression in hepatitis C infection
1.4.1.1.2. Fibrosis risk, association with
1.4.1.1.3. Hemangioma
1.4.1.1.3.1. Capillary malformation-arteriovenous malformation
1.4.1.1.3.2. Central nervous system hemangioma
1.4.1.1.3.2.1. Cerebral cavernous malformations
1.4.1.1.3.3. Haemangioma, infantile, association with
1.4.1.1.3.4. Hemangioblastoma
1.4.1.1.3.4.1. Hemangioblastoma in VHL, association with
1.4.1.1.3.4.2. Von Hippel-Lindau syndrome
1.4.1.1.4. Lipoma
1.4.1.1.4.1. Lipoma of other skin and subcutaneous tissue
1.4.1.1.5. Phaeochromocytoma
1.4.1.2. Organ system benign neoplasm
1.4.1.2.1. Endocrine organ benign neoplasm
1.4.1.2.1.1. Adenoma of hypophisis
1.4.1.2.1.2. Pituitary adenoma
1.4.1.2.1.2.1. Pituitary adenoma, susceptibility to
1.4.1.2.1.3. Sporadic pituitary adenoma
1.4.1.2.2. Gastrointestinal system benign neoplasm
1.4.1.2.2.1. Intestinal benign neoplasm
1.4.1.2.2.1.1. Colorectal adenoma
1.4.1.2.2.1.1.1. Advanced distal colorectal adenoma, increased risk, association
1.4.1.2.2.1.1.2. Colorectal adenoma, association with
1.4.1.2.2.1.1.3. Colorectal adenoma, increased risk, association with
1.4.1.2.2.1.1.4. Colorectal adenoma, risk, association with
1.4.1.2.3. Integumentary organ benign neoplasm
1.4.1.2.3.1. Skin
1.4.1.2.3.1.1. Cutaneous nevi
1.4.1.2.4. Musculoskeletal system benign neoplasm
1.4.1.2.4.1. Connective tissue benign neoplasm
1.4.1.2.4.1.1. Bone benign neoplasm
1.4.1.2.4.1.1.1. Multiple osteochondromas
1.4.1.2.5. Reproductive organ benign neoplasm
1.4.1.2.5.1. Female reproductive organ benign neoplasm
1.4.1.2.5.1.1. Uterine benign neoplasm
1.4.1.2.5.1.1.1. Uterine fibroids
1.4.1.2.6. Thoracic benign neoplasm
1.4.1.2.6.1. Breast benign neoplasm
1.4.1.2.6.1.1. Benign breast tumours, association with
1.4.2. Cancer
1.4.2.1. Cancer risk
1.4.2.1.1. Cancer susceptibility, association with
1.4.2.1.2. Cancer suseptibility, association with
1.4.2.1.3. Cancer, accelerated progression, association with
1.4.2.1.4. Cancer, association with
1.4.2.1.5. Cancer, increased risk
1.4.2.1.6. Cancer, predisposition to
1.4.2.1.7. Cancer, risk, association with
1.4.2.1.8. Cancer, susceptibility to
1.4.2.2. Cell type cancer
1.4.2.2.1. Germ cell cancer
1.4.2.2.1.1. Germ cell and embryonal cancer
1.4.2.2.1.1.1. Trophoblastic neoplasm
1.4.2.2.1.1.1.1. Hydatidiform mole
1.4.2.2.1.1.1.2. Hydatidiform mole, association with
1.4.2.2.2. Germ cell tumor
1.4.2.2.2.1. Advanced germ cell tumors, association with
1.4.2.2.2.2. Neuroectodermal tumours, association with
1.4.2.2.2.3. Seminoma
1.4.2.2.3. Malignant glioma
1.4.2.2.3.1. Astrocytoma
1.4.2.2.3.1.1. Glioblastoma multiforme, association with ?
1.4.2.2.3.1.2. Glioblastoma, risk, association with
1.4.2.2.3.2. Oligodendroglioma
1.4.2.2.3.2.1. Oligodendroglioma development, association with
1.4.2.2.4. Melanoma
1.4.2.2.4.1. Malignant melanoma, association with
1.4.2.2.4.2. Melanoma / renal cell carcinoma, predisposition to
1.4.2.2.4.3. Melanoma, association with
1.4.2.2.4.4. Melanoma, increased risk, association with
1.4.2.2.4.5. Melanoma, susceptibility, association with
1.4.2.2.5. Carcinoma
1.4.2.2.5.1. Squamous cell carcinoma
1.4.2.2.5.1.1. Multiple self-healing squamous epithelioma, modifer of
1.4.2.2.5.1.2. Squamous cell carcinoma, association with
1.4.2.2.5.1.3. Squamous cell carcinoma, increased risk, association
1.4.2.2.5.1.4. Adenocarcinoma/squamous cell carcinoma, association with
1.4.2.3. Organ system cancer
1.4.2.3.1. Aerodigestive tract
1.4.2.3.1.1. Upper aerodigestive tract cancer, association with
1.4.2.3.1.2. Upper aerodigestive tract cancer, increased risk
1.4.2.3.2. Breast or lung cancer, association with
1.4.2.3.3. Breast or prostate cancer, increased risk
1.4.2.3.4. Colon, liver and lung cancer, increased risk, association with
1.4.2.3.5. Colorectal and prostate cancer, association with
1.4.2.3.6. Multiple sessile serrated adenoma
1.4.2.3.7. Multiple cancers lung cancer, gastric cancer, and squamous cell carcinoma
1.4.2.3.8. Upper aerodigestive tract cancers
1.4.2.3.9. Endocrine gland cancer
1.4.2.3.9.1. Pancreatic cancer
1.4.2.3.9.1.1. Pancreatic cancer, increased risk, association with
1.4.2.3.9.1.2. Pacreatic cancer, clinical outcome, association with
1.4.2.3.9.2. Thyroid cancer
1.4.2.3.9.2.1. Thyroid cancer Papillary, radiation-related
1.4.2.3.9.2.2. Thyroid cancer susceptibility, association with
1.4.2.3.9.2.3. Thyroid cancer, association with
1.4.2.3.9.2.4. Thyroid cancer, increased risk, association with
1.4.2.3.9.2.5. Thyroid cancer, risk, association with
1.4.2.3.9.2.6. Thyroid carcinoma
1.4.2.3.9.2.6.1. Thyroid carcinoma, increased risk
1.4.2.3.9.2.6.2. Thyroid carcinoma, association with
1.4.2.3.9.2.6.3. Follicular thyroid carcinoma
1.4.2.3.9.2.6.3.1. Differentiated thyroid carcinoma, association with
1.4.2.3.9.2.6.3.2. Thyroid carcinoma, follicular, lower risk, association
1.4.2.3.9.2.6.3.3. Thyroid carcinoma, medullary
1.4.2.3.9.2.6.4. Oncocytic thyroid carcinoma
1.4.2.3.9.2.6.5. Papillary thyroid carcinoma
1.4.2.3.9.2.7. Tumour size, reduced, in papillary thyorid carcinoma, association with
1.4.2.3.10. Gastrointestinal system cancer
1.4.2.3.10.1. Esophageal cancer
1.4.2.3.10.1.1. Esophageal cancer, risk, association with
1.4.2.3.10.1.2. Oesophageal cancer, association with
1.4.2.3.10.1.3. Oesophageal cancer, risk, association with
1.4.2.3.10.1.4. Esophageal squamous cell carcinoma
1.4.2.3.10.1.4.1. Esophageal squamous cell carcinoma, increased risk
1.4.2.3.10.1.4.2. Oesophageal squamous cell carcinoma, increased risk
1.4.2.3.10.1.4.3. Esophageal squamous cell carcinoma, survival, association with
1.4.2.3.10.2. Gallbladder cancer
1.4.2.3.10.3. Helicobacter pylori-induced duodenal ulcer and gastritis, association
1.4.2.3.10.4. Helicobacter pylori-related gastric carcinoma, association with
1.4.2.3.10.5. Intestinal cancer
1.4.2.3.10.5.1. Large intestine cancer
1.4.2.3.10.5.1.1. Colon cancer
1.4.2.3.10.5.1.1.1. Colon cancer, association with
1.4.2.3.10.5.1.1.2. Colon cancer, increased risk, association with
1.4.2.3.10.5.1.1.3. Colon polyposis and cancer, association with
1.4.2.3.10.5.1.1.4. Proximal colon cancer, increased risk, association with
1.4.2.3.10.5.1.2. Colorectal cancer
1.4.2.3.10.5.1.2.1. Colorectal cancer risk, microsatellite-stable, association with
1.4.2.3.10.5.1.2.2. Colorectal cancer, age of onset, association with
1.4.2.3.10.5.1.2.3. Colorectal cancer, association with
1.4.2.3.10.5.1.2.4. Colorectal cancer, improved survival, association with
1.4.2.3.10.5.1.2.5. Colorectal cancer, increased risk
1.4.2.3.10.5.1.2.6. Colorectal cancer, increased risk, association with
1.4.2.3.10.5.1.2.7. Colorectal cancer, late-onset, association with
1.4.2.3.10.5.1.2.8. Colorectal cancer, non-polyposis
1.4.2.3.10.5.1.2.9. Colorectal cancer, predisposition to, association
1.4.2.3.10.5.1.2.10. Colorectal cancer, predisposition, association
1.4.2.3.10.5.1.2.11. Colorectal cancer, risk, association with
1.4.2.3.10.5.1.2.12. Colorectal cancer, survival, association with
1.4.2.3.10.5.1.2.13. Colorectal cancer, susceptibility to
1.4.2.3.10.5.1.2.14. Familial colorectal cancer, type X
1.4.2.3.10.5.1.2.15. Familial colorectal cancer, type X, increased risk
1.4.2.3.10.5.1.2.16. Rectal cancer risk, association with
1.4.2.3.10.5.1.2.17. Rectal cancer, association with
1.4.2.3.10.5.1.2.18. Rectal cancer, increased risk
1.4.2.3.10.5.1.3. Colorectal cancer calcium intake interaction
1.4.2.3.10.5.1.4. Colorectal cancer diet interaction
1.4.2.3.10.6. Liver cancer
1.4.2.3.10.6.1. Hepatocellular carcinoma
1.4.2.3.10.6.2. Hepatocellular carcinoma hepatitis B virus related
1.4.2.3.10.6.3. Hepatocellular carcinoma, association with
1.4.2.3.10.6.4. Hepatocellular carcinoma, HCV-related, increased risk
1.4.2.3.10.6.5. Hepatocellular carcinoma, in hepatitis C--infected patients, association with
1.4.2.3.10.6.6. Hepatocellular carcinoma, increased risk, association with
1.4.2.3.10.7. Oral cavity cancer
1.4.2.3.10.7.1. Oral cancer in light smokers, association with
1.4.2.3.10.7.2. Oral cancer, association with
1.4.2.3.10.7.3. Oral squamous cell carcinoma, increased risk
1.4.2.3.10.8. Pharynx cancer
1.4.2.3.10.8.1. Hypopharynx cancer
1.4.2.3.10.8.1.1. Oesophageal tumours
1.4.2.3.10.8.2. Nasopharyngeal carcinoma
1.4.2.3.10.8.3. Nasopharyngeal carcinoma, association with
1.4.2.3.10.8.4. Nasopharyngeal carcinoma, increased risk, association with
1.4.2.3.10.8.5. Orolaryngeal carcinoma, risk, association with
1.4.2.3.10.9. Stomach cancer
1.4.2.3.10.9.1. Gastric cancer
1.4.2.3.10.9.1.1. Gastric cancer, association with
1.4.2.3.10.9.1.2. Gastric cancer, early-onset, diffuse, association with
1.4.2.3.10.9.1.3. Gastric cancer, increased risk, association with
1.4.2.3.10.9.1.4. Gastric cancer, intestinal type, association with
1.4.2.3.10.9.1.5. Gastric cancer, non-cardia, increased risk
1.4.2.3.10.9.1.6. Gastric cancer, predisposition to
1.4.2.3.10.9.1.7. Gastric cancer, susceptibility to
1.4.2.3.10.9.1.8. Gastric cancer/ulcer, increased risk, association with
1.4.2.3.10.9.2. Cardia gastric cancer
1.4.2.3.10.9.3. Non-cardia gastric cancer
1.4.2.3.10.9.4. Stomach carcinoma
1.4.2.3.10.9.4.1. Gastric adenocarcinoma histologically verified
1.4.2.3.10.9.4.2. Gastric adenocarcinoma and oesophageal SCC, association with
1.4.2.3.10.9.4.3. Gastric adenocarcinoma, increased risk
1.4.2.3.11. Head and neck cancer
1.4.2.3.11.1. Head and neck cancer, association with
1.4.2.3.11.2. Head and neck cancer, increased risk
1.4.2.3.11.3. Head and neck cancer, modifer of
1.4.2.3.11.4. Head and neck cancer, second primary tumour, association
1.4.2.3.11.5. Head and neck carcinoma
1.4.2.3.11.5.1. Head and neck squamous cell carcinoma
1.4.2.3.11.5.1.1. Squamous cell carcinoma of head & neck, association with
1.4.2.3.11.5.1.2. Squamous cell carcinoma of the head and neck, increased risk
1.4.2.3.12. Immune system cancer
1.4.2.3.12.1. Hematologic cancer
1.4.2.3.12.1.1. Bone marrow cancer
1.4.2.3.12.1.1.1. Myelodysplastic syndrome, association with
1.4.2.3.12.1.1.2. Myeloid neoplasm
1.4.2.3.12.1.1.2.1. Multiple myeloma
1.4.2.3.12.1.1.2.2. Multiple myeloma and monoclonal gammopathy
1.4.2.3.12.1.1.2.3. Multiple myeloma hyperdiploidy
1.4.2.3.12.1.1.2.4. Multiple myeloma IgH translocation
1.4.2.3.12.1.1.2.5. Multiple myeloma, association with
1.4.2.3.12.1.1.2.6. Multiple myeloma, increased risk
1.4.2.3.12.1.1.2.7. Myeloproliferative neoplasms
1.4.2.3.12.1.2. Leukemia
1.4.2.3.12.1.2.1. Leukaemia risk, association with
1.4.2.3.12.1.2.2. Leukaemia, association with
1.4.2.3.12.1.2.3. Leukaemia, myelodysplastic syndrome, melanoma, association with
1.4.2.3.12.1.2.4. Leukaemia, risk , association with
1.4.2.3.12.1.2.5. Leukaemia, risk, association with
1.4.2.3.12.1.2.6. Leukoaraiosis, association with
1.4.2.3.12.1.2.7. Lymphoblastic leukemia
1.4.2.3.12.1.2.7.1. Acute lymphocytic leukemia
1.4.2.3.12.1.2.7.2. Acute lymphoblastic leukemia childhood
1.4.2.3.12.1.2.7.3. Acute lymphoblastic leukemia adolescents and young adults
1.4.2.3.12.1.2.7.4. Acute lymphoblastic leukemia B-cell precursor
1.4.2.3.12.1.2.7.5. Acute lymphoblastic leukaemia
1.4.2.3.12.1.2.7.6. Acute lymphoblastic leukaemia, association with
1.4.2.3.12.1.2.7.7. Acute lymphoblastic leukaemia, in males, association with
1.4.2.3.12.1.2.7.8. Childhood acute lymphoblastic leukaemia, association with
1.4.2.3.12.1.2.7.9. Chronic lymphocytic leukemia
1.4.2.3.12.1.2.7.10. Chronic lymphocytic leukaemia
1.4.2.3.12.1.2.7.11. Chronic lymphocytic leukaemia risk, association with
1.4.2.3.12.1.2.7.12. Chronic lymphocytic leukaemia, association with
1.4.2.3.12.1.2.7.13. Chronic lymphocytic leukaemia, susceptibility to
1.4.2.3.12.1.2.7.14. Disease progression in chronic lymphocytic leukaemia, association with
1.4.2.3.12.1.2.7.15. Lymphocytic leukaemia, risk, association with
1.4.2.3.12.1.2.7.16. Reduced event-free survival, in acute lymphoblastic leukaemia, association with
1.4.2.3.12.1.2.7.17. Richter syndrome, increased risk, association with
1.4.2.3.12.1.2.8. Myeloid leukemia
1.4.2.3.12.1.2.8.1. Chronic myeloid leukemia
1.4.2.3.12.1.2.8.2. Chronic myelogenous leukaemia, association with
1.4.2.3.12.1.2.8.3. Acute myeloid leukaemia, association with
1.4.2.3.12.1.2.8.4. Acute myeloid leukaemia, increased risk, association with
1.4.2.3.12.1.2.8.5. Acute myeloid leukaemia, relapse, increased risk
1.4.2.3.12.1.2.8.6. Myeloid leukaemia, increased risk, association with
1.4.2.3.12.1.3. Lymphoma
1.4.2.3.12.1.3.1. Lymphoma, increased risk, association with
1.4.2.3.12.1.3.2. Hodgkins lymphoma
1.4.2.3.12.1.3.3. Hodgkin lymphoma, association with
1.4.2.3.12.1.3.4. Non-Hodgkin lymphoma
1.4.2.3.12.1.3.4.1. B cell non-Hodgkin lymphoma
1.4.2.3.12.1.3.4.2. Diffuse large B cell lymphoma
1.4.2.3.12.1.3.4.3. Diffuse large B-cell lymphoma, association
1.4.2.3.12.1.3.4.4. Follicular lymphoma, association with
1.4.2.3.12.1.3.4.5. Follicular lymphoma
1.4.2.3.12.1.3.4.6. Macroglobulinaemia, Waldenstrom's, association with
1.4.2.3.12.1.3.4.7. Marginal zone lymphoma
1.4.2.3.12.1.3.4.8. Non-Hodgkin lymphoma, increased risk, association with
1.4.2.3.12.1.3.5. Primary gastric diffuse large B-cell lymphoma, association
1.4.2.3.13. Integumentary system cancer
1.4.2.3.13.1. Skin cancer
1.4.2.3.13.1.1. Skin cancer, association with
1.4.2.3.13.1.2. Non-melanoma skin cancer
1.4.2.3.13.1.3. Basal cell carcinoma
1.4.2.3.13.1.3.1. Basal cell carcinoma, increased risk, association with
1.4.2.3.13.1.4. Cutaneous melanoma
1.4.2.3.13.1.4.1. Cutaneous malignant melanoma
1.4.2.3.13.1.4.2. Cutaneous melanoma, susceptibility to, association with
1.4.2.3.13.1.5. Acral melanoma, increased risk, association with
1.4.2.3.14. Musculoskeletal system cancer
1.4.2.3.14.1. Connective tissue cancer
1.4.2.3.14.1.1. Bone cancer
1.4.2.3.14.1.1.1. Ewing sarcoma, susceptibility to 
1.4.2.3.14.1.1.2. Notochordal cancer
1.4.2.3.14.1.1.2.1. Chordoma, increased risk
1.4.2.3.14.1.1.3. Osteosarcoma 
1.4.2.3.14.2. Muscle cancer
1.4.2.3.14.2.1. Skeletal muscle cancer
1.4.2.3.14.2.1.1. Rhabdomyosarcoma
1.4.2.3.15. Nervous system cancer
1.4.2.3.15.1. Central nervous system cancer
1.4.2.3.15.1.1. Glioma
1.4.2.3.15.1.2. Glioma high-grade
1.4.2.3.15.1.3. Glioma, adult-onset, association with
1.4.2.3.15.1.4. Glioma, increased risk, association with
1.4.2.3.15.1.5. Glioblastoma
1.4.2.3.15.1.6. Meningioma
1.4.2.3.15.2. Peripheral nervous system neoplasm
1.4.2.3.15.2.1. Autonomic nervous system neoplasm
1.4.2.3.15.2.1.1. Neuroblastoma
1.4.2.3.15.2.1.2. Neuroblastoma high-risk
1.4.2.3.15.3. Sensory system cancer
1.4.2.3.15.3.1. Ocular cancer
1.4.2.3.15.3.1.1. Retinal cancer
1.4.2.3.15.3.1.1.1. Retinoblastoma
1.4.2.3.15.3.1.1.2. Retinoblastoma, increased risk
1.4.2.3.16. Reproductive organ cancer
1.4.2.3.16.1. Female reproductive organ cancer
1.4.2.3.16.1.1. Breast and ovarian cancer, increased risk
1.4.2.3.16.1.2. Breast and/or ovarian cancer
1.4.2.3.16.1.3. Breast and/or ovarian cancer, association with
1.4.2.3.16.1.4. Breast and/or ovarian cancer, increased risk, association with
1.4.2.3.16.1.5. Cervical cancer
1.4.2.3.16.1.5.1. Cervical cancer, increased risk, association with
1.4.2.3.16.1.5.2. Cervical cancer, papilloma virus related, association with
1.4.2.3.16.1.5.3. Cervical carcinoma
1.4.2.3.16.1.5.3.1. Cervical carcinoma, association with
1.4.2.3.16.1.5.3.2. Cervical carcinoma, increased risk, association with
1.4.2.3.16.1.6. Endometriosis
1.4.2.3.16.1.6.1. Endometriosis, association with
1.4.2.3.16.1.6.2. Endometriosis, increased risk
1.4.2.3.16.1.7. Ovarian cancer
1.4.2.3.16.1.7.1. Ovarian cancer in BRCA1 mutation carriers
1.4.2.3.16.1.7.2. Epithelial ovarian cancer, increased risk, association
1.4.2.3.16.1.7.3. Ovarian cancer susceptibility, association with
1.4.2.3.16.1.7.4. Ovarian cancer, association with
1.4.2.3.16.1.7.5. Ovarian cancer, epithelial, increased risk
1.4.2.3.16.1.7.6. Ovarian cancer, increased risk in BRCA1 carriers, association
1.4.2.3.16.1.7.7. Ovarian cancer, increased risk, association with
1.4.2.3.16.1.7.8. Ovarian cancer, poor survival, association with
1.4.2.3.16.1.7.9. Ovarian cancer, relapse, increased risk
1.4.2.3.16.1.7.10. Ovarian cancer, risk, association with
1.4.2.3.16.1.7.11. Ovarian cancer, susceptibility to
1.4.2.3.16.1.8. Uterine caner
1.4.2.3.16.1.8.1. Endometrial cancer
1.4.2.3.16.1.8.1.1. Endometrial cancer
1.4.2.3.16.1.8.1.2. Endometrial cancer risk, association with
1.4.2.3.16.1.8.1.3. Endometrial cancer, association with
1.4.2.3.16.1.8.1.4. Endometrial cancer, increased risk
1.4.2.3.16.1.8.1.5. Endometrial cancer, increased risk, association
1.4.2.3.16.1.8.1.6. Uterine endometrial cancer, association with
1.4.2.3.16.2. Male reproductive organ cancer
1.4.2.3.16.2.1. Prostate cancer
1.4.2.3.16.2.1.1. Breast or prostate cancer
1.4.2.3.16.2.1.2. Prostate cancer early onset
1.4.2.3.16.2.1.3. Prostate cancer
1.4.2.3.16.2.1.4. Prostate cancer aggressiveness
1.4.2.3.16.2.1.5. Prostate cancer aggressiveness, association with
1.4.2.3.16.2.1.6. Prostate cancer risk, association with
1.4.2.3.16.2.1.7. Prostate cancer, aggressive early-onset, association with
1.4.2.3.16.2.1.8. Prostate cancer, association with
1.4.2.3.16.2.1.9. Prostate cancer, higher grade, association  with
1.4.2.3.16.2.1.10. Prostate cancer, increased risk
1.4.2.3.16.2.1.11. Prostate cancer, increased risk, association with
1.4.2.3.16.2.1.12. Prostate cancer, risk, association with
1.4.2.3.16.2.1.13. Prostate cancer, susceptibility to
1.4.2.3.16.2.1.14. Prostate cancer, susceptibility, association with
1.4.2.3.16.2.1.15. Prostrate cancer, increased risk
1.4.2.3.16.2.2. Testicular cancer
1.4.2.3.16.2.2.1. Testicular cancer
1.4.2.3.16.2.2.2. Testicular germ cell cancer
1.4.2.3.16.2.2.3. Testicular germ cell tumor
1.4.2.3.16.2.2.4. Testicular germ cell tumour
1.4.2.3.17. Respiratory system cancer
1.4.2.3.17.1. Lung cancer
1.4.2.3.17.1.1. Increased lung cancer risk, association with
1.4.2.3.17.1.2. Lung adenocarcinoma
1.4.2.3.17.1.3. Lung cancer asbestos exposure interaction
1.4.2.3.17.1.4. Lung Cancer DNA repair capacity
1.4.2.3.17.1.5. Lung cancer smoking interaction
1.4.2.3.17.1.6. Lung cancer, association with
1.4.2.3.17.1.7. Lung cancer, increased risk in females, non-smokers and non-drinkers
1.4.2.3.17.1.8. Lung cancer, increased risk, association with
1.4.2.3.17.1.9. Lung cancer, risk, association with
1.4.2.3.17.1.10. Lung cancer, smoking induced, association with
1.4.2.3.17.1.11. Lung cancer, suceptibility association with
1.4.2.3.17.1.12. Lung cancer, susceptibility to in never smokers, association with
1.4.2.3.17.1.13. Lung cancer, susceptibility to, association with
1.4.2.3.17.1.14. Lung cancer, susceptibility, association with
1.4.2.3.17.1.15. Lung carcinoma
1.4.2.3.17.1.15.1. Lung adenocarcinoma, association with
1.4.2.3.17.1.15.2. Lung adenocarcinoma, increased risk, association with
1.4.2.3.17.1.15.3. Lung adenocarcinoma, risk, association with
1.4.2.3.17.1.15.4. Lung adenocarcinoma, susceptibility to, association with
1.4.2.3.17.1.15.5. Non-small cell lung carcinoma
1.4.2.3.17.1.15.5.1. Non-small cell lung cancer
1.4.2.3.17.1.15.5.2. Non-small cell lung cancer recurrence rate
1.4.2.3.17.1.15.5.3. Non-small cell lung cancer, increased risk, association with
1.4.2.3.17.1.15.5.4. Non-small-cell lung cancer, association with
1.4.2.3.17.1.15.5.5. Non-small-cell lung cancer, increased risk, association with
1.4.2.3.17.1.15.6. Lung small cell carcinoma
1.4.2.3.17.1.15.6.1. Small cell lung cancer, increased risk
1.4.2.3.18. Thoracic cancer
1.4.2.3.18.1. Breast cancer
1.4.2.3.18.1.1. Breast cancer progression, association with
1.4.2.3.18.1.2. Breast cancer risk in older women, association
1.4.2.3.18.1.3. Breast cancer risk in radiographers, association with
1.4.2.3.18.1.4. Breast cancer risk, association with
1.4.2.3.18.1.5. Breast cancer, age of onset, association with
1.4.2.3.18.1.6. Breast cancer, association with
1.4.2.3.18.1.7. Breast cancer, bilateral, association with
1.4.2.3.18.1.8. Breast cancer, early-onset, increased risk
1.4.2.3.18.1.9. Breast cancer, ER negative, association with
1.4.2.3.18.1.10. Breast cancer, HER2-positive, increased risk
1.4.2.3.18.1.11. Breast cancer, increased risk
1.4.2.3.18.1.12. Breast cancer, increased risk in BRCA2 carriers, association with
1.4.2.3.18.1.13. Breast cancer, increased risk, association with
1.4.2.3.18.1.14. Breast cancer, increased risk, in African American women, association with
1.4.2.3.18.1.15. Breast cancer, male, association with
1.4.2.3.18.1.16. Breast cancer, non-BRCA1/BRCA2 related
1.4.2.3.18.1.17. Breast cancer, oestrogen receptor-positive, association with
1.4.2.3.18.1.18. Breast cancer, oestrogen-dependence, association with
1.4.2.3.18.1.19. Breast cancer, risk, association with
1.4.2.3.18.1.20. Breast cancer, sporadic, protection against
1.4.2.3.18.1.21. Breast cancer, susceptibility association with
1.4.2.3.18.1.22. Breast cancer, susceptibility to
1.4.2.3.18.1.23. Breast cancer, susceptibility to, association with
1.4.2.3.18.1.24. Breast cancer in BRCA1 mutation carriers
1.4.2.3.18.1.25. Breast cancer estrogen-receptor negative, progesterone-receptor negative, and human epidermal growth factor-receptor negative
1.4.2.3.19. Urinary system cancer
1.4.2.3.19.1. Kidney cancer
1.4.2.3.19.1.1. Renal carcinoma, association with
1.4.2.3.19.1.2. Renal cell carcinoma, association with
1.4.2.3.19.1.3. Renal cell carcinoma, increased risk, association with
1.4.2.3.19.1.4. Renal cell carcinoma
1.4.2.3.19.1.5. Wilms tumor
1.4.2.3.19.2. Urinary bladder cancer
1.4.2.3.19.2.1. Bladder cancer
1.4.2.3.19.2.2. Bladder cancer in benzidine-exposed workers, association with
1.4.2.3.19.2.3. Bladder cancer risk, association with
1.4.2.3.19.2.4. Bladder cancer, association with
1.4.2.3.19.2.5. Bladder cancer, increased risk
1.4.2.3.19.2.6. Bladder cancer, increased risk, association with
1.4.2.3.19.2.7. Bladder cancer, susceptibility to, assoc with
1.4.2.3.19.2.8. Bladder disease, non-syndromic
1.4.2.3.19.2.9. Urinary bladder cancer
1.4.3. Lymphoproliferative disease, fatal
1.4.4. Lymphoproliferative disorder
1.4.5. Metastasis, association with
1.4.6. Neoplastic disease, increased risk, association
1.4.7. Phaeochromocytoma and paraganglioma
1.5. Disease of mental health
1.5.1. Cognitive disorder
1.5.1.1. Preschool internalizing problems
1.5.1.2. Anxiety and major depressive disorder
1.5.1.3. Anxiety and depressive disorder
1.5.1.4. Anxiety disorder
1.5.1.4.1. Obsessive-compulsive disorder, association with
1.5.1.4.2. Post-traumatic stress disorder
1.5.1.4.3. Post-traumatic stress disorder, in females, association with
1.5.1.4.4. Panic disorder, association with
1.5.1.4.5. Panic disorder, in males, association with
1.5.1.4.6. Panic and agoraphobia symptom severity, association
1.5.1.4.7. Anxiety in major depressive disorder
1.5.1.4.8. Anxiety-related traits, gender-dependent
1.5.1.4.9. Hoarding
1.5.1.4.10. Stress disorder
1.5.1.4.10.1. Job-related exhaustion
1.5.1.5. Dementia
1.5.1.5.1. Lewy body disease
1.5.1.5.2. Vascular dementia
1.5.1.5.2.1. Female vascular dementia, association with
1.5.1.6. Impaired cognitive development, association with
1.5.1.7. Impaired cognitive function, association with
1.5.1.8. Peripartum major depression and anxiety, increased risk
1.5.1.9. Mental retardation, in women, association with
1.5.1.10. Schizophrenia plus additional cognitive disorders
1.5.1.10.1. Bipolar disorder and schizophrenia
1.5.1.10.2. Bipolar disorder and schizophrenia, association with
1.5.1.10.3. Bipolar disorder/schizophrenia association with
1.5.1.10.4. Reduced cognitive performance, in schizophrenia, association with
1.5.1.10.5. Schizophrenia & major depressive disorder, association with
1.5.1.10.6. Schizophrenia / bipolar disorder, assoc with
1.5.1.10.7. Schizophrenia, major depressive/bipolar disorder, association with
1.5.1.10.8. Schizophrenia, bipolar disorder and depression combined
1.5.1.11. Mood disorder
1.5.1.11.1. Mood disorder, association with
1.5.1.11.2. Bipolar disorder
1.5.1.11.2.1. Bipolar I disorder
1.5.1.11.2.2. Bipolar disorder mania
1.5.1.11.2.3. Bipolar disorder with mood-incongruent psychosis
1.5.1.11.2.4. Bipolar affective disorder, association with
1.5.1.11.2.5. Bipolar affective disorder, increased risk, assoc with
1.5.1.11.2.6. Bipolar I disorder, association with
1.5.1.11.2.7. Bipolar disorder, age of onset, association with
1.5.1.11.2.8. Bipolar disorder, association with
1.5.1.11.2.9. Bipolar disorder, early-onset, association with
1.5.1.11.2.10. Bipolar disorder, increased risk
1.5.1.11.2.11. Bipolar disorder, increased risk, association with
1.5.1.11.2.12. Mood instability in bipolar disorder patients, association with
1.5.1.11.3. Mental depression
1.5.1.11.3.1. Depression
1.5.1.11.3.2. Depression, ataxia and cardiomyopathy
1.5.1.11.3.3. Depression quantitative trait
1.5.1.11.3.4. Major depressive disorder
1.5.1.11.3.5. Major depressive disorder broad
1.5.1.11.3.6. Major depression
1.5.1.11.3.7. Major depression and suicide, association with
1.5.1.11.3.8. Major depression in women, association with
1.5.1.11.3.9. Major depressive disorder, association with
1.5.1.11.3.10. Major depressive disorder, increased risk
1.5.1.11.3.11. Seasonal affective disorder, association with
1.5.1.12. Psychotic disorder
1.5.1.12.1. Schizoaffective disorder, association with
1.5.1.12.2. Schizophrenia
1.5.1.12.2.1. Cognitive deficit in schizophrenia
1.5.1.12.2.2. Schizophrenia, modifier, association with
1.5.1.12.2.3. Schizophrenia, risk, association with
1.5.1.12.2.4. Schizophrenia, severe, increased risk, association
1.5.1.12.2.5. Schizophrenia in females, association with
1.5.1.12.2.6. Schizophrenia, association with
1.5.1.12.2.7. Schizophrenia, familial, association with
1.5.1.12.2.8. Schizophrenia, in Basques, association with
1.5.1.12.2.9. Schizophrenia, in females, association with
1.5.1.12.2.10. Schizophrenia, increased risk, association with
1.5.1.12.2.11. Schizophrenia negative symptoms
1.5.1.12.2.12. Schizophrenia treatment resistant
1.5.1.12.2.13. Schizophrenia cytomegalovirus infection interaction
1.5.1.12.3. Drug-induced mental disorder
1.5.1.12.3.1. Psychosis methamphetamine induced
1.5.2. Developmental disorder of mental health
1.5.2.1. Pervasive developmental disorder
1.5.2.1.1. Autism
1.5.2.1.1.1. Autism spectrum disorder
1.5.2.1.1.2. Autism spectrum disorder cognitive deficit, association with
1.5.2.1.1.3. Autism spectrum disorder with Van Maldergem syndrome 2
1.5.2.1.1.4. Autism spectrum disorder, association with
1.5.2.1.1.5. Autism spectrum disorder, increased risk
1.5.2.1.1.6. Autism, association with
1.5.2.1.1.7. Autism, increased risk
1.5.2.2. Specific developmental disorder
1.5.2.2.1. Attention deficit hyperactivity disorder
1.5.2.2.1.1. Attention-deficit hyperactivity disorder, association with
1.5.2.2.1.2. Attention deficit hyperactivity disorder combined symptoms
1.5.2.2.1.3. Attention deficit hyperactivity disorder hyperactivity-impulsivity symptoms
1.5.2.2.1.4. Attention deficit hyperactivity disorder inattention symptoms
1.5.2.2.1.5. Attention deficit hyperactivity disorder symptoms interaction
1.5.2.2.1.6. Attention deficit hyperactivity disorder time to onset
1.5.2.2.2. Communication disorder
1.5.2.2.2.1. Speech disorder
1.5.2.2.2.1.1. Articulation disorder
1.5.2.2.2.1.1.1. Stuttering
1.5.2.2.3. Conduct disorder
1.5.2.2.3.1. Conduct disorder interaction
1.5.2.2.3.2. Conduct disorder symptom count
1.5.2.2.4. Attention deficit hyperactivity disorder and conduct disorder
1.5.2.2.5. Eating disorder
1.5.2.2.5.1. Anorexia nervosa/bulimia nervosa
1.5.2.2.5.2. Bulimia nervosa
1.5.2.2.5.3. Anorexia nervosa
1.5.2.2.5.4. Anorexia nervosa, association with
1.5.2.2.5.5. Eating disorders, association with
1.5.2.2.6. Intellectual disability
1.5.2.2.6.1. Intellectual disability and seizures
1.5.2.2.6.2. Intellectual disability, cerebellar taxia
1.5.2.2.6.3. Intellectual disability, epilepsy and behavioural complexities
1.5.2.2.6.4. Intellectual disability, microcephaly, brain stem and cerebellum hypoplasia and delayed myelination
1.5.2.2.6.5. Intellectual disability, microcephaly, cerebellar atrophy
1.5.2.2.6.6. Intellectual disability, nonsyndromic, autosomal recessive
1.5.2.2.6.7. Intellectual disability, seizures, microcephaly
1.5.2.2.7. Language disorder
1.5.2.2.7.1. Aphasia, progressive nonfluent
1.5.2.2.7.2. Childhood apraxia of speech
1.5.2.2.7.3. Parent of origin effect on language impairment paternal
1.5.2.2.7.4. Specific language impairment, increased risk
1.5.2.2.8. Learning disability
1.5.2.2.8.1. Reading disorder
1.5.2.2.8.1.1. Dyslexia, association with
1.5.2.2.9. Tic disorder
1.5.2.2.9.1. Tourette syndrome
1.5.3. Psychiatric disorders, association with
1.5.4. Sexual disorder
1.5.4.1. Sexual dysfunction female
1.5.4.2. Sexual dysfunction SSRISNRI-related
1.5.5. Sleep disorder
1.5.5.1. Excessive daytime sleepiness
1.5.5.2. Hypersomnia HLA-DQB1*06:02 negative
1.5.5.3. Insomnia
1.5.5.4. Insomnia caffeine-induced
1.5.5.5. Late insomnia in major depression, association with
1.5.5.6. Obstructive sleep apnea
1.5.5.7. Narcolepsy
1.5.5.7.1. Narcolepsy age of onset
1.5.5.7.2. Narcolepsy with cataplexy
1.5.5.7.3. Narcolepsy, association with
1.5.6. Substance-related disorder
1.5.6.1. Substance dependence
1.5.6.1.1. Addiction
1.5.6.1.2. Drug addiction, association with
1.5.6.1.3. Drug intake, association with
1.5.6.1.4. Drug/alcohol abuse, association with
1.5.6.1.5. Illicit drug use
1.5.6.1.6. Methamphetamine dependence
1.5.6.1.7. Nicotine dependence
1.5.6.1.8. Nicotine use
1.5.6.1.9. Nicotine dependence risk, association with
1.5.6.1.10. Nicotine dependence, association with
1.5.6.1.11. Opiate addiction, association with
1.5.6.1.12. Opiate-dependence, treatment response, association with
1.5.6.1.13. Opioid dependence, association with
1.5.6.1.14. Opioid sensitivity
1.5.7. Mental health disorder across categories
1.5.7.1. Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia combined
1.5.7.2. Tourettes syndrome or obsessive-compulsive disorder
1.6. Disease of metabolism
1.6.1. Acquired metabolic disease
1.6.1.1. Amyloidosis
1.6.1.1.1. Cerebral amyloid angiopathy
1.6.1.1.1.1. Amyloidosis, primary cutaneous
1.6.1.1.1.2. Amyloidotic polyneuropathy
1.6.1.1.1.3. AA amyloidosis, association with
1.6.1.2. Carbohydrate metabolism disease
1.6.1.2.1. Fucosyltransferase deficiency
1.6.1.2.2. Fucosyltransferase deficiency, partial
1.6.1.2.3. Glucose metabolism disease
1.6.1.2.3.1. Diabetes mellitus
1.6.1.2.3.1.1. Diabetes
1.6.1.2.3.1.2. Diabetes gestational
1.6.1.2.3.1.3. Diabetes in overweight people, association with
1.6.1.2.3.1.4. Diabetes, ketosis-prone, increased risk
1.6.1.2.3.1.5. Diabetes, MODY
1.6.1.2.3.1.6. Diabetes, MODY3
1.6.1.2.3.1.7. Diabetes, NIDDM
1.6.1.2.3.1.8. Diabetes, permanent neonatal
1.6.1.2.3.1.9. Diabetes, suceptibility, association with
1.6.1.2.3.1.10. Gestational hyperglycaemia, association with
1.6.1.2.3.1.11. Insulin resistance syndrome, association with
1.6.1.2.3.1.12. Insulin resistance syndrome, type A
1.6.1.2.3.1.13. Type 1 diabetes
1.6.1.2.3.1.13.1. Diabetes, type 1, association with
1.6.1.2.3.1.13.2. Diabetes, type 1, increased risk, association with
1.6.1.2.3.1.13.3. IDDM, association with
1.6.1.2.3.1.14. Type 2 diabetes
1.6.1.2.3.1.14.1. Diabetes, type 2 risk, association with
1.6.1.2.3.1.14.2. Diabetes, type 2, association with
1.6.1.2.3.1.14.3. Diabetes, type 2, increased risk
1.6.1.2.3.1.14.4. Diabetes, type 2, increased risk, association
1.6.1.2.3.1.14.5. Diabetes, type 2, risk, association with
1.6.1.2.3.1.14.6. Diabetes, type 2, susceptibility to
1.6.1.2.3.1.14.7. Diabetes, type 2, susceptibility to, association
1.6.1.2.3.1.14.8. Diabetes, type 2, susceptibility, association with
1.6.1.2.3.1.14.9. Diabetes, type II,  in middle-aged subjects, association with
1.6.1.2.3.1.14.10. Type 2 diabetes, age of onset, association with
1.6.1.2.3.1.14.11. Type 2 diabetes, association with
1.6.1.2.3.1.14.12. Type 2 diabetes and other traits
1.6.1.2.3.1.14.13. Type 2 diabetes young onset and obesity
1.6.1.2.3.1.15. Cystic fibrosis-related diabetes
1.6.1.2.3.1.16. Resistin levels
1.6.1.2.3.2. Hyperglycemia
1.6.1.2.3.2.1. Glucose / galactose malabsorption
1.6.1.2.3.2.2. Hyperglycinaemia, non-ketotic
1.6.1.2.4. Galactosaemia
1.6.1.2.4.1. Galactosaemia epimerase deficiency
1.6.1.2.4.2. Galactosaemia, Duarte variant
1.6.1.2.5. Glycogen metabolism disorder
1.6.1.2.5.1. Glycogen storage disease
1.6.1.2.5.1.1. Glycogen storage disease 1a
1.6.1.2.5.1.2. Glycogen storage disease 2
1.6.1.2.5.1.3. Glycogen storage disease 3
1.6.1.2.5.1.4. Glycogen storage disease 6
1.6.1.2.5.1.5. Glycogen storage disease 9c
1.6.1.2.5.1.6. Glycogen storage disease, modifier of
1.6.1.2.5.1.7. McArdle disease
1.6.1.2.5.1.8. McArdle disease, modifier of, association with
1.6.1.2.6. Sedoheptulokinase deficiency, isolated
1.6.1.2.7. Sucrase isomaltase deficiency
1.6.1.3. Metabolic syndrome
1.6.1.3.1. Metabolic syndrome bivariate traits
1.6.1.3.2. Metabolic syndrome, association with
1.6.1.3.3. Metabolic syndrome, increased risk
1.6.1.3.4. Metabolic syndrome, susceptibility, association
1.6.1.4. Mineral metabolism disease
1.6.1.4.1. Calcium metabolic disease
1.6.1.4.1.1. Calcinosis
1.6.1.4.1.1.1. Tumoural calcinosis
1.6.1.4.1.1.2. Tumoural calcinosis, normophosphataemic
1.6.1.4.1.2. Hypercalcemia
1.6.1.4.1.2.1. Absorptive hypercalciuria, association with
1.6.1.4.1.2.2. Hypercalcaemia
1.6.1.4.1.2.3. Hypercalcaemia, association with
1.6.1.4.1.2.4. Hypercalcaemia, hypocalciuric
1.6.1.4.1.2.5. Hypercalcaemia, idiopathic infantile
1.6.1.4.2. Iron metabolism disease
1.6.1.4.2.1. Aceruloplasminaemia
1.6.1.4.2.2. Altered iron status
1.6.1.5. Nutrition disease
1.6.1.5.1. Overnutrition
1.6.1.5.1.1. Abdominal adiposity in obese men, association with
1.6.1.5.1.2. Adiposity
1.6.1.5.1.3. Obesity early onset extreme
1.6.1.5.1.4. Obesity extreme
1.6.1.5.1.5. Obesity
1.6.1.5.1.6. Obesity-related traits
1.6.1.5.1.7. Obesity, association with
1.6.1.5.1.8. Obesity, autosomal dominant
1.6.1.5.1.9. Obesity, autosomal dominant, association with
1.6.1.5.1.10. Obesity, early onset
1.6.1.5.1.11. Obesity, early onset, association with
1.6.1.5.1.12. Obesity, early-onset, association with
1.6.1.5.1.13. Obesity, extreme, association with
1.6.1.5.1.14. Obesity, increased risk
1.6.1.5.1.15. Obesity, late-onset, association with
1.6.1.5.1.16. Obesity, male, association with
1.6.1.5.1.17. Obesity, modifier of risk, association with
1.6.1.5.1.18. Obesity, severe, early-onset
1.6.1.5.1.19. Obesity, severe, with diabetes
1.6.1.5.1.20. Obesity, susceptibility to, association with
1.6.1.5.1.21. Obesity-related traits, association with
1.6.1.5.1.22. Obesity related phenotype modifer, association with
1.6.1.5.1.23. Severe obesity, in men, association with
1.6.2. Inherited metabolic disorder
1.6.2.1. Amino acid metabolic disorder (inherited)
1.6.2.1.1. 2-hydroxyglutaric aciduria
1.6.2.1.1.1. L-2-Hydroxyglutaric aciduria
1.6.2.1.1.2. Phenylketonuria
1.6.2.1.2. Altered methionine metabolism
1.6.2.1.3. Argininosuccinate lyase deficiency
1.6.2.1.4. Aromatic L-amino acid decarboxylase deficiency
1.6.2.1.5. Alkaptonuria
1.6.2.1.6. Disorder of lysine and hydroxylysine metabolism
1.6.2.1.6.1. 2-aminoadipic & 2-oxoadipic aciduria
1.6.2.1.7. Carnitine deficiency, systemic primary
1.6.2.1.8. Cystinuria
1.6.2.1.8.1. Cystinuria, type I/III
1.6.2.1.9. Disorder of serine or glycine metabolism
1.6.2.1.9.1. Neurometabolic disorder due to serine deficiency
1.6.2.1.9.1.1. 3-phosphoglycerate dehydrogenase deficiency
1.6.2.1.9.1.2. 3-phosphoserine phosphatase deficiency
1.6.2.1.10. Disorder of urea cycle metabolism and ammonia detoxification
1.6.2.1.10.1. Citrullinaemia
1.6.2.1.10.2. Citrullinemia
1.6.2.1.10.2.1. Citrin deficiency
1.6.2.1.11. Fumarylacetocacetase pseudodeficiency
1.6.2.1.12. Glutaric aciduria 3
1.6.2.1.13. Glutaricacidaemia I
1.6.2.1.14. Hartnup disorder
1.6.2.1.15. Hyper-beta-aminoisobutyric aciduria
1.6.2.1.16. Hyperhomocysteinaemia, association with
1.6.2.1.17. Hyperphenylalaninaemia
1.6.2.1.18. Homocystinuria
1.6.2.1.19. Hyperprolinaemia, association with
1.6.2.1.20. Iminoglycinuria, association with
1.6.2.1.21. Multiple carboxylase deficiency
1.6.2.1.21.1. Biotinidase deficiency
1.6.2.1.21.2. Biotinidase deficiency, partial
1.6.2.1.22. Organic acidemia
1.6.2.1.22.1. 2-Methylbutyryl-CoA dehydrogenase deficiency
1.6.2.1.22.2. 3-methylcrotonyl-CoA carboxylase deficiency
1.6.2.1.22.3. Cerebral organic aciduria
1.6.2.1.22.3.1. Aminoacylase I deficiency
1.6.2.1.22.4. Isovaleric acidaemia
1.6.2.1.22.5. Malonic & methylmalonic aciduria, combined
1.6.2.1.22.6. Maple syrup urine disease
1.6.2.1.22.7. Methylmalonic academia
1.6.2.1.22.7.1. Ethylmalonic aciduria, association with
1.6.2.1.22.7.2. Methylmalonic acidaemia
1.6.2.1.22.7.3. Methylmalonic aciduria
1.6.2.1.22.8. Propionic acidaemia
1.6.2.1.22.9. Tyrosinemia
1.6.2.1.22.9.1. Tyrosinaemia 3
1.6.2.2. Bilirubin metabolic disorder (inherited)
1.6.2.2.1. Dubin-Johnson syndrome
1.6.2.2.2. Hyperbilirubinaemia, association with
1.6.2.3. Dimethylglycine dehydrogenase deficiency
1.6.2.4. Disorder of biogenic amine metabolism and transport (inherited)
1.6.2.4.1. Metabolic disease involving other neurotransmitter deficiency
1.6.2.4.1.1. Butyrylcholinesterase variant
1.6.2.5. Carbohydrate metabolic disorder (inherited)
1.6.2.5.1. Altered carbohydrate metabolism
1.6.2.5.2. Altered sugar binding activity
1.6.2.5.3. Congenital disorder of glycosylation
1.6.2.5.3.1. Congenital disorder of glycosylation 1a
1.6.2.5.3.2. Congenital disorder of glycosylation 1c, mild
1.6.2.5.3.3. Congenital disorder of glycosylation 1c, modifier of
1.6.2.5.3.4. Congenital disorder of glycosylation 1k
1.6.2.5.4. Fructose intolerance
1.6.2.5.5. Hyperinsulinaemic hypoglycaemia, association with
1.6.2.5.6. Hyperphosphatasia with mental retardation syndrome
1.6.2.6. Disorder of energy metabolism (inherited)
1.6.2.6.1. Disorder of fatty acid oxidation and ketone body metabolism
1.6.2.6.1.1. Acyl-CoA-dehydrogenase deficiency
1.6.2.7. Disorder of purine or pyrimidine metabolism (inherited)
1.6.2.7.1. Disorder of purine metabolism
1.6.2.7.1.1. Adenosine deaminase deficiency
1.6.2.7.1.2. Adenosine monophosphate deaminase deficiency
1.6.2.7.2. Disorder of pyrimidine metabolism
1.6.2.7.2.1. Beta-ureidopropionase deficiency
1.6.2.7.3. Purine-pyrimidine metabolic disorder
1.6.2.7.3.1. Dihydropyrimidine dehydrogenase deficiency
1.6.2.7.3.2. Dihydropyrimidine dehydrogenase deficiency, partial
1.6.2.7.4. Xanthinuria
1.6.2.7.4.1. Xanthinuria, type 1
1.6.2.8. Lipid metabolism disorder (inherited)
1.6.2.8.1. Altered CETP activity
1.6.2.8.2. Carnitine palmitoyltransferase 2 deficiency
1.6.2.8.3. Smith-Lemli-Opitz syndrome
1.6.2.8.4. HDL deficiency
1.6.2.8.5. Hypercholesterolaemia
1.6.2.8.6. Hypercholesterolaemia, association with
1.6.2.8.7. Hypercholesterolaemia, autosomal dominant
1.6.2.8.8. Hyperlipidemia
1.6.2.8.8.1. Familial combined hyperlipidaemia, association with
1.6.2.8.8.2. Hyperchylomicronaemia
1.6.2.8.8.3. Hyperlipidaemia, association with
1.6.2.8.8.4. Hyperlipoproteinaemia I
1.6.2.8.8.5. Hyperlipoproteinaemia III
1.6.2.8.8.6. Hypertriglyceridaemia
1.6.2.8.8.7. Hypertriglyceridaemia, association with
1.6.2.8.8.8. Hypertriglyceridemia
1.6.2.8.9. Hypocholesterolaemia
1.6.2.8.10. Hypocholesterolaemia, association with
1.6.2.8.11. Hypolipoproteinemia
1.6.2.8.11.1. Tangier disease
1.6.2.8.11.2. Hyperalphalipoproteinaemia, association with
1.6.2.8.11.3. Hypoalphalipoproteinemia
1.6.2.8.11.3.1. Apolipoprotein B deficiency
1.6.2.8.11.3.2. Apolipoprotein C1 variant
1.6.2.8.11.3.3. Apolipoprotein C2 deficiency
1.6.2.8.11.3.4. Apolipoprotein C3 variant
1.6.2.8.11.3.5. Apolipoprotein E deficiency
1.6.2.8.11.3.6. Apolipoprotein H deficiency, association with
1.6.2.8.11.3.7. Cholesterol ester transfer protein deficiency
1.6.2.8.11.4. Hypobetalipoproteinaemia
1.6.2.8.12. Medium and short-chain 3-hydroxyacyl-CoA dehydrogenase deficiency
1.6.2.8.13. Medium chain acyl CoA dehydrogenase deficiency
1.6.2.8.14. Medium chain acyl CoA dehydrogenase deficiency, modifier of
1.6.2.8.15. Steroid inherited metabolic disorder
1.6.2.8.15.1. 21-hydroxylase deficiency
1.6.2.8.15.2. 21-hydroxylase deficiency, non-classical
1.6.2.8.15.3. Adrenal hyperplasia
1.6.2.8.15.4. Macronodular adrenal hyperplasia
1.6.2.8.15.5. Bile acid malabsorption, primary
1.6.2.8.15.6. Congenital adrenal hyperplasia
1.6.2.8.15.6.1. Congenital lipoid adrenal hyperplasia
1.6.2.8.16. Very long chain acyl-CoA dehydrogenase deficiency
1.6.2.9. Lysosomal storage disease (inherited)
1.6.2.9.1. Cystinosis
1.6.2.9.2. Cystinosis, nephropathic
1.6.2.9.3. Lipid storage disease
1.6.2.9.3.1. Chanarin-Dorfman syndrome
1.6.2.9.3.2. Cholesterol ester storage disease
1.6.2.9.3.3. Fatty liver disease
1.6.2.9.3.3.1. Nonalcoholic fatty liver disease, association with
1.6.2.9.3.3.2. Non-alcoholic fatty liver disease, association with
1.6.2.9.3.3.3. Non-alcoholic fatty liver disease, increased risk
1.6.2.9.3.3.4. Nonalcoholic fatty liver disease, increased risk, association with
1.6.2.9.3.3.5. Steatohepatitis, non-alcoholic, association with
1.6.2.9.3.4. Neuronal ceroid lipofuscinosis
1.6.2.9.3.4.1. Neuronal ceroid lipofuscinosis, late infantile
1.6.2.9.3.5. Non-alcoholic fatty liver disease histology AST
1.6.2.9.3.6. Non-alcoholic fatty liver disease histology lobular
1.6.2.9.3.7. Non-alcoholic fatty liver disease histology other
1.6.2.9.3.8. Non-alcoholic fatty liver disease
1.6.2.9.3.9. Nonalcoholic fatty liver disease
1.6.2.9.3.10. Gaucher disease severity
1.6.2.9.3.11. Sphingolipidosis
1.6.2.9.3.11.1. Arylsulphatase A pseudodeficiency, association
1.6.2.9.3.11.2. Gangliosidosis GM1
1.6.2.9.3.11.3. Gangliosidosis GM1, modulating effect, association with
1.6.2.9.3.11.4. Gangliosidosis GM2
1.6.2.9.3.11.4.1. Tay-Sachs disease
1.6.2.9.3.11.5. Gaucher disease 1
1.6.2.9.3.11.6. Krabbe disease
1.6.2.9.3.11.7. Krabbe disease, association with
1.6.2.9.3.11.8. Krabbe disease, late-onset
1.6.2.9.3.11.9. Metachromatic leukodystrophy
1.6.2.9.3.12. Xanthomatosis
1.6.2.9.3.12.1. Cerebrotendinous xanthomatosis
1.6.2.9.4. Mucolipidosis II
1.6.2.9.5. Mucopolysaccharidosis
1.6.2.9.5.1. Hurler syndrome
1.6.2.9.5.2. Mucopolysaccharidosis I
1.6.2.9.5.3. Mucopolysaccharidosis IIIC
1.6.2.9.5.4. Mucopolysaccharidosis IVa
1.6.2.9.5.5. Mucopolysaccharidosis VI
1.6.2.9.5.6. Sanfilippo syndrome A
1.6.2.9.5.7. Sanfilippo syndrome B
1.6.2.10. Metal metabolism disorder (inherited)
1.6.2.10.1. Acrodermatitis enteropathica
1.6.2.10.2. Familial periodic paralysis
1.6.2.10.2.1. Hypokalaemic periodic paralysis, association with
1.6.2.10.3. Haemochromatosis
1.6.2.10.3.1. Haemochromatosis, association with
1.6.2.10.3.2. Haemochromatosis, HFE related
1.6.2.10.3.3. Haemochromatosis, phenotype modifier, association with
1.6.2.10.3.4. Iron overload
1.6.2.10.3.5. Iron overload trait, association with
1.6.2.10.3.6. Iron overload, severe, in HFE haemochromatosis
1.6.2.10.4. Periodic paralysis
1.6.2.10.5. Wilson disease
1.6.2.11. Mitochondrial metabolism disease
1.6.2.11.1. ATP synthase deficiency
1.6.2.11.2. Combined oxidative phosphorylation deficiency
1.6.2.11.3. Complex 1 and II deficiency
1.6.2.11.4. Complex 1 deficiency
1.6.2.11.5. Complex 3 deficiency
1.6.2.11.6. Complex I deficiency
1.6.2.11.7. Cytochrome P450 deficiency
1.6.2.11.8. Isolated Complex I deficiency
1.6.2.11.9. Mitochondrial DNA depletion syndrome
1.6.2.11.10. Mitochondrial DNA depletion syndrome 3
1.6.2.11.11. Mitochondrial neurogastrointestinal encephalopathy
1.6.2.11.12. POLG deficiency
1.6.2.11.13. Steroid-11 beta-hydroxylase deficiency
1.6.2.11.14. Steroid-11 beta-hydroxylase deficiency, non-classic
1.6.2.12. Norepinephrine deficiency
1.6.2.13. Peroxisomal disease
1.6.2.13.1. Zellweger syndrome C
1.6.2.13.2. Disorder of peroxisomal alpha-, beta- and omega-oxidation
1.6.2.13.2.1. Acatalasaemia
1.6.2.13.3. Peroxisome biogenesis disorder
1.6.2.13.4. Peroxisome biogenesis disorder 3
1.6.2.14. Plasma protein metabolism disease
1.6.2.14.1. Antitrypsin alpha 1 deficiency
1.6.2.14.2. Antitrypsin alpha 1 deficiency, partial
1.6.2.14.3. Antitrypsin M2 variant
1.6.2.15. Porphyria
1.6.2.15.1. Acute porphyria
1.6.2.15.1.1. Protoporphyria, erythropoietic
1.6.2.15.1.2. Protoporphyria, erythropoietic, association with
1.6.2.15.2. Porphyria, acute intermittent
1.6.2.15.3. Porphyria, acute intermittent, non-erythroid type
1.6.2.15.4. Porphyria, cutanea tarda
1.6.2.15.5. Porphyria, variegate
1.6.2.16. TPMT deficiency, association with
1.6.2.17. Trimethylaminuria, association with
1.6.3. Uncategorized Metabolite Deficiencies
1.6.3.1. CD1A deficiency
1.6.3.2. Chitotriosidase deficiency
1.6.3.3. Ciliary neurotrophic factor deficiency
1.6.3.4. DNAase deficiency
1.6.3.5. Epoxide hydrolase deficiency, association with
1.6.3.6. Gamma-glutamyl carboxylase deficiency
1.6.3.7. Glutathione synthetase deficiency
1.6.3.8. Haptoglobin deficiency, association with
1.6.3.9. Heparin cofactor 2 deficiency
1.6.3.10. Hepatic lipase deficiency
1.6.3.11. Histatin 2 deficiency
1.6.3.12. HLA class I deficiency
1.6.3.13. IgG receptor I, phagocytic, deficiency
1.6.3.14. ITPase deficiency
1.6.3.15. ITPase deficiency, association with
1.6.3.16. Kallikrein deficiency
1.6.3.17. Lipoprotein lipase deficiency
1.6.3.18. Lipoprotein lipase deficiency, association with
1.6.3.19. Mannose-binding protein deficiency, association
1.6.3.20. Mercaptopyruvate sulphurtransferase deficiency, association with
1.6.3.21. Molybdenum cofactor deficiency
1.6.3.22. Myeloperoxidase deficiency
1.6.3.23. OATP1B1 deficiency
1.6.3.24. OKT4-epitope deficiency
1.6.3.25. Organic cation transporter deficiency
1.6.3.26. Phosphoglycerate mutase deficiency
1.6.3.27. Phytanoyl-CoA hydroxylase deficiency, partial
1.6.3.28. Pk synthase deficiency (p phenotype)
1.6.3.29. Plasminogen activator inhibitor 1 deficiency
1.6.3.30. Plasminogen deficiency
1.6.3.31. POR deficiency
1.6.3.32. Prekallikrein deficiency
1.6.3.33. Prolidase deficiency
1.6.3.34. Proline-rich protein PRB1 deficiency
1.6.3.35. Proline-rich protein PRB4 deficiency
1.6.3.36. Riboflavin responsive complex 1 deficiency
1.6.3.37. Ribonuclease L deficiency
1.6.3.38. SIGLEC1 deficiency
1.6.3.39. TRAF3 deficiency
1.6.3.40. TRIF deficiency
1.6.4. Uncategorized/multiple categories metabolism
1.6.4.1. Alcohol dehydrogenase beta variant
1.6.4.2. Alcohol dehydrogenase gamma variant
1.6.4.3. Altered (S)-methadone metabolism
1.6.4.4. Altered acetylcarnitine metabolism
1.6.4.5. Altered glucocorticoid sensitivity
1.6.4.6. Altered activity
1.6.4.7. Altered activity, association with
1.6.4.8. Altered antagonist binding
1.6.4.9. Altered beta-carotene metabolism, association with
1.6.4.10. Altered beta-carotene metabolism, association with
1.6.4.11. Altered level of 5-HETE
1.6.4.12. Altered N-acetylglucosamine binding
1.6.4.13. Altered N-acetylornithine metabolism
1.6.4.14. Altered N-linked glycosylation
1.6.4.15. Altered one-carbon metabolism
1.6.4.16. Altered p53 binding
1.6.4.17. Altered p53 transactivation
1.6.4.18. Attenuated insulin resistance in obese children, association with
1.6.4.19. Altered methylation
1.6.4.20. Glucose/Lipid metabolism,  association with
1.6.4.21. Hyperammonaemia, association with
1.6.4.22. Increased whole-body insulin sensitivity, association with
1.6.4.23. Insulin resistance, association with
1.6.4.24. Insulin resistance, mild, association with
1.6.4.25. Insulin sensitivity and waist circumference, association with
1.6.4.26. Insulin sensitivity, association with
1.6.4.27. Low insulin sensitivity, association with
1.6.4.28. Lower insulin resistance, association with
1.6.4.29. Obesity and diabetes type 2, association with
1.6.4.30. Obesity and diabetes, association with
1.6.4.31. Obesity and glucose homeostasis traits, association with
1.6.4.32. Obesity and insulin resistance
1.6.4.33. Obesity and triglyceride levels, association with
1.6.4.34. Proteolysis by ADAMTS13, susceptibility to
1.6.4.35. Pseudohyperkalaemia, familial
1.6.4.36. Reduced alcohol metabolism, association with
1.6.4.37. Thiopurine intolerance
1.6.4.38. Ultrarapid metaboliser
1.6.4.39. Whole body insulin sensitivity, association with
1.7. Genetic disease
1.7.1. Aromatase deficiency
1.7.2. Chromosomal disease
1.7.2.1. Down's syndrome/HSCR phenotype, association with
1.7.3. Ciliopathy
1.7.3.1. Joubert syndrome
1.7.3.2. Joubert syndrome, modifier of
1.7.3.3. Meckel-Gruber syndrome
1.7.3.4. Meckel-Gruber-like syndrome
1.7.3.5. Primary ciliary dyskinesia
1.7.3.5.1. Primary ciliary dyskinesia with central complex defects
1.7.4. Malignant hyperthermia
1.7.5. Monogenic Disease
1.7.5.1. Alport syndrome
1.7.5.1.1. Alport syndrome / thin basement membrane nephropathy
1.7.5.2. Autosomal genetic disease
1.7.5.2.1. Polycystic kidney disease
1.7.5.2.2. Autosomal dominant disease
1.7.5.2.2.1. Autosomal dominant polycystic kidney disease
1.7.5.2.2.1.1. Polycystic kidney disease 1
1.7.5.2.2.1.2. Polycystic kidney disease 2
1.7.5.2.2.1.3. Polycystic kidney disease, autosomal dominant
1.7.5.2.2.2. Blepharophimosis/ptosis/epicanthus inversus syndrome
1.7.5.2.2.3. Branchio-oto-renal syndrome
1.7.5.2.2.4. Cowden disease
1.7.5.2.2.5. Cowden syndrome
1.7.5.2.2.6. Gastrointestinal polyposis, late onset
1.7.5.2.2.7. Holt-Oram syndrome
1.7.5.2.2.8. Hypophosphatasia
1.7.5.2.2.9. Hypophosphatasia, association with
1.7.5.2.2.10. Ichthyosis vulgaris
1.7.5.2.2.11. Ichthyosis, autosomal recessive
1.7.5.2.2.12. Ichthyosis, harlequin
1.7.5.2.2.13. Ichthyosis, lamellar
1.7.5.2.2.14. Lynch syndrome
1.7.5.2.2.14.1. HNPCC, early onset, association with
1.7.5.2.2.14.2. Lynch syndrome, modifier of
1.7.5.2.2.14.3. Mismatch repair defect, partial
1.7.5.2.2.14.4. Muir-Torre syndrome
1.7.5.2.2.15. Multiple endocrine neoplasia 1
1.7.5.2.2.16. Neurofibromatosis 1
1.7.5.2.2.17. Neurofibromatosis 2
1.7.5.2.2.18. Neurofibromatosis, cafe-au-lait macule count, association with
1.7.5.2.2.19. Polyposis, juvenile intestinal
1.7.5.2.2.20. Popliteal pterygium syndrome
1.7.5.2.2.20.1. Bartsocas-Papas syndrome
1.7.5.2.2.20.2. Birt-Hogg-DubÃ© syndrome
1.7.5.2.2.21. Treacher-Collins syndrome
1.7.5.2.2.22. Tuberous sclerosis
1.7.5.2.3. Autosomal recessive disease
1.7.5.2.3.1. ABCD syndrome
1.7.5.2.3.2. Aicardi-GoutiÃ¨res syndrome
1.7.5.2.3.3. Acetoacetyl-CoA-thiolase deficiency
1.7.5.2.3.4. Bardet-Biedl syndrome
1.7.5.2.3.4.1. Bardet-Biedl syndrome modifier, association with
1.7.5.2.3.4.2. Bardet-Biedl syndrome, modifier of
1.7.5.2.3.5. Beta-ketothiolase deficiency
1.7.5.2.3.6. Cystic fibrosis
1.7.5.2.3.6.1. CFTR-related disorder
1.7.5.2.3.6.2. Cystic fibrosis lung disease, modifier of
1.7.5.2.3.6.3. Cystic fibrosis related disorder
1.7.5.2.3.6.4. Cystic fibrosis severity
1.7.5.2.3.6.5. Cystic fibrosis severity, association with
1.7.5.2.3.6.6. Cystic fibrosis, modifier of
1.7.5.2.3.6.7. Severity in cystic fibrosis, association with
1.7.5.2.3.7. Cockayne syndrome
1.7.5.2.3.8. Epidermodysplasia verruciformis, susceptibility in HIV, association
1.7.5.2.3.9. Fraser syndrome
1.7.5.2.3.10. McKusick-Kaufman syndrome
1.7.5.2.3.11. Oculocutaneous albinism
1.7.5.2.3.11.1. Albinism, oculocutaneous
1.7.5.2.3.11.2. Albinism, oculocutaneous 1
1.7.5.2.3.11.3. Albinism, oculocutaneous 1, association with
1.7.5.2.3.11.4. Albinism, oculocutaneous 1A
1.7.5.2.3.11.5. Albinism, oculocutaneous 1B
1.7.5.2.3.11.6. Albinism, oculocutaneous 3
1.7.5.2.3.11.7. Albinism, oculocutaneous II
1.7.5.2.3.12. Asphyxiating thoracic dystrophy
1.7.5.2.3.12.1. Short rib-polydactyly syndrome, type 3
1.7.5.2.3.12.2. Short rib-polydactyly syndrome, Majewski type
1.7.5.2.3.13. Immunodeficiency, centromeric instability and facial anomalies syndrome
1.7.5.2.3.14. Laron dwarfism
1.7.5.2.3.15. Nephronophthisis
1.7.5.2.3.16. Nephronophthisis 2
1.7.5.2.3.17. Nephronophthisis 3
1.7.5.2.3.18. Nephronophthisis-related ciliopathy
1.7.5.2.3.19. Polycystic kidney disease,  autosomal recessive
1.7.5.2.3.20. Polycystic kidney disease, autosomal recessive
1.7.5.2.3.21. Prothrombin deficiency
1.7.5.2.3.22. Pseudoxanthoma elasticum
1.7.5.2.3.23. Pseudoxanthoma elasticum, autosomal recessive
1.7.5.2.3.24. Salt and Pepper syndrome
1.7.5.2.3.25. Seckel syndrome
1.7.5.2.3.26. Schwartz-Jampel syndrome type 1
1.7.5.2.3.27. Senior-Loken syndrome 5
1.7.5.2.3.28. Usher syndrome
1.7.5.2.3.28.1. Usher syndrome 1
1.7.5.2.3.28.1.1. Usher syndrome 1b
1.7.5.2.3.28.1.2. Usher syndrome 1d
1.7.5.2.3.28.2. Usher syndrome 2
1.7.5.2.3.28.2.1. Usher syndrome 2a
1.7.5.2.3.28.3. Usher syndrome 3
1.7.5.2.3.29. Werner syndrome
1.7.5.2.3.30. Wolcott-Rallison syndrome
1.7.5.2.3.31. Xeroderma pigmentosum
1.7.5.2.3.31.1. Xeroderma pigmentosum (C)
1.7.5.2.3.32. Thalassemia
1.7.5.2.3.32.1. Severity in thalassaemia, association with
1.7.5.2.3.32.2. Thalassaemia beta
1.7.5.2.3.32.3. Thalassaemia delta
1.7.5.2.3.32.4. Thalassaemia intermedia
1.7.5.2.3.33. Thyroid dyshormonogenesis
1.7.5.2.4. Factor XI deficiency
1.7.5.2.5. Factor XII deficiency
1.7.5.3. Ectodermal dysplasia
1.7.6. Sickle cell anaemia
1.7.6.1. Sickle cell anemia haemolysis
1.8. Factor V and factor VIII deficiency, combined
1.9. Physical disorder
1.9.1. Cryptorchidism
1.9.2. Classic bladder exstrophy
1.9.3. Congenital nervous system abnormality
1.9.3.1. Holoprosencephaly
1.9.3.2. Microcephaly
1.9.3.2.1. Microcephaly, early infantile epileptic encephalopathy, Leigh-like syndrome, dilated cardiomyopathy, and renal insufficiency
1.9.3.2.2. Microcephaly, primary
1.9.3.2.3. Primary microcephaly
1.9.3.3. Periventricular heterotopia with microcephaly
1.9.4. Heterotaxy
1.9.5. Hypospadias, association with
1.9.6. Hypospadias
1.9.7. Klippel-Feil syndrome
1.9.8. Limb deficiency defect, association with
1.9.9. Omphalocele, association with
1.9.10. Orbicularis oris defect
1.9.11. Orofacial clefts
1.9.11.1. Cleft lip
1.9.11.1.1. Cleft lip / palate, association with
1.9.11.1.2. Cleft lip and palate
1.9.11.1.3. Cleft lip and palate with tooth agenesis, association with
1.9.11.1.4. Cleft lip and palate, incomplete, association with
1.9.11.1.5. Cleft lip and palate, non-syndromic
1.9.11.1.6. Cleft lip and palate, nonsyndromic, increased risk
1.9.11.1.7. Cleft lip with or without cleft palate, association
1.9.11.1.8. Cleft lip, association with
1.9.11.1.9. Cleft lip/palate, association with
1.9.11.1.10. Cleft lip/palate, in North American Caucasians, association with
1.9.11.2. Nonsyndromic cleft lip with or without cleft palate
1.9.11.3. Cleft plate environmental tobacco smoke interaction
1.9.11.4. Cleft palate, non-syndromic
1.9.11.5. Orofacial clefts, non-syndromic, association with
1.9.11.6. Orofacial clefts interaction
1.9.12. Polydactyly
1.9.12.1. Postaxial polydactyly A/B
1.9.13. Situs ambiguus
1.10. Syndrome
1.10.1. Acrocallosal syndrome
1.10.2. Beckwith-Wiedemann syndrome
1.10.3. Cardio-facio-cutaneous syndrome
1.10.4. CHARGE syndrome
1.10.5. Cohen syndrome
1.10.6. Irritable bowel syndrome
1.10.7. Irritable bowel syndrome, diarrhoea predominant, association with
1.10.8. Irritable bowel syndrome, diarrhoea predominant, in females, association
1.10.9. Kabuki syndrome
1.10.10. Mainzer-Saldino syndrome
1.10.11. Noonan syndrome
1.10.12. Psoriatic arthritis
1.10.13. Polycystic ovary syndrome
1.10.14. Polycystic ovaries, association with
1.10.15. Polycystic ovary syndrome, association with
1.10.16. Polycystic ovary syndrome, in lean women, association with
1.10.17. Polycystic ovary syndrome, increased risk
1.10.18. Robinow syndrome
1.10.18.1. Robinow syndrome, autosomal recessive
1.10.19. Sudden infant death syndrome
1.10.19.1. Sudden infant death syndrome, association with
1.10.19.2. Sudden infant death, increased risk
1.10.19.3. Sudden unexpected death in infancy
1.10.20. Wolfram syndrome
2. Biological Processes
2.1. Cellular process
2.1.1. Apoptosis, unable to induce, association with
2.1.2. Single-organism cellular process
2.1.2.1. Cellular localization
2.1.2.1.1. Abnormal cellular localization
2.2. Hippocampal atrophy 
2.3. Weight loss gastric bypass surgery
2.4. Increased weight gain, association with
2.5. Reduced weight loss during fasting, association with
2.6. Weight loss due to dieting in overweight women, association
2.7. Aging
2.7.1. Age-related phenotypes, association with
2.7.2. Aging facial
2.7.3. Aging time to death
2.7.4. Aging time to event
2.8. Behavior
2.8.1. Aggressive behaviour
2.8.2. Alcohol and tobacco use, age of initiation
2.8.3. Anger
2.8.4. Alcohol and nictotine co-dependence
2.8.5. Behavioural disinhibition generation interaction
2.8.6. Callous-unemotional behavior
2.8.7. Cognitive ability, association with
2.8.8. Cognitive function
2.8.9. Gambling
2.8.10. Medication adherence in chronic diseases
2.8.11. Non-substance related behavioral disinhibition
2.8.12. Smoking behavior
2.8.13. Cannabis
2.8.13.1. Cannabis use age at onset
2.8.13.2. Cannabis use initiation
2.8.14. Drinking behavior
2.8.14.1. Coffee
2.8.14.1.1. Coffee consumption cups per day
2.8.14.1.2. Coffee consumption
2.8.14.1.3. Caffeine consumption
2.8.14.2. Alcohol
2.8.14.2.1. Alcohol consumption
2.8.14.2.2. Alcohol consumption transferrin glycosylation
2.8.14.2.3. Alcohol dependence
2.8.14.2.3.1. Alcohol dependence age at onset
2.8.14.2.3.2. Alcoholism, association with
2.8.14.2.3.3. Alcohol dependence, association with
2.8.14.2.3.4. Alcoholism 12-month weekly alcohol consumption
2.8.14.2.3.5. Alcoholism alcohol dependence factor score
2.8.14.2.3.6. Alcoholism alcohol use disorder factor score
2.8.14.2.3.7. Alcoholism heaviness of drinking
2.8.14.2.4. Reduced alcohol consumption, association with
2.8.15. Social recognition skills, association with
2.8.16. Sociobehavioural deficits, association with
2.8.17. Suicide behavior
2.8.17.1. Suicide risk
2.8.17.2. Suicide
2.8.17.3. Suicide ideation score in major depressive disorder
2.8.17.4. Suicide in bipolar disorder
2.8.17.5. Suicide attempts in bipolar disorder
2.8.17.6. Suicide attempts in depression or bipolar disorder
2.8.17.7. Suicide attempts in major depressive disorder
2.8.17.8. Suicidal ideation
2.8.17.9. Suicidal ideation in depression or bipolar disorder
2.8.17.10. Suicidal ideation, in major depression, association with
2.8.17.11. Suicide, association with
2.9. Mental process
2.9.1. Cognition
2.9.1.1. Information processing speed
2.9.1.2. Intelligence childhood
2.9.1.3. Reading or mathematical ability
2.9.1.4. Reading
2.9.1.4.1. Word reading
2.9.1.4.2. Non-word repetition
2.9.1.4.3. Reading and spelling
2.9.1.5. Speech perception in dyslexia
2.9.2. Verbal declarative memory
2.10. Odontogenesis
2.10.1. Permanent tooth development
2.10.2. Primary tooth development number of teeth
2.10.3. Primary tooth development time to first tooth eruption
2.11. Regulation of gene expression
2.11.1. Altered gene expression
2.11.2. Altered gene expression in liver
2.11.3. Decreased hepatic target gene expression
2.11.4. DNA methylation parent-of-origin
2.11.5. DNA methylation variation
2.11.6. Gene methylation in lung tissue
2.11.7. Increased gene expression
2.11.8. Reduced gene expression
2.12. Response to stimulus
2.12.1. Atypical porphyrinogenic response to mercury
2.12.2. Cellular response to cadmium, association with
2.12.3. Diminished calcium response
2.12.4. Graft versus host disease, association with
2.12.5. Graft-versus-host disease, increased risk, association with
2.12.6. Increased response to UV, association with
2.12.7. Magnesium, altered sensitivity to, association with
2.12.8. Multiple organ dysfunction, after trauma, association with
2.12.9. Paradoxical heat sensation, association with
2.12.10. Variable RAAS response to salt-loading, association with
2.12.11. Response to drug
2.12.11.1. Adverse response to antihypertensive drugs
2.12.11.2. Altered affinity for atypical antipsychotic drugs
2.12.11.3. ara-C resistance, association with
2.12.11.4. Antiepileptic drug pharmacoresistance
2.12.11.5. Asparaginase hypersensitivity in acute lymphoblastic leukemia
2.12.11.6. Aspirin exacerbated respiratory disease in asthmatics
2.12.11.7. Aspirin-exacerbated respiratory disease
2.12.11.8. Asthma bronchodilator response
2.12.11.9. Atorvastatin response, association with
2.12.11.10. Atorvastatin sensitivity
2.12.11.11. Azathioprine haematotoxicity in TPMT carriers, association with
2.12.11.12. Beta-lactam antibiotic allergy, association with
2.12.11.13. Bronchodilator response in asthma inhaled corticosteroid treatment interaction
2.12.11.14. Capecitabine sensitivity, association with
2.12.11.15. Clozapine response, association with
2.12.11.16. Clozapine-induced agranulocytosis
2.12.11.17. Cough in response to angiotensin-converting enzyme inhibitor drugs
2.12.11.18. Fentanyl-induced emesis, association with
2.12.11.19. Glycemic response to metformin in T2D patients, assoc with
2.12.11.20. Haloperidol-induced toxicity, association with
2.12.11.21. Lipoprotein-associated phospholipase A2 activity change in response to statin therapy
2.12.11.22. Morphine dose requirement in tonsillectomy and adenoidectomy surgery
2.12.11.23. Non-response to antiepilepsy medication in epileptics, association
2.12.11.24. Pharmacokinetics of antiepileptic drugs in severe mental disorder concentration drug ratio
2.12.11.25. Poor montelukast metabolism
2.12.11.26. Reduced multidrug resistance
2.12.11.27. Reduced sensitivity to clozapine, association with
2.12.11.28. Reduced response to glucocorticoids in asthmatics
2.12.11.29. Response to antineoplastic agents
2.12.11.30. Response to abacavir-containing treatment in HIV-1 infection virologic failure
2.12.11.31. Response to angiotensin II receptor blocker therapy opposite direction w diuretic therapy
2.12.11.32. Response to angiotensin II receptor blocker therapy
2.12.11.33. Response to anti-TNF treatment in rheumatoid arthritis 
2.12.11.34. Response to cholinesterase inhibitors in Alzheimers disease
2.12.11.35. Response to citalopram treatment
2.12.11.36. Response to Dalcetrapib treatment in acute coronary syndrome
2.12.11.37. Response to diuretic therapy in hypertension
2.12.11.38. Response to efavirenz-containing treatment in HIV 1 infection virologic failure
2.12.11.39. Response to fenofibrate
2.12.11.40. Response to haloperidol in psychosis
2.12.11.41. Response to hepatitis C treatment
2.12.11.42. Response to metformin in type 2 diabetes glycemic
2.12.11.43. Response to metformin
2.12.11.44. Response to methotrexate in juvenile idiopathic arthritis
2.12.11.45. Response to methotrexate in rheumatoid arthritis
2.12.11.46. Response to statins
2.12.11.47. Response to Vitamin E supplementation
2.12.11.48. Rubella vaccine-induced immune response, association with
2.12.11.49. Sodium valproate-induced liver toxicity, association with
2.12.11.50. Thiazide-induced adverse metabolic effects in hypertensive patients
2.12.11.51. Torsades de Pointes, drug-induced, association with
2.12.11.52. Urticaria
2.12.11.52.1. Acute urticaria
2.12.11.52.1.1. Acute urticaria and angioedema non-steroidal anti-inflammatory drug-induced 
2.12.11.52.1.2. Acute urticaria, aspirin-intolerant, association
2.12.11.52.1.3. Acute urticaria/angioedema, NSAID induced, reduced risk
2.12.11.53. Warfarin maintenance dose
2.12.11.54. Warfarin resistance
2.12.11.55. Warfarin resistance, association with
2.12.11.56. Warfarin sensitivity
2.12.11.57. Warfarin sensitivity, association with
2.12.11.58. Anticoagulant levels
2.12.11.59. Cerivastatin-induced rhabdomyolysis
2.12.11.60. Thionamide-induced agranulocytosis in Graves' disease
2.12.11.61. Creatine kinase in statin users
2.12.11.62. Cytokine and corticosteroid-stimulated IL-6 production
2.12.11.63. Cytokine-stimulated IL-6 production
2.12.11.64. Nevirapine-induced rash
2.12.11.65. Paclitaxel-induced neuropathy
2.12.11.66. Change in intraocular pressure in response to steroid treatment triamcinolone acetonide
2.12.11.67. Response to thiopurine immunosuppressants in inflammatory bowel disease pancreatitis azathioprine and mercaptopurine
2.12.11.68. Response to TNF antagonist treatment
2.12.11.69. Response to simvastatin treatment PCSK9 protein level change
2.12.11.70. Response to statins LDL cholesterol change
2.12.11.71. Response to statin therapy
2.12.11.72. Response to methylphenidate treatment in attention-deficithyperactivity disorder blood pressure
2.12.11.73. Response to montelukast in asthma change in FEV1
2.12.11.74. Ribavirin-induced anemia 
2.12.11.75. Response to interferon beta therapy
2.12.11.76. Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia
2.12.11.77. Response to antibiotic
2.12.11.77.1. Peak creatinine levels in vancomycin therapy
2.12.11.78. Response to chemotherapy
2.12.11.78.1. Altered herceptin treatment response
2.12.11.78.2. Poor paclitaxel metabolism
2.12.11.78.3. Response to bleomycin chromatid breaks 
2.12.11.78.4. Response to gemcitabine in pancreatic cancer
2.12.11.78.5. Response to platinum-based chemotherapy in non-small-cell lung cancer
2.12.11.78.6. Response to treatment for acute lymphoblastic leukemia 
2.12.11.78.7. Response to tamoxifen in breast cancer
2.12.11.78.8. Response to radiotherapy in prostate cancer toxicity
2.12.11.78.9. Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer
2.12.11.78.10. Response to irinotecan in non-small-cell lung cancer 
2.12.11.78.11. Obesity in adult survivors of childhood cancer exposed to cranial radiation
2.12.11.78.12. Adverse response to chemotherapy in breast cancer alopecia anti-microtubule
2.12.11.78.13. Adverse response to chemotherapy in breast cancer alopecia cyclophosphamide+doxorubicin+-5FU
2.12.11.78.14. Adverse response to chemotherapy in breast cancer alopecia cyclophosphamide+epirubicin+-5FU
2.12.11.78.15. Adverse response to chemotherapy in breast cancer alopecia docetaxel
2.12.11.78.16. Adverse response to chemotherapy in breast cancer alopecia paclitaxel
2.12.11.78.17. Adverse response to chemotherapy in breast cancer alopecia
2.12.11.78.18. Adverse response to chemotherapy neutropenialeucopenia 5-fluorouracil
2.12.11.78.19. Adverse response to chemotherapy neutropenialeucopenia all anthracycline-based drugs
2.12.11.78.20. Adverse response to chemotherapy neutropenialeucopenia all antimetabolite drugs
2.12.11.78.21. Adverse response to chemotherapy neutropenialeucopenia all antimicrotubule drugs
2.12.11.78.22. Adverse response to chemotherapy neutropenialeucopenia all platinum-based drugs
2.12.11.78.23. Adverse response to chemotherapy neutropenialeucopenia all topoisomerase inhibitors
2.12.11.78.24. Adverse response to chemotherapy neutropenialeucopenia camptothecin
2.12.11.78.25. Adverse response to chemotherapy neutropenialeucopenia carboplatin
2.12.11.78.26. Adverse response to chemotherapy neutropenialeucopenia cisplatin
2.12.11.78.27. Adverse response to chemotherapy neutropenialeucopenia cyclophosphamide
2.12.11.78.28. Adverse response to chemotherapy neutropenialeucopenia docetaxel
2.12.11.78.29. Adverse response to chemotherapy neutropenialeucopenia doxorubicin
2.12.11.78.30. Adverse response to chemotherapy neutropenialeucopenia epirubicin
2.12.11.78.31. Adverse response to chemotherapy neutropenialeucopenia etoposide
2.12.11.78.32. Adverse response to chemotherapy neutropenialeucopenia gemcitabine
2.12.11.78.33. Adverse response to chemotherapy neutropenialeucopenia paclitaxel + carboplatin
2.12.11.78.34. Adverse response to chemotherapy neutropenialeucopenia paclitaxel 
2.12.11.78.35. Anthracycline-induced cardiotoxicity
2.12.11.78.36. Anthracycline-induced cardiotoxicity in childhood cancer
2.12.11.78.37. Methotrexate clearance acute lymphoblastic leukemia
2.12.11.78.38. Methotrexate phramacokinetics acute lymphoblastic leukemia
2.12.11.78.39. Tissue response in radiotherapy, association with
2.12.11.79. Response to antidepressants
2.12.11.79.1. Response to antidepressant treatment citalopram
2.12.11.79.2. Pharmacokinetics of antidepressant drugs in severe mental disorder concentration dose ratio
2.12.11.79.3. Response to anti-depressant treatment in major depressive disorder
2.12.11.80. Response to antipsychotic treatment
2.12.11.80.1. Pharmacokinetics of antipsychotic drugs in severe mental disorder concentration drug ratio
2.12.11.80.2. Response to iloperidone treatment QT prolongation
2.12.11.81. Thiopurine-induced leukopaenia, association with
2.12.12. Subjective responses to alcohol and nicotine, association with
2.13. Sensory perception
2.13.1. Sensory perception of taste
2.13.1.1. Aloin and saccharin taste sensitivity, association
2.13.1.2. Bitter taste sensitivity, association with
2.13.1.3. Coffee taste perception, association with
2.13.1.4. Phenylthiocarbamide taste sensitivity, association
2.13.1.5. Quinine taste sensitivity, association with
2.13.1.6. Saccharin taste sensitivity, association
3. Measurements
3.1. Adhesion molecule measurement
3.1.1. Soluble levels of adhesion molecules
3.2. Allergy measurement
3.2.1. Allergic sensitization
3.2.2. Allergic sensitisation, association with
3.2.3. Expression of allergic symptoms, association with
3.3. Amino acid levels
3.3.1. Altered homocysteine levels
3.3.2. Altered methionine sulfoxide levels
3.3.3. Homocysteine levels
3.3.4. Plasma homocysteine levels post-methionine load test
3.3.5. Plasma homocysteine levels
3.3.6. L-arginine levels
3.4. Anthropometric measurements
3.4.1. Adipose tissue
3.4.1.1. Subcutaneous adipose tissue
3.4.1.2. Visceral adipose tissuesubcutaneous adipose tissue ratio
3.4.1.3. Visceral fat
3.4.1.4. Visceral adipose tissue adjusted for BMI
3.4.1.5. Renal sinus fat
3.4.2. Body weights and measures
3.4.2.1. Body composition in African American women, association with
3.4.2.2. Body mass index
3.4.2.2.1. BMI, association with
3.4.2.2.2. Body mass index in asthmatics
3.4.2.2.3. Body mass index in non-asthmatics
3.4.2.2.4. Body mass index in women, association with
3.4.2.2.5. Body mass index variability, association with
3.4.2.2.6. Body mass index, association with
3.4.2.2.7. Height adjusted BMI
3.4.2.2.8. Overweight status
3.4.2.2.9. Underweight status
3.4.2.2.10. Body mass index age interaction
3.4.2.2.11. Body mass index interaction
3.4.2.2.12. Body mass index change over time
3.4.2.3. Body ratio measurement
3.4.2.3.1. Digit length ratio
3.4.2.3.2. Sitting height ratio
3.4.2.3.3. Waist circumference, association with
3.4.2.3.4. Waist-hip ratio
3.4.2.3.4.1. Waist-to-hip ratio, association with
3.4.2.3.4.2. Waist-to-hip ratio adjusted for body mass index
3.4.2.3.4.3. Waist-to-hip circumference ratio interaction
3.4.2.4. Brachial circumference
3.4.2.5. Breast size
3.4.2.6. Head circumference infant
3.4.2.7. Height
3.4.2.7.1. Adult height, association with
3.4.2.7.2. Birth length
3.4.2.7.3. Infant length
3.4.2.7.4. Short stature
3.4.2.7.5. Tall stature, association with
3.4.2.8. Hip bone size
3.4.2.9. Hip circumference psychosocial stress interaction
3.4.2.10. Percentage fat mass, association with
3.4.2.11. Waist circumference
3.4.2.11.1. Waist circumference and related phenotypes
3.4.2.12. Weight
3.4.2.12.1. Birth weight
3.4.2.12.2. Birthweight, association with
3.4.3. Anthropometric traits in newborns
3.4.4. Body mass lean
3.4.5. Body mass in chronic obstructive pulmonary disease
3.4.6. Sexual dimorphism in anthropometric traits
3.4.7. Fat body mass
3.4.8. Fat distribution HIV
3.4.9. Comprehensive strength and appendicular lean mass
3.5. Antibody measurement
3.5.1. Antibody level in response to infection
3.5.1.1. Cytomegalovirus antibody response
3.5.2. IgE levels
3.5.3. IgG levels
3.5.4. Immunoglobulin G index levels in multiple sclerosis
3.5.5. Helicobacter pylori serologic status
3.5.6. IgM levels
3.5.7. Food antigen IgG levels
3.5.8. IgE levels in asthmatics D.f. specific
3.5.9. IgE levels in asthmatics D.p. specific
3.5.10. IgG glycosylation
3.5.11. Thyroid peroxidase antibody levels
3.5.12. Thyroid peroxidase antibody positivity
3.6. Blood toxic metal measurement
3.6.1. Lead levels in blood
3.7. Bone measurement
3.7.1. Bone density
3.7.1.1. Bone mineral density
3.7.1.2. Bone mineral density hip
3.7.1.3. Bone mineral density paediatric, lower limb
3.7.1.4. Bone mineral density paediatric, skull
3.7.1.5. Bone mineral density paediatric, total body less head
3.7.1.6. Bone mineral density paediatric, upper limb
3.7.1.7. Bone mineral density and vertebral fracture, association with
3.7.1.8. Bone mineral density spine
3.7.1.9. Bone mineral density
3.7.1.10. Bone mineral density wrist
3.7.1.11. Cortical bone thickness/bone mineral density, association with
3.7.1.12. Hip bone mineral density, association with
3.7.1.13. Low bone density
3.7.1.14. Low bone mineral density, association with
3.7.1.15. Lower bone mineral density, association with
3.7.1.16. Lower femoral neck BMD, association with
3.7.1.17. Lower femoral neck bone mineral density in women, association
3.7.1.18. Lower femoral neck bone mineral density, association with
3.7.1.19. Lower lumbar bone mineral density, association
3.7.1.20. Lower lumbar bone mineral density, association with
3.7.1.21. Lumbar spine bone mineral density, association with
3.7.1.22. Lumbar spine bone-mineral content, association with
3.7.1.23. Pediatric areal bone mineral density radius
3.7.1.24. Pediatric bone mineral content radius
3.7.1.25. Total body bone mineral density, association
3.7.1.26. Variation in bone mineral density, association with
3.7.2. Bone mass, association with
3.7.3. Bone properties heel
3.7.4. Femoral neck width, association with
3.7.5. Femoral neck-bone mineral density, association with
3.7.6. Lower body mass index, association with
3.7.7. Spine bone size
3.8. Brain measurement
3.8.1. Brain structure
3.8.1.1. Brain structure hippocampal volume
3.8.1.2. Brain structure temporal lobe volume
3.8.2. Brain volume measurement
3.8.2.1. Cranial volume, association with
3.8.2.2. Superior frontal gyrus grey matter volume
3.8.2.3. Hippocampal volume
3.8.2.4. Intracranial volume
3.8.2.5. Lentiform nucleus volume
3.8.2.6. Subcortical brain region volumes
3.8.3. Caudate nucleus volume
3.8.4. Cortical thickness
3.8.5. Heschls gyrus morphology
3.8.6. White matter integrity
3.8.7. White matter hyperintensity burden
3.8.8. White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy
3.9. Carbohydrate measurement
3.9.1. N-glycan levels
3.9.2. Plasma glucose concentration, association with
3.9.3. Reduced serum myo-inositol concentration
3.10. Cardiovascular measurement
3.10.1. Cardiac structure and function
3.10.2. Cardiovascular disease risk factors
3.10.3. Maximal oxygen consumption, association with
3.10.4. Uric acid levels
3.11. Carotid artery measurement
3.11.1. Carotid intima media thickness
3.11.2. Carotid artery intima media thickness sex interaction
3.11.3. Carotid intima media thickness, association with
3.11.4. Carotid intima-media thicknesses, in HIV, association with
3.12. Cerebrospinal fluid biomarker measurement
3.12.1. Cerebrospinal AB1-42 levels
3.12.2. Cerebrospinal AB1-42 levels in Alzheimers disease dementia
3.12.3. Cerebrospinal fluid levels of Alzheimers disease-related proteins
3.12.4. Cerebrospinal P-tau181p levels
3.12.5. Cerebrospinal T-tau levels
3.13. Disease biomarkers
3.13.1. Alzheimer’s disease biomarkers
3.13.1.1. Longitudinal change in brain amyloid plaque burden
3.13.1.2. Neuritic plaque
3.13.1.3. Neurofibrillary tangles
3.13.1.4. Plasma amyloid beta peptide concentrations ABx-40
3.13.1.5. Plasma amyloid beta peptide concentrations ABx-42
3.13.2. Cancer biomarker measurement
3.13.2.1. Circulating cell-free DNA
3.13.2.2. Insulin-like growth factors 
3.13.2.3. PCA3 expression level
3.13.2.4. Prostate-specific antigen levels
3.13.2.5. Tumor biomarkers
3.13.3. Cardiovascular disease biomarker
3.13.3.1. Plasma cystastin c levels in acute coronary syndrome
3.13.3.2. Ankle-brachial index
3.13.3.3. Aortic root size
3.13.3.4. Arterial stiffness
3.13.3.5. Arterial stiffness, association with
3.13.3.6. B-type natriuretic peptide
3.13.3.7. C4b binding protein levels
3.13.3.8. Cardiac repolarization
3.13.3.9. Cardiac repolarisation, association with
3.13.3.10. Carotid plaque burden smoking interaction
3.13.3.11. Carotid plaque, in coronary heart disease, association with
3.13.3.12. Circulating myeloperoxidase levels plasma
3.13.3.13. Circulating myeloperoxidase levels serum
3.13.3.14. Circulating vasoactive peptide levels
3.13.3.15. Increased pulse pressure
3.13.3.16. Lower pulse pressure and CIMT, association with
3.13.3.17. Natriuretic peptide levels
3.13.3.18. Osteoprotegerin levels
3.13.3.19. Paraoxonase activity
3.13.3.20. Plasma plasminogen activator levels
3.13.3.21. Pulse pressure alcohol consumption interaction
3.13.3.22. Pulse pressure in young-onset hypertension
3.13.3.23. Plasma renin activity levels
3.13.3.24. Heart function measurement
3.13.3.24.1. Atrioventricular conduction
3.13.3.24.2. Cardiac Troponin-T levels
3.13.3.24.3. Electrocardiography
3.13.3.24.3.1. PR interval
3.13.3.24.3.2. PR segment
3.13.3.24.3.3. P wave duration
3.13.3.24.3.4. QRS duration
3.13.3.24.3.5. QT interval interaction
3.13.3.24.3.6. QT interval
3.13.3.24.3.7. RR interval heart rate
3.13.4. Diabetes mellitus biomarker
3.13.4.1. Homeostasis model assessment of beta-cell function interaction
3.13.4.2. Homeostasis model assessment of insulin resistance interaction
3.13.4.3. Glucose measurement
3.13.4.3.1. Elevated fasting plasma glucose, association in NIDDM
3.13.4.3.2. Fasting glucose-related traits
3.13.4.3.3. Fasting plasma glucose
3.13.4.3.4. Fasting plasma glucose childhood
3.13.4.3.5. Fasting plasma glucose level, association with
3.13.4.3.6. Fasting plasma glucose levels, association with
3.13.4.3.7. Glycated hemoglobin levels
3.13.4.3.8. Glycemic traits pregnancy
3.13.4.3.9. Glycemic traits
3.13.4.3.10. Two-hour glucose challenge
3.13.4.3.11. Type 1 diabetes autoantibodies
3.13.4.4. Insulin measurement
3.13.4.4.1. Adipocyte insulin action, association with
3.13.4.4.2. Insulin-related traits
3.13.4.4.3. Fasting insulin-related traits
3.13.4.4.4. Fasting insulin interaction
3.13.4.4.5. Fasting insulin levels, association with
3.13.4.4.6. Fasting proinsulin concentration, association with
3.13.4.4.7. Lower serum insulin level
3.13.4.4.8. Proinsulin levels
3.13.4.5. Reduced fasting serum C-peptide concentration, association
3.13.5. Infectious disease biomarker
3.13.5.1. HPV seropositivity
3.13.5.2. Reduced HIV viral load, association with
3.13.6. Liver disease biomarker
3.13.6.1. Bilirubin levels
3.13.6.2. Post-transplant serum bilirubin levels, association with
3.13.6.3. Total bilirubin levels in HIV-1 infection
3.13.7. Respiratory disease biomarker
3.13.7.1. Airway imaging phenotypes
3.13.7.2. Chronic obstructive pulmonary disease-related biomarkers
3.13.7.3. Percentage gas trapping
3.13.7.4. Local histogram emphysema pattern
3.14. Coagulation factor levels
3.14.1. Fibrinogen
3.14.2. Fibrinogen levels smoking status, alcohol consumption or body mass index interaction
3.14.3. Protein C levels
3.14.4. Increased protein C levels
3.14.5. Reduced factor V levels
3.14.6. Reduced plasma F7 levels, association with
3.14.7. Reduced Protein C levels
3.14.8. Reduced plasma Protein S
3.14.9. Reduced Protein Z concentration
3.14.10. Reduced vWF plasma protein levels
3.14.11. vWF and FVIII levels
3.15. Employment status
3.15.1. Self-employment
3.16. Eye measurement
3.16.1. Anterior chamber depth
3.16.2. Axial length
3.16.3. Intraocular pressure
3.16.4. Pupillary light response, association with
3.16.5. Retinal arteriolar caliber
3.16.6. Retinal vascular caliber
3.16.7. Corneal topography
3.16.7.1. Corneal curvature
3.16.7.2. Corneal curvature, association with
3.16.7.3. Corneal structure
3.16.7.4. Central corneal thickness
3.17. Fatty acid measurement
3.17.1. Choline requirement, association with
3.17.2. Increased triglyceride level in males
3.17.3. Increased triglyceride levels
3.17.4. Increased triglyceride levels, association with
3.17.5. Increased triglyceride levels, in endogenous hypertriglyceridaemic subjects, association with
3.17.6. Lipid levels in hyperlipidaemia, association with
3.17.7. Low triglyceride levels
3.17.8. Lower plasma triglyceride level
3.17.9. Lower plasma triglyceride level, association with
3.17.10. Lower triglyceride level, association with
3.17.11. Oleic acid 18:1n-9 plasma levels
3.17.12. Trans fatty acid levels
3.17.13. Very long-chain saturated fatty acid levels fatty acid 20:0
3.17.14. Very long-chain saturated fatty acid levels fatty acid 22:0
3.17.15. Very long-chain saturated fatty acid levels fatty acid 24:0
3.17.16. Plasma omega-6 polyunsaturated fatty acid levels adrenic acid
3.17.17. Plasma omega-6 polyunsaturated fatty acid levels arachidonic acid
3.17.18. Plasma omega-6 polyunsaturated fatty acid levels dihomo-gamma-linolenic acid
3.17.19. Plasma omega-6 polyunsaturated fatty acid levels gamma-linolenic acid
3.17.20. Plasma omega-6 polyunsaturated fatty acid levels linoleic acid
3.17.21. Red blood cell fatty acid levels
3.17.22. Reduced plasma triglyceride levels, association with
3.17.23. Reduced serum triglyceride concentration
3.17.24. Triacylglycerol and HDL levels, association with
3.17.25. Triglyceride levels, association with
3.18. Gait measurement
3.18.1. Gait rhythm
3.18.2. Gait variability
3.18.3. Tandem gait
3.19. General measures
3.19.1. Biochemical measures
3.19.2. Biomedical quantitative traits
3.19.3. Metabolic traits
3.19.4. Quantitative traits
3.20. Genomic measurement
3.20.1. Altered double-strand break repair
3.20.2. Altered level of single strand breaks
3.20.3. Altered mRNA expression
3.20.4. Altered mRNA folding
3.20.5. Altered mRNA stability
3.20.6. Altered splicing
3.20.7. Altered splicing efficiency
3.20.8. Altered transcription
3.20.9. Altered transcriptional regulation
3.20.10. Alternate splicing
3.20.11. Alternative splicing
3.20.12. DNA repair rate, association with


3.20.13. Increased genomic instability
3.20.14. Increased transcription
3.20.15. Increased transcriptional activity
3.20.16. Increased translation rate
3.20.17. Telomere length
3.20.18. Recombination measurement
3.20.18.1. Altered recombination frequency
3.20.18.2. Genome-wide recombination rate, association with
3.20.18.3. Recombination measurement females
3.20.18.4. Recombination measurement males
3.20.18.5. Recombination rate females
3.20.18.6. Recombination rate males
3.20.19. Reduced crossover rate
3.20.20. Reduced mRNA expression
3.20.21. Reduced mRNA levels
3.20.22. Reduced mRNA splicing efficiency
3.20.23. Reduced mRNA stability
3.20.24. Reduced transcription
3.20.25. Reduced transcriptional activity
3.20.26. Reduced transcriptional efficiency
3.20.27. Reduced transcriptional efficiency, association
3.20.28. Shorter telomere length, association with
3.20.29. Shorter transcript, association with
3.21. Hematological measurement
3.21.1. Activated partial thromboplastin time
3.21.2. Erythrocyte sedimentation rate, association with
3.21.3. Haptoglobin levels
3.21.4. Hematocrit
3.21.5. Hematological and biochemical traits
3.21.6. Hematological parameters
3.21.7. Hematology traits
3.21.8. Hemostatic factors and hematological phenotypes
3.21.9. Monocyte count
3.21.9.1. Altered monocyte receptor levels
3.21.9.2. Circulating monocyte count, association with
3.21.10. Mean cell volume, association with
3.21.11. Mean corpuscular volume, association with
3.21.12. Plasma lipid concentration association with
3.21.13. Plasma lipids, association with
3.21.14. Prothrombin time
3.21.15. Reactive oxygen species levels, in peripheral blood  mononuclear cells, association with
3.21.16. Red blood cell count
3.21.17. Red blood cell count, association with
3.21.18. White blood cell count, association with
3.21.19. White blood cell count
3.21.19.1. White blood cell types
3.21.20. Erythrocyte measurement
3.21.20.1. Mean corpuscular hemoglobin concentration
3.21.20.2. Mean corpuscular hemoglobin
3.21.20.3. Mean corpuscular volume
3.21.20.4. Other erythrocyte phenotypes
3.21.21. Hemoglobin levels
3.21.21.1. Hemoglobin
3.21.21.2. Haemoglobin concentrations, association with
3.21.21.3. Haemoglobin levels, association with
3.21.21.4. Lower haemoglobin levels, association with
3.21.21.5. Mean cell haemoglobin concentration, association with
3.21.21.6. Mean cell haemoglobin, association with
3.21.21.7. Mean corpuscular hemoglobin concentration, association with
3.21.21.8. Mean corpuscular hemoglobin, association with
3.21.21.9. Fetal hemoglobin levels
3.21.21.10. F-cell distribution
3.21.21.11. HbA2 levels
3.21.21.12. Hemoglobin A2 levels in sickle cell anemia
3.21.21.13. Red blood cell traits
3.21.21.14. Reduced haemoglobin A1C levels
3.21.21.15. Reduced haemoglobin levels
3.21.22. Neutrophil count
3.21.22.1. Neutrophil count in HIV-infection
3.21.23. Platelet measurement
3.21.23.1. Altered platelet volume
3.21.23.2. Mean platelet volume
3.21.23.3. Lower platelet binding capacity
3.21.23.4. Lower platelet binding capacity, association with
3.21.23.5. Lower platelet levels, association with
3.21.23.6. Platelet count
3.21.23.7. Platelet aggregation
3.21.23.8. Platelet count, association with
3.21.23.9. Platelet count and volume, association with
3.21.23.10. Platelet volume, association with
3.22. Hormone measurements
3.22.1. Androgen levels
3.22.2. Elevated basal serum calcitonin
3.22.3. Increased thyroid hormone levels, association with
3.22.4. Low testosterone, increased risk, assoc with
3.22.5. Low serum adiponectin level, association with
3.22.6. Lower telomerase activity
3.22.7. Lower testosterone levels
3.22.8. Free thyroxine concentration
3.22.9. Follicule stimulating hormone
3.22.10. Testosterone levels
3.22.11. Thyroid stimulating hormone
3.22.12. Thyroid hormone levels
3.22.13. Dehydroepiandrosterone sulphate levels
3.22.14. Plasma thyroid-stimulating hormone levels
3.22.15. Reduced serum FSH
3.22.16. Reduced serum thyroxine
3.22.17. Sex hormone-binding globulin levels
3.22.18. Sex hormone levels
3.22.19. Soluble leptin receptor levels
3.22.20. Thyroid-stimulating hormone concentration, association with
3.23. Inflammatory biomarkers
3.23.1. Inflammatory biomarkers in Kawasaki disease
3.23.2. Amyloid A serum levels
3.23.3. CD4:CD8 lymphocyte ratio
3.23.4. Interleukin-18 levels
3.23.5. Proinflammatory cytokine levels
3.24. Iron levels
3.24.1. Iron status biomarkers ferritin levels
3.24.2. Iron status biomarkers iron levels
3.24.3. Iron status biomarkers transferrin levels
3.24.4. Iron status biomarkers transferrin saturation
3.24.5. Iron status biomarkers
3.25. Lipid or lipoprotein measurement
3.25.1. Cholesterol and Triglycerides
3.25.2. Fasting HDL cholesterol, association with
3.25.3. HDL-C and triglyceride levels, in African Americans, association with
3.25.4. HDL and triglyceride levels, association with
3.25.5. HDL cholesterol and proinsulin levels, association with
3.25.6. HDL Cholesterol - Triglycerides HDLC-TG
3.25.7. Lipid measurement
3.25.7.1. Lipid traits 
3.25.7.2. Sphingolipid levels
3.25.7.3. Triglycerides
3.25.7.4. Phospholipid measurement
3.25.7.4.1. Phospholipid levels plasma
3.25.7.4.2. Glycerophospholipid levels
3.25.7.4.3. Palmitic acid 16:0 plasma levels
3.25.7.4.4. Palmitoleic acid 16:1n-7 plasma levels
3.25.7.4.5. Stearic acid 18:0 plasma levels
3.25.7.5. Elevated plasma lipid concentration, association in diabetes
3.25.8. Lipoprotein measurement
3.25.8.1. Altered HDL cholesterol level in hypercholesterolaemia
3.25.8.2. Altered HDL cholesterol levels
3.25.8.3. Cholesterol, total
3.25.8.4. Cholesterol level
3.25.8.5. Decreased HDL cholesterol, association with
3.25.8.6. Decreased HDL3-C and apoA-I level in females
3.25.8.7. Elevated HDL-cholesterol, association with
3.25.8.8. Elevated serum APOA1, association with
3.25.8.9. HDL cholesterol concentration, association with
3.25.8.10. HDL cholesterol levels, association with
3.25.8.11. HDL cholesterol levels, in women, association with
3.25.8.12. HDL cholesterol, association with
3.25.8.13. HDL-C levels, association with
3.25.8.14. HDL-C levels, in African blacks, association with
3.25.8.15. Increased serum cholesterol, association with
3.25.8.16. Increased serum cholesterol, in low-cholesterol consumers
3.25.8.17. Increased total cholesterol
3.25.8.18. HDL cholesterol
3.25.8.19. LDL cholesterol
3.25.8.20. LDL cholesterol levels, association with
3.25.8.21. LDL-cholesterol & total cholesterol levels, association
3.25.8.22. LDL-cholesterol levels, association with
3.25.8.23. LDL-cholesterol, association with
3.25.8.24. Lipoprotein levels, association with
3.25.8.25. Lipoprotein/Triglyceride levels, association with
3.25.8.26. Low LDL cholesterol
3.25.8.27. Low LDL cholesterol, association with
3.25.8.28. Lower HDL cholesterol level
3.25.8.29. Lower plasma LDL and HDL levels, association with
3.25.8.30. Lower plasma LDL cholesterol, association with
3.25.8.31. Lower total cholesterol, association with
3.25.8.32. Lp a levels
3.25.8.33. Apolipoprotein Levels
3.25.8.33.1. Altered APOB levels
3.25.8.34. LDL peak particle diameter total fat intake interaction
3.25.8.35. Lipoprotein-associated phospholipase A2 activity and mass
3.25.8.36. LDL oxidized
3.25.8.37. Plasma cholesterol levels, association with
3.25.8.38. Plasma HDL cholesterol
3.25.8.39. Plasma HDL cholesterol, association with
3.25.8.40. Reduced LDL cholesterol levels
3.25.8.41. Reduced LDL cholesterol levels, association with
3.25.8.42. Reduced plasma cholesterol
3.25.8.43. Reduced plasma HDL cholesterol
3.25.8.44. Reduced plasma HDL cholesterol, association with
3.25.8.45. Reduced plasma LDL cholesterol in FH, association with
3.25.8.46. Reduced serum noncholesterol sterols
3.25.8.47. Reduced serum noncholesterol sterols, association with
3.25.8.48. Reduced total cholesterol
3.25.8.49. Total cholesterol levels, association with
3.26. Liver enzyme levels
3.26.1. Gamma gluatamyl transferase levels
3.26.2. Gamma glutamyl transpeptidase
3.26.3. Liver enzyme levels alanine transaminase
3.26.4. Liver enzyme levels alkaline phosphatase
3.26.5. Liver enzyme levels aspartate transaminase
3.26.6. Liver enzyme levels gamma-glutamyl transferase
3.27. Mammographic density
3.27.1. Percent mammographic density
3.27.2. Mammographic density dense area
3.27.3. Mammographic density non-dense area
3.28. Mental or behavioral disorder biomarker
3.28.1. Attention function in attention deficit hyperactive disorder
3.28.2. Childhood and early adolescence aggressive behavior
3.28.3. Middle childhood and early adolescence aggressive behavior
3.28.4. Seasonality
3.28.5. Neuranatomic and neurocognitive phenotypes
3.28.6. Depressive symptoms SSRI exposure interaction
3.29. Metabolite measurement
3.29.1. Acylcarnitine levels
3.29.2. AR-C124910XX levels in individuals with acute coronary syndromes treated with ticagrelor
3.29.3. Blood metabolite levels
3.29.4. Blood metabolite ratios
3.29.5. Metabolite levels 5-HIAA MHPG Ratio
3.29.6. Metabolite levels 5-HIAA
3.29.7. Metabolite levels Dihydroxy docosatrienoic acid
3.29.8. Metabolite levels HVA-5-HIAA Factor score
3.29.9. Metabolite levels HVA5-HIAA ratio
3.29.10. Metabolite levels HVAMHPG ratio
3.29.11. Metabolite levels HVA
3.29.12. Metabolite levels MHPG
3.29.13. Metabolite levels Pyroglutamine
3.29.14. Metabolite levels
3.29.15. Metabolite levels  X-11787
3.29.16. Urinary metabolites
3.29.16.1. Urinary metabolites H-NMR features
3.29.16.2. Urinary uromodulin levels
3.29.16.3. Urinary albumin excretion rate in type 1 diabetes
3.29.16.4. Urinary albumin excretion
3.30. Nitric oxide exhalation measurement
3.30.1. Fractional exhaled nitric oxide levels
3.30.2. Fractional exhaled nitric oxide childhood
3.31. Optic disc measurement
3.31.1. Optic cup area
3.31.2. Optic disc area
3.31.3. Optic disc parameters
3.31.4. Optic nerve measurement cup area
3.31.5. Optic nerve measurement cup-to-disc ratio
3.31.6. Optic nerve measurement disc area
3.31.7. Optic nerve measurement rim area
3.31.8. Vertical cup-disc ratio
3.32. Protein
3.32.1. Angiotensin-converting enzyme activity
3.32.2. ADAMTS13 activity
3.32.3. Adiponectin levels
3.32.4. Beta-2 Microglobulin
3.32.4.1. ?2-Microglobulin deficiency
3.32.4.2. Beta-2 microglubulin plasma levels
3.32.5. Butyrylcholinesterase levels
3.32.6. C-reactive protein levels
3.32.7. C-reactive protein
3.32.8. CRIPTO serum levels, association with
3.32.9. D-dimer levels
3.32.10. Elevated plasma fibrinogen levels
3.32.11. Elevated serum MGP
3.32.12. Increased protein levels
3.32.13. L-selectin levels, association with
3.32.14. Immunoglobulin A
3.32.15. Matrix metalloproteinase levels
3.32.16. Non-albumin protein levels
3.32.17. Protein biomarker
3.32.18. Soluble E-selectin levels
3.32.19. Soluble ICAM-1
3.32.20. Tamm Horsfall protein levels, association with
3.32.21. Vascular endothelial growth factor levels
3.32.22. Plasma plasminogen levels
3.32.23. Complement C3 and C4 levels
3.32.24. Cytokine measurement
3.32.24.1. Interferon alpha levels in systemic lupus erythematosus
3.32.24.2. Monocyte chemoattractant protein-1
3.33. Puberty
3.33.1. Pubertal anthropometrics
3.33.2. Puberty onset breast development
3.33.3. Puberty onset genital enlargement
3.33.4. Puberty onset
3.33.4.1. Central precocious puberty, idiopathic
3.33.4.2. Delayed puberty
3.33.4.3. Precocious puberty
3.34. Pulmonary function
3.34.1. Airflow obstruction
3.34.2. Airway responsiveness in chronic obstructive pulmonary disease
3.34.3. Altered lung function, association with
3.34.4. Altered pulmonary function, association with
3.34.5. Forced expiratory volume in 1 second
3.34.6. Forced expiratory volume in 1 second environmental interaction
3.34.7. Forced vital capacity
3.34.8. Lung function in smokers, association with
3.34.9. Maximal oxygen uptake response
3.34.10. Pulmonary function in asthmatics
3.34.11. Pulmonary function interaction
3.34.12. Resting oxygen saturation in chronic osbtructive pulmonary disease pulse oximetry
3.35. Renal system measurement
3.35.1. Acute kidney injury in coronary artery bypass surgery creatinine rise
3.35.2. Beta-trace protein levels
3.35.3. Creatinine levels
3.35.4. Glomerular filtration rate
3.35.5. Renal function and chronic kidney disease
3.35.6. Renal function-related traits BUN
3.35.7. Renal function-related traits eGRFcrea
3.35.8. Renal function-related traits sCR
3.35.9. Renal function-related traits urea
3.35.10. Chronic kidney disease and serum creatinine levels
3.35.11. Kidney function decline traits
3.36. Selenium measurement
3.36.1. Blood and toenail selenium levels
3.36.2. Toenail selenium levels
3.37. Serum measurements
3.37.1. Serum dimethylarginine measurement
3.37.1.1. Asymmetrical dimethylarginine levels
3.37.1.2. Symmetrical dimethylarginine levels
3.37.2. Serum albumin level
3.37.3. Serum alkaline phosphatase levels
3.37.4. Serum alpha1
3.37.5. Serum ceruloplasmin levels
3.37.6. Serum dimethylarginine levels asymmetricsymetric ratio
3.37.7. Serum IgA levels
3.37.8. Serum IgE levels
3.37.9. Serum lipase activity
3.37.10. Serum metabolite levels
3.37.11. Serum prostate-specific antigen levels
3.37.12. Serum protein levels sST2
3.37.13. Serum selenium levels
3.37.14. Serum tamsulosin hydrochloride concentration
3.37.15. Serum thyroid-stimulating hormone levels
3.37.16. Serum total protein level
3.37.17. Serum uric acid levels
3.37.18. Serum VEGFR2 concentration
3.37.19. Serum vitamin D-binding protein levels
3.37.20. Blood trace element Cu levels
3.37.21. Blood trace element Se levels
3.37.22. Blood trace element Zn levels
3.37.23. Lower serum APOC3 level
3.38. Sleep measurement
3.38.1. Deep sleep, duration and intensity, association with
3.38.2. Sleep duration
3.38.3. Sleep quality
3.38.4. Sleep time
3.39. Smoking behavior measurement
3.39.1. Age at smoking initiation in chronic obstructive pulmonary disease
3.39.2. Current cigarettes per day in chronic obstructive pulmonary disease
3.39.3. Lifetime average cigarettes per day in chronic obstructive pulmonary disease
3.39.4. Smoking cessation in chronic obstructive pulmonary disease
3.40. Temporal measurement
3.40.1. Life expectancy in centenarians, association with
3.40.2. Longevity
3.40.3. Longevity, association with
3.40.4. Longevity 85 years and older
3.40.5. Longevity 90 years and older
3.40.6. Age
3.40.6.1. Menarche age at onset
3.40.6.1.1. Age at menarche, association with
3.40.6.2. Menarche and menopause age at onset
3.40.6.3. Menopause age at onset
3.40.6.3.1. Age at menopause
3.40.6.3.2. Age at menopause, association with
3.40.7. Clinical temporal measurement
3.40.7.1. Survival in endocrine treated breast cancer estrogen-receptor positive
3.40.7.2. Breast cancer survival
3.40.7.3. Disease-free survival in breast cancer
3.40.7.4. Multiple myeloma survival
3.40.7.5. Non-small cell lung cancer survival
3.40.7.6. Progression free survival in metastatic colorectal cancer CAPOX-B vs CAPOX-B plus cetuximab
3.40.7.7. Progression free survival in metastatic colorectal cancer treatment interaction
3.40.7.8. Prostate cancer survival
3.40.7.9. Small-cell lung cancer survival
3.41. Thyroid function
3.41.1. Thyroid volume 
3.42. Uncategorized measurements
3.42.1. 3-Hydroxybuyrate levels, association with
3.42.2. Advanced glycation end-product levels
3.42.3. Allogeneic hematopoietic stem cell transplantation, outcome, association with
3.42.4. Altered methionine sulfoxide levels
3.42.5. Aspirin hydrolysis plasma
3.42.6. Brain connectivity 
3.42.7. C-reactive protein and white blood cell count
3.42.8. Calcium levels
3.42.9. Carotenoid and tocopherol levels
3.42.10. Cotinine glucuronidation
3.42.11. Fecundability, association with
3.42.12. Hearing function
3.42.13. High serum lipase activity
3.42.14. Homoarginine levels
3.42.15. Longitudinal alcohol consumption
3.42.16. Magnesium levels
3.42.17. Menstrual cycle, length, association with
3.42.18. Metastasis at diagnosis in osteosarcoma
3.42.19. MGMT methylation in smokers
3.42.20. Monocyte early outgrowth colony forming units
3.42.21. Nicotine glucouronidation 
3.42.22. Oligoclonal band status in multiple sclerosis
3.42.23. Ovarian follicle number, association with
3.42.24. Phosphorus levels
3.42.25. Phytosterol levels
3.42.26. Progranulin levels
3.42.27. Renal transplant outcome 
3.42.28. Thrombin generation potential phenotypes
3.42.29. Ticagrelor levels in individuals with acute coronary syndromes treated with ticagrelor
3.42.30. Vaspin levels
3.43. Urate levels
3.43.1. Urate levels BMI interaction
3.43.2. Urate levels in lean individuals
3.43.3. Urate levels in obese individuals
3.43.4. Urate levels in overweight individuals
3.43.5. Uric acid concentration, association with
3.44. Vital signs
3.44.1. Blood pressure
3.44.1.1. Ambulatory blood pressure
3.44.1.2. Ambulatory blood pressure variation
3.44.1.3. Blood pressure anthropometric measures interaction
3.44.1.4. Blood pressure measurement cold pressor test
3.44.1.5. Blood pressure measurement high sodium and potassium intervention
3.44.1.6. Blood pressure measurement high sodium intervention
3.44.1.7. Blood pressure measurement low sodium intervention
3.44.1.8. Blood pressure variation in response to potassium, association with
3.44.1.9. Blood pressure variation, association with
3.44.1.10. Blood pressure, association with
3.44.1.11. Blood pressure, systolic, association with
3.44.1.12. Diastolic blood pressure
3.44.1.13. Diastolic blood pressure alcohol consumption interaction
3.44.1.14. Lower blood pressure in males, association with
3.44.1.15. Lower blood pressure, association with
3.44.1.16. Systolic blood pressure
3.44.1.17. Systolic blood pressure in sickle cell anemia
3.44.1.18. Systolic blood pressure alcohol consumption interaction
3.44.1.19. Reduced blood pressure, association with
3.44.1.20. Reduced diastolic blood pressure, association with
3.44.1.21. Systolic blood pressure, association with
3.44.1.22. Blood pressure age interaction
3.44.1.23. Mean arterial pressure alcohol consumption interaction
3.44.2. Heart rate
3.44.2.1. Heart rate response to submaximal exercise, association with
3.44.2.2. Heart rate, association with
3.44.2.3. Heart rate. association with
3.44.2.4. Resting heart rate
3.45. Vitamin measurements
3.45.1. Circulating phylloquinone levels
3.45.2. Folate pathway vitamin levels
3.45.3. Vitamin B12 levels
3.45.4. Vitamin B levels in ischemic stroke
3.45.5. Vitamin D levels
3.45.6. Vitamin E levels
3.45.7. Retinol levels
3.45.8. Reduced serum folate
3.45.9. Serum vitamin B12 levels, association with
3.45.10. Serum VitB12 level, association with
3.45.11. Vitamin D affinity, association with
3.45.12. Vitamin D status / height, association with
3.46. Wine liking
3.46.1. Red wine liking
3.46.2. White wine liking
4. Quality
4.1. Aerobic endurance, association with
4.2. Common traits Other 
4.3. Medicine type
4.3.1. Yu-Zhi constitution type in type 2 diabetes
4.3.2. Sasang constitutional medicine type So-Eum
4.4. Personality
4.4.1. Personality dimensions
4.4.2. Temperament
4.4.3. Neuroticism
4.5. Phenotype
4.5.1. Male fertility
4.5.2. Birbeck granules deficiency
4.5.3. Blood phenotype
4.5.3.1. Blood groups
4.5.3.1.1. At(a-) blood group variation
4.5.3.1.2. Blood group variant In(Lu)
4.5.3.1.3. Blood group variation
4.5.3.1.4. Colton blood group variant
4.5.3.1.5. Cromer blood group
4.5.3.1.6. Dombrock blood group variation
4.5.3.1.7. Duffy blood group antigen, absence
4.5.3.1.8. Duffy blood group variation
4.5.3.1.9. Histo-blood group variant (P1/P2)
4.5.3.1.10. Kell blood group variation
4.5.3.1.11. Kidd blood group variant
4.5.3.1.12. Knops blood group variation
4.5.3.1.13. Lan(-) blood group variant
4.5.3.1.14. Lan(w) blood group variant
4.5.3.1.15. Lewis antigen, absence
4.5.3.1.16. RhD blood group variant
4.5.3.1.17. Rhesus blood group variant
4.5.3.1.18. Rhesus negative blood group
4.5.3.1.19. Scianna blood group variation
4.5.3.1.20. Ss blood group variation
4.5.3.1.21. YT2 blood group antigen
4.5.3.2. Red blood cell traits, association with
4.5.3.3. White blood cell traits, association with
4.5.4. Body measurement
4.5.4.1. Birthweight
4.5.4.1.1. Higher birth weight, association with
4.5.4.1.2. Increased birth weight, association with
4.5.4.2. BMI
4.5.4.2.1. Higher body mass index, association with
4.5.4.2.2. Higher bone mass density, association with
4.5.4.2.3. Increased BMI in adult males, association with
4.5.4.2.4. Increased BMI, association with
4.5.4.2.5. Increased body mass index, association with
4.5.4.2.6. Reduced BMI, association with
4.5.4.2.7. Reduced BMI, in adult males, association with
4.5.4.2.8. Reduced BMI, in COPD, association with
4.5.4.3. Body weight
4.5.4.3.1. Increased body weight, association with
4.5.4.3.2. Weight variance, association with
4.5.5. Cardiometabolic traits, association with
4.5.6. CYP2B6 expression
4.5.7. Dark hair and brown eyes, association with
4.5.8. Diurnal preference traits, association with
4.5.9. Diurnal preference, association with
4.5.10. Eye
4.5.10.1. Crypt frequency in the iris, association with
4.5.10.2. Eye color
4.5.10.2.1. Blue eye colour, association with
4.5.10.2.2. Blue vs. brown eyes
4.5.10.2.3. Blue vs. green eyes
4.5.10.2.4. Darker eye colour, association with
4.5.10.2.5. Iris characteristics
4.5.11. Facial morphology
4.5.11.1. Facial pigmentation
4.5.12. Furrow contractions in the iris, association with
4.5.13. Hair morphology
4.5.13.1. Hair color
4.5.13.2. Hair colour, association with
4.5.13.3. Blond hair colour
4.5.13.4. Black vs. blond hair color
4.5.13.5. Black vs. red hair color
4.5.13.6. Blond vs. brown hair color
4.5.13.7. Fair hair, association with
4.5.13.8. Red hair, increased risk
4.5.13.9. Red vs non-red hair color
4.5.14. Ear
4.5.14.1. Earwax type, association with
4.5.14.2. Outer ear morphology
4.5.14.2.1. Antitragus size
4.5.14.2.2. Folding of antihelix
4.5.14.2.3. Helix rolling
4.5.14.2.4. Lobe attachment
4.5.14.2.5. Lobe size
4.5.15. Phenotypic abnormality
4.5.15.1. Coronary arterial lesions in patients with Kawasaki disease
4.5.15.2. Dysphagia
4.5.15.3. LachrymalSalivary gland lesion in type 1 autoimmune pancreatitis
4.5.15.4. Ocular & skeletal abnormalities
4.5.15.5. Abnormality of metabolism/homeostasis
4.5.15.5.1. Abnormality of ion homeostasis
4.5.15.5.1.1. Abnormality of sodium homeostasis
4.5.15.5.1.1.1. Hyponatraemia, association with
4.5.15.6. Abnormality of the nervous system
4.5.15.6.1. Cognitive decline
4.5.15.6.2. Headache
4.5.15.6.2.1. Cluster headache, association with
4.5.15.6.3. Febrile seizures
4.5.15.6.3.1. Febrile seizures MMR vaccine-related
4.5.15.6.3.2. Febrile seizures MMR vaccine-unrelated
4.5.15.6.3.3. Febrile seizures, association with
4.5.15.6.4. Smaller decline in cholesterol synthesis after weight loss
4.5.15.6.5. Smaller reference luminal diameter, association
4.5.16. Premature birth
4.5.16.1. Preterm birth, association with
4.5.16.2. Preterm delivery, increased risk, association with
4.5.16.3. Spontaneous preterm birth preterm birth
4.5.16.4. Spontaneous preterm birth preterm delivery
4.5.17. Skin pigmentation
4.5.17.1. Ephelides, increased risk, association with
4.5.17.2. Freckles
4.5.17.3. Freckling
4.5.17.4. Olive skin colour in Caucasians, association with
4.5.17.5. Skin colour saturation
4.5.17.6. Skin pigmentation, association with
4.5.17.7. Perceived skin darkness
4.5.17.8. Tanning
4.5.18. Sign or symptom
4.5.18.1. Abnormal insulin secretion
4.5.18.2. Acute insulin response, association with
4.5.18.3. Airway hyperresponsiveness
4.5.18.3.1. Airway hyperresponsiveness, association with
4.5.18.3.2. Airway hyperresponsiveness after viral infection, association with
4.5.18.4. Chronic mucus hypersecretion
4.5.18.5. Coronary artery calcification
4.5.18.5.1. Coronary artery calcification, in African Americans, association with
4.5.18.6. Delayed memory recall, association with
4.5.18.7. Dementia and core Alzheimers disease neuropathologic changes
4.5.18.8. Gucose-stimulated insulin secretion, association with
4.5.18.9. HIV-associated dementia
4.5.18.10. Formal thought disorder in schizophrenia
4.5.18.11. Insulin resistanceresponse
4.5.18.12. Pulmonary artery enlargement in chronic obstructive pulmonary disease
4.5.18.13. Pulmonary artery enlargement and chronic obstructive pulmonary disease
4.5.18.14. Vein graft stenosis in coronary artery bypass grafting
4.5.18.15. Autism spectrum disorder symptom
4.5.18.15.1. Social communication problems
4.5.18.15.2. Social autistic-like traits
4.5.18.16. Functional laterality
4.5.18.16.1. Handedness in dyslexia
4.5.18.16.2. Relative hand skill in reading disability
4.5.18.17. Pain
4.5.18.17.1. Abdominal pain, association with
4.5.18.17.2. Chronic non-paroxysmal neuropathic pain
4.5.18.17.3. Congenital indifference to pain, partial
4.5.18.17.4. Increased chronic pain, association with
4.5.18.17.5. Pain insensitivity, congenital
4.5.18.17.6. Pain perception, association with
4.5.18.17.7. Neuropathic pain in type 2 diabetes
4.5.18.18. Plaque calcification, increased risk, association with
4.5.19. Uncategorized Variants
4.5.19.1. CYP3A4 variant
4.5.19.2. CYP3A5 variant
4.5.19.3. Fibrinogen variant
4.5.19.4. FMO1 variant
4.5.19.5. FMO2 variant
4.5.19.6. FMO3 variant
4.5.19.7. FMO4 variant
4.5.19.8. Gamma-glutamyl carboxylase deficiency
4.5.19.9. Glutathione synthetase deficiency
4.5.19.10. Haemoglobin variant
4.5.19.11. Luteinizing hormone variant
4.5.19.12. Paraoxonase activity variant
4.5.19.13. Splice variant
4.5.19.14. Thiopurine S-methyltransferase variant
4.5.19.15. Transferrin variant
4.5.19.16. Wolframin variant
4.5.20. QRS interval, association with
4.5.21. Reduced semen quality, association with
4.5.22. Renal traits, association with
4.5.23. Thyroid hormone resistance modifier
4.5.24. TRAR3 null allele
4.5.25. VWF binding, association with
5. Process
5.1. Planned process
5.1.1. Self-rated health
6. Disease: reduced/decreased risk, protection against, survival
6.1. Disease by infectious agent
6.1.1. Bacterial infectious disease
6.1.1.1. Invasive pneumococcal disease, protection against
6.1.1.2. Meningococcal disease, reduced risk, association with
6.1.1.3. Primary bacterial infectious disease
6.1.1.3.1. Leprosy
6.1.1.3.1.1. Leprosy, protection against, association with
6.1.1.3.2. Tuberculosis
6.1.1.3.2.1. Paediatric tuberculosis, reduced risk, association with
6.1.1.3.2.2. Pulmonary tuberculosis, protection, association with
6.1.1.3.2.3. Tuberculosis caused by Mycobacterium tuberculosis, protection against, association
6.1.1.3.2.4. Tuberculosis, reduced susceptibility, association with
6.1.2. Fungal infectious disease
6.1.3. Parasitic infectious disease
6.1.3.1. Parasitic protozoa infectious disease
6.1.3.1.1. Malaria
6.1.3.1.1.1. Malaria, protection against, association with
6.1.3.2. Resistance to Trypanosoma brucei rhodesiense parasite, association with
6.1.4. Infectious disease, protection against, association with
6.1.5. Viral infectious disease
6.1.5.1. Dengue disease
6.1.5.1.1. Dengue disease, protection against, association with
6.1.5.2. Hepatitis
6.1.5.2.1. Hepatitis B, protection against, association with
6.1.5.3. Haemorrhagic fever with renal syndrome, reduced severity, association with
6.1.5.4. Human immunodeficiency virus infectious disease
6.1.5.4.1. AIDS progression
6.1.5.4.1.1. AIDS progression, protection, association with
6.1.5.4.2. HIV 1 infection, reduced risk, association with
6.1.5.4.3. HIV 1, resistance to, association with
6.1.5.5. SarS-CoV infection, protection, association
6.2. Disease of anatomical entity
6.2.1. Cardiovascular system disease
6.2.1.1. Cardiovascular disease biomarkers
6.2.1.1.1. Carotid plaques, protection against in SLE, association with
6.2.1.2. Heart disease
6.2.1.2.1. Cardiac hypertrophy, protection, association
6.2.1.2.2. Cardiomyopathy
6.2.1.2.2.1. Cardiomyopathy, dilated, reduced risk
6.2.1.2.2.2. Intrinsic cardiomyopathy
6.2.1.2.2.2.1. Acquired long QT syndrome, protection against, association
6.2.1.2.3. Congenital heart defect, protection against
6.2.1.2.4. Congenital heart disease
6.2.1.2.4.1. Congenital heart disease, reduced susceptibility
6.2.1.2.5. Decreased mortality in heart failure, association with
6.2.1.2.6. Heart disease, reduced risk, association with
6.2.1.2.7. Heart failure, survival, association with
6.2.1.3. Pericardium disease
6.2.1.4. Vascular disease
6.2.1.4.1. Artery disease
6.2.1.4.1.1. Abdominal aortic aneurysm
6.2.1.4.1.1.1. Abdominal aortic aneurysm, reduced risk
6.2.1.4.1.2. Cerebrovascular disease
6.2.1.4.1.2.1. Pulmonary arterial hypertension
6.2.1.4.1.2.1.1. Pulmonary arterial hypertension, reduced risk
6.2.1.4.1.2.2. Stroke
6.2.1.4.1.2.2.1. Ischaemic stroke, haemorrhagic transformation, reduced risk
6.2.1.4.1.2.2.2. Ischaemic stroke, protection against
6.2.1.4.1.2.2.3. Ischaemic stroke, reduced risk
6.2.1.4.1.2.2.4. Ischemic stroke, protection against
6.2.1.4.1.2.2.5. Reduced post-stroke mortality, association with
6.2.1.4.1.2.2.6. Stroke, protection against, association with
6.2.1.4.1.2.2.7. Stroke, reduced risk in sickle cell anaemia
6.2.1.4.1.2.2.8. Stroke, reduced risk, association with
6.2.1.4.1.3. Coronary artery disease
6.2.1.4.1.3.1. Coronary artery disease, lower risk, association
6.2.1.4.1.3.2. Coronary artery disease, protection against, association with
6.2.1.4.1.3.3. Coronary artery disease, protection, association with
6.2.1.4.1.3.4. Coronary artery disease, reduced risk, association with
6.2.1.4.1.3.5. Coronary artery vasospasm
6.2.1.4.1.3.5.1. Angina pectoris, reduced risk
6.2.1.4.1.3.6. Coronary heart disease
6.2.1.4.1.3.6.1. Coronary heart disease, decreased risk
6.2.1.4.1.3.6.2. Coronary heart disease, lower risk
6.2.1.4.1.3.6.3. Coronary heart disease, reduced risk
6.2.1.4.1.3.6.4. Incident coronary heart disease, decreased risk, association
6.2.1.4.1.3.7. Coronary stenosis
6.2.1.4.1.3.7.1. Coronary stenosis, reduced risk
6.2.1.4.1.3.8. Lower total cholesterol levels and myocardial infarction, reduced risk
6.2.1.4.1.3.9. Myocardial infraction
6.2.1.4.1.3.9.1. Myocardial infarction, decreased risk, association with
6.2.1.4.1.3.9.2. Myocardial infarction, lower risk, association
6.2.1.4.1.3.9.3. Myocardial infarction, protection, association
6.2.1.4.1.3.9.4. Myocardial infarction, protection, association with
6.2.1.4.1.3.9.5. Myocardial infarction, reduced risk, association
6.2.1.4.1.3.9.6. Myocardial infarction, reduced risk, association with
6.2.1.4.1.3.10. Reduced risk of coronary artery disease, association
6.2.1.4.1.3.11. Reduced risk of coronary artery disease, association with
6.2.1.4.1.4. Hypertension
6.2.1.4.1.4.1. Essential hypertension
6.2.1.4.1.4.1.1. Essential hypertension, protection in low risk individials
6.2.1.4.1.4.1.2. Essential hypertension, reduced risk, association with
6.2.1.4.1.4.2. Hypertension, protection against, association with
6.2.1.4.1.4.3. Hypertension, reduced risk, association with
6.2.1.4.1.4.4. Insulin resistance hypertension, reduced risk, association
6.2.1.4.1.4.5. Low renin hypertension, association with
6.2.1.4.1.4.6. Pre-eclampsia
6.2.1.4.1.4.6.1. Preeclampsia, reduced risk, association with
6.2.1.4.1.4.7. Raised blood pressure, reduced risk, association with
6.2.1.4.1.4.8. Ventricular hypertrophy in hypertension, protection against
6.2.1.4.2. Ischemia
6.2.1.4.2.1. Brain ischemia
6.2.1.4.2.1.1. Cerebral Ischemia
6.2.1.4.2.1.1.1. Cerebral ischaemia, protection against, association
6.2.1.4.3. Vasculitis
6.2.1.4.3.1. Behcets disease
6.2.1.4.3.1.1. BehÃ§et disease, reduced risk, association with
6.2.1.4.4. Vein disease
6.2.1.4.4.1. Venous thrombosis
6.2.1.4.4.1.1. Deep vein thrombosis, reduced risk
6.2.1.4.4.1.2. Thrombosis, venous
6.2.1.4.4.1.3. Venous thromboembolism, protection against, in Caucasians, association with
6.2.1.4.4.1.4. Venous thromboembolism, reduced risk
6.2.1.4.4.1.5. Venous thrombosis, reduced risk, association
6.2.1.4.5. Thrombosis
6.2.1.4.5.1. Thromboembolic disease, association with
6.2.1.4.5.2. Thrombosis, increased risk
6.2.1.4.5.3. Thrombosis, increased risk, association with
6.2.1.4.5.4. Thrombotic microangiopathy following transplantation
6.2.2. Endocrine system disease
6.2.2.1. Adrenal gland disease
6.2.2.2. Cortisone reductase deficiency
6.2.2.3. Gonadal disease
6.2.2.4. Pancreas disease
6.2.2.4.1. Pancreatitis, chronic, protection against
6.2.2.4.2. Pancreatitis, reduced risk, association with
6.2.2.5. Parathyroid gland disease
6.2.2.6. Pituitary gland disease
6.2.2.7. Thyroid gland disease
6.2.3. Gastrointestinal system disease
6.2.3.1. Diarrhea
6.2.3.1.1. Diarrhea in travellers, reduced risk
6.2.3.2. Intestinal disease
6.2.3.2.1. Colonic disease
6.2.3.2.1.1. Megacolon
6.2.3.2.1.1.1. Hirschsprung disease, protection against, association with
6.2.3.2.2. Inflammatory bowel disease
6.2.3.2.2.1. Crohn’s disease
6.2.3.2.2.1.1. Crohn's disease, protection against
6.2.3.2.2.1.2. Crohn's disease and ulcerative colitis, reduced risk
6.2.3.2.2.2. Ulcerative colitis
6.2.3.2.2.2.1. Ulcerative colitis with colectomy, reduced risk
6.2.3.2.2.2.2. 
6.2.3.3. Mouth disease
6.2.3.3.1. Tooth disease
6.2.3.3.1.1. Periodontal disease
6.2.3.3.1.1.1. Periodontitis
6.2.3.3.1.1.1.1. Aggressive periodontitis, reduced risk, assoc with
6.2.4. Hematopoietic system disease
6.2.4.1. Anemia
6.2.4.1.1. Malarial anaemia, severe, protection against, association with
6.2.4.1.2. Normocytic anemia
6.2.4.1.2.1. Hemolytic anemia
6.2.4.1.2.1.1. Haemolytic uraemic syndrome, reduced susceptibility
6.2.4.1.3. Protection against malarial anaemia, association with
6.2.4.2. Blood coagulation disease
6.2.4.2.1. Hemophilia
6.2.4.2.1.1. Haemophilia A, inhibitor development, protection against
6.2.4.2.2. Thrombophilia
6.2.4.2.2.1. Thrombotic thrombocytopaenic purpura
6.2.4.3. Reduced hemolysis, in sickle cell disease, association with
6.2.5. Immune system disease
6.2.5.1. Hypersensitivity reaction disease
6.2.5.1.1. Atopy
6.2.5.1.1.1. Atopy, reduced risk, association with
6.2.5.1.2. Hypersensitivity reaction type II disease
6.2.5.1.2.1. Autoimmune disease of the nervous system
6.2.5.1.2.1.1. Autoimmune disease of the peripheral nervous system
6.2.5.1.2.1.1.1. Guillain-Barre syndrome
6.2.5.1.2.1.1.1.1. Guillain-Barre syndrome, reduced risk, association with
6.2.5.1.3. Hypersensitivity reaction type IV disease
6.2.5.1.3.1. Autoimmune disease of the gastrointestinal tract
6.2.5.1.3.1.1. Celiac disease
6.2.5.1.3.1.1.1. Celiac disease, reduced risk
6.2.5.1.3.2. Sjogren's syndrome, protection against, association with
6.2.6. Integumentary system disease
6.2.6.1. Hair disease
6.2.6.2. Nail disease
6.2.6.3. Skin disease
6.2.6.3.1. Dermatitis
6.2.6.3.1.1. Atopic dermatitis
6.2.6.3.1.1.1. Atopic dermatitis, protection against
6.2.6.3.1.1.2. Atopic dermatitis, reduced risk, association with
6.2.6.3.1.1.3. Reduced severity in atopic dermatitis, association with
6.2.6.3.1.2. Post burn hypertrophic scarring, decreased severity, association with
6.2.6.3.2. Psoriasis
6.2.6.3.2.1. Psoriasis, reduced risk
6.2.6.3.3. Urticaria
6.2.6.3.3.1. Urticaria, chronic, aspirin intolerant, reduced risk, association with
6.2.7. Musculoskeletal system disease
6.2.7.1. Connective tissue disease
6.2.7.1.1. Bone disease
6.2.7.1.1.1. Bone inflammation disease
6.2.7.1.1.1.1. Arthritis
6.2.7.1.1.1.1.1. Psoriatic arthritis, protection against, association with
6.2.7.1.1.1.1.2. Juvenile arthritis, lower risk, association
6.2.7.1.1.1.1.3. Juvenile rheumatoid arthritis, reduced risk, assoc
6.2.7.1.1.1.1.4. Rheumatoid arthritis
6.2.7.1.1.1.1.4.1. Rheumatoid arthritis, protection against
6.2.7.1.1.1.1.4.2. Rheumatoid arthritis, reduced risk
6.2.7.1.1.1.1.4.3. Rheumatoid arthritis, seropositive, reduced risk
6.2.7.1.1.2. Bone remodeling disease
6.2.7.1.1.2.1. Hyperostosis
6.2.7.1.1.2.1.1. Paget’s disease of bone
6.2.7.1.1.2.1.1.1. Paget disease of bone, reduced risk
6.2.7.1.2. Collagen disease
6.2.7.1.2.1. Scleroderma
6.2.7.1.2.1.1. Systemic scleroderma
6.2.7.1.2.1.1.1. Systemic sclerosis, protection against, association with
6.2.7.1.3. Ossification, protection against, association with
6.2.7.1.4. Systemic lupus erythematosus
6.2.7.1.4.1. Systemic lupus erythematosus, decreased susceptibility
6.2.7.1.4.2. Systemic lupus erythematosus, protection against, assoc
6.2.7.1.4.3. Systemic lupus erythematosus, protection against, association
6.2.7.1.4.4. Systemic lupus erythematosus, reduced risk, association
6.2.7.2. Muscular disease
6.2.8. Nervous system disease
6.2.8.1. Central nervous system disease
6.2.8.1.1. Brain disease
6.2.8.1.1.1. Epilepsy
6.2.8.1.1.1.1. Epilepsy, symptomatic, reduced risk
6.2.8.1.1.1.2. Epilepsy-related seizure, resistance to
6.2.8.1.1.2. Prion disease
6.2.8.1.1.2.1. Creutzfeldt-Jakob syndrome, protection, association with
6.2.8.1.2. Central nervous system malformation
6.2.8.1.2.1. Non-syndromic central nervous system malformation
6.2.8.1.2.1.1. Neural tube defects
6.2.8.1.2.1.1.1. Spina bifida, reduced risk, association with
6.2.8.1.3. Neurodegenerative disease
6.2.8.1.3.1. Demyelinating disease
6.2.8.1.3.1.1. Multiple sclerosis
6.2.8.1.3.1.1.1. Multiple sclerosis, protection, association
6.2.8.1.3.1.1.2. Multiple sclerosis, protection, association with
6.2.8.1.3.1.1.3. Multiple sclerosis, reduced risk, association with
6.2.8.1.3.2. Synucleinopathy
6.2.8.1.3.2.1. Multiple system atrophy
6.2.8.1.3.2.1.1. Multiple system atrophy, reduced risk
6.2.8.1.3.2.2. Parkinson’s disease
6.2.8.1.3.2.2.1. Parkinson disease, lower risk, association with
6.2.8.1.3.2.2.2. Parkinson disease, protection against, association
6.2.8.1.3.2.2.3. Parkinson disease, reduced risk, association with
6.2.8.1.3.2.2.4. Parkinson disease, sporadic, reduced risk
6.2.8.1.3.2.2.5. 
6.2.8.1.3.3. Tauopathy
6.2.8.1.3.3.1. Alzheimer’s disease
6.2.8.1.3.3.1.1. Alzheimer disease, early-onset, decreased risk, association
6.2.8.1.3.3.1.2. Alzheimer disease, late onset, protection against
6.2.8.1.3.3.1.3. Alzheimer disease, late-onset, decreased risk
6.2.8.1.3.3.1.4. Alzheimer disease, late-onset, reduced risk, association with
6.2.8.1.3.3.1.5. Alzheimer disease, protection against
6.2.8.1.3.3.1.6. Alzheimer disease, protection against, association
6.2.8.1.3.3.1.7. Alzheimer disease, reduced risk
6.2.8.1.3.3.1.8. Alzheimer disease, reduced risk, association with
6.2.8.2. Hyperekplexia
6.2.8.3. Peripheral nervous system disease
6.2.8.3.1. Neuropathy
6.2.8.3.1.1. Peripheral neuropathy, chemotherapy-induced, protection against, association with
6.2.8.4. Sensory system disease
6.2.8.4.1. Eye disease
6.2.8.4.1.1. Refractive error
6.2.8.4.1.1.1. Myopia
6.2.8.4.1.1.1.1. High myopia, protection against, association with
6.2.8.4.1.2. Retinal disease
6.2.8.4.1.2.1. Retinal degeneration
6.2.8.4.1.2.1.1. Macular degeneration
6.2.8.4.1.2.1.1.1. Chloroquine induced maculopathy, protection against
6.2.8.4.1.2.1.1.2. Macular degeneration, age related, neovascular, reduced risk
6.2.8.4.1.2.1.1.3. Macular degeneration, age related, protection against
6.2.8.4.1.2.1.1.4. Macular degeneration, age related, reduced risk
6.2.8.4.1.2.2. Retinal detachment
6.2.8.4.1.2.2.1. Rhegmatogenous retinal detachment, reduced risk
6.2.8.4.1.3. Night blindness
6.2.8.4.1.3.1. Nyctalopia, decreased peripheral vision & history of plaquenil
6.2.8.4.1.3.2. Stationary night blindness, complete congenital
6.2.8.4.1.3.3. Stationary night blindness, congenital
6.2.9. Reproductive system disease
6.2.9.1. Female reproductive system disease
6.2.9.1.1. Endometriosis
6.2.9.1.1.1. Endometriosis, protection against, association with
6.2.9.1.2. Preterm premature rupture of membranes, protection, association
6.2.9.1.3. Recurrent spontaneous abortion, decreased risk
6.2.9.1.4. Ovarian disease
6.2.9.1.4.1. Premature ovarian failure, reduced risk
6.2.9.1.5. Uterine disease
6.2.9.1.5.1. Endometriosis and adenomyosis, decreased risk, association with
6.2.9.1.5.2. Placenta disease
6.2.9.1.5.2.1. Foetal growth restriction, lower risk, association
6.2.9.1.5.3. Polyp of corpus uteri
6.2.9.2. Infertility
6.2.9.2.1. Infertility, protection against, association with
6.2.9.3. Male reproductive system disease
6.2.9.3.1. Male infertility
6.2.9.3.1.1. Oligospermia, reduced risk, association with
6.2.10. Respiratory system disease
6.2.10.1. Lower respiratory tract disease
6.2.10.1.1. Bronchial disease
6.2.10.1.1.1. Asthma
6.2.10.1.1.1.1. Asthma, decreased risk
6.2.10.1.1.1.2. Asthma, protection against, association with
6.2.10.1.1.1.3. Asthma, aspirin-intolerant, reduced risk
6.2.10.1.1.1.4. Asthma, atopic, protection, association with
6.2.10.1.1.1.5. Asthma, decreased risk, association with
6.2.10.1.1.1.6. Asthma, protection against, association with
6.2.10.1.1.1.7. Asthma, reduced risk, association with
6.2.10.1.1.1.8. Childhood asthma, reduced risk
6.2.10.1.2. Lung disease
6.2.10.1.2.1. Acute lung injury
6.2.10.1.2.1.1. Acute lung injury, ventilator-induced, reduced risk
6.2.10.1.2.2. Respiratory failure
6.2.10.1.2.2.1. Sepsis-associated acute respiratory distress syndrome, protection from
6.2.10.2. Respiratory disease, aspirin-exacerbated, reduced risk
6.2.10.3. Upper respiratory tract disease
6.2.10.3.1. Nose disease
6.2.10.3.1.1. Rhinitis
6.2.10.3.1.1.1. Allergic rhinitis, reduced risk, association with
6.2.11. Thoracic disease
6.2.12. Urinary system disease
6.2.12.1. Bladder disease
6.2.12.2. Kidney disease
6.2.12.2.1. Nephritis
6.2.12.2.1.1. Glomerulonephritis
6.2.12.2.1.1.1. IgA nephropathy, reduced risk
6.2.12.2.1.1.2. Glomerulosclerosis
6.2.12.2.1.1.2.1. Focal segmental glomerulosclerosis, reduced risk, association with
6.2.12.2.1.2. Lupus nephritis, protection against, association
6.2.12.2.2. Nephropathy, reduced risk, association with
6.2.12.2.3. Pyelitis
6.2.12.2.3.1. Pyelonephritis
6.2.12.2.3.1.1. Acute pyelonephritis, reduced risk in adults, association with
6.3. Disease of cellular proliferation
6.3.1. Benign neoplasm
6.3.1.1. Cell type benign neoplasm
6.3.1.1.1. Fibrosis progression in hepatitis C infection, protection against
6.3.1.1.2. Hemangioma
6.3.1.1.2.1. Central nervous system hemangioma
6.3.1.1.2.1.1. Cerebral cavernous malformation, protection against
6.3.2. Cancer
6.3.2.1. Cell type cancer
6.3.2.1.1. Malignant glioma
6.3.2.1.1.1. Astrocytoma
6.3.2.1.1.1.1. Glioblastoma multiforme, survival, association with
6.3.2.1.1.2. Oligodendroglioma
6.3.2.1.1.2.1. Reduced risk oligodendroglioma development, association
6.3.2.1.2. Melanoma
6.3.2.1.2.1. Melanoma, increased overall survival, association with
6.3.2.1.2.2. Melanoma, reduced risk, association with
6.3.2.2. Organ system cancer
6.3.2.2.1. Gastrointestinal system cancer
6.3.2.2.1.1. Esophageal cancer
6.3.2.2.1.1.1. Esophageal squamous cell carcinoma
6.3.2.2.1.1.1.1. Esophageal squamous cell carcinoma, reduced risk
6.3.2.2.1.1.1.2. Esophageal squamous cell carcinoma, survival, association with
6.3.2.2.1.1.1.3. Oesophageal squamous cell carcinoma, reduced risk
6.3.2.2.1.1.1.4. Oesophageal squamous cell carcinoma, reduced risk, association with
6.3.2.2.1.1.1.5. Oesophageal squamous cell carcinoma, reduced risk, in non-smokers,
6.3.2.2.1.2. Intestinal cancer
6.3.2.2.1.2.1. Large intestine cancer
6.3.2.2.1.2.1.1. Colon cancer
6.3.2.2.1.2.1.1.1. Colon adenocarcinoma, reduced risk, association
6.3.2.2.1.2.1.2. Colorectal cancer
6.3.2.2.1.2.1.2.1. Colorectal cancer, improved survival, association with
6.3.2.2.1.2.1.2.2. Colorectal cancer, survival, association with
6.3.2.2.1.2.1.2.3. Colorectal cancer, reduced risk, association
6.3.2.2.1.2.1.2.4. Colorectal cancer, reduced risk, association with
6.3.2.2.1.2.1.2.5. Colorectal neoplasia, reduced risk, association
6.3.2.2.1.2.1.2.6. Colorectal neoplasia, reduced risk, association with
6.3.2.2.1.3. Liver cancer
6.3.2.2.1.3.1. Hepatocellular carcinoma, HBV-related, decreased risk
6.3.2.2.1.3.2. Hepatocellular carcinoma, in hepatitis B carriers, reduced risk
6.3.2.2.1.3.3. Hepatocellular carcinoma, reduced risk, association with
6.3.2.2.1.4. Oral cavity cancer
6.3.2.2.1.4.1. Oral cancer, decreased risk
6.3.2.2.1.5. Pharynx cancer
6.3.2.2.1.5.1. Nasopharyngeal carcinoma, reduced risk, association with
6.3.2.2.1.6. Stomach cancer
6.3.2.2.1.6.1. Gastric cancer
6.3.2.2.1.6.1.1. Gastric cancer, decreased risk, association with
6.3.2.2.1.6.1.2. Gastric cancer, lower risk in males
6.3.2.2.1.6.1.3. Gastric cancer, reduced risk, association with
6.3.2.2.1.6.2. Stomach carcinoma
6.3.2.2.1.6.2.1. Gastric adenocarcinoma, decreased risk
6.3.2.2.2. Head and neck cancer
6.3.2.2.2.1. Head and neck cancer, reduced risk
6.3.2.2.2.2. Head and neck cancer, second primary tumour, reduced risk, assoc
6.3.2.2.2.3. Head and neck cancer, second primary tumour, reduced risk, association
6.3.2.2.2.4. Head and neck carcinoma
6.3.2.2.2.4.1. Head and neck squamous cell carcinoma
6.3.2.2.2.4.1.1. Squamous cell carcinoma of the head and neck, reduced risk, assoc
6.3.2.2.3. Immune system cancer
6.3.2.2.3.1. Hematologic cancer
6.3.2.2.3.1.1. Bone marrow cancer
6.3.2.2.3.1.1.1. Myeloid neoplasm
6.3.2.2.3.1.1.1.1. Multiple myeloma, survival, association with
6.3.2.2.3.1.1.1.2. Reduced risk of multiple myeloma, association
6.3.2.2.3.1.2. Leukemia
6.3.2.2.3.1.2.1. Lymphoblastic leukemia
6.3.2.2.3.1.2.1.1. Acute lymphoblastic leukaemia, decreased risk
6.3.2.2.3.1.2.2. Myeloid leukemia
6.3.2.2.3.1.2.2.1. Acute myeloid leukaemia, reduced risk, association with
6.3.2.2.3.1.3. Lymphoma
6.3.2.2.3.1.3.1. Lymphoma, reduced risk, association with
6.3.2.2.3.1.3.2. Non-Hodgkin lymphoma
6.3.2.2.3.1.3.2.1. Diffuse large B-cell lymphoma, reduced risk
6.3.2.2.3.1.3.2.2. Non-Hodgkin lymphoma, reduced risk, association with
6.3.2.2.3.1.3.2.3. Non-Hodgkin lymphoma, survival, association with
6.3.2.2.4. Integumentary system cancer
6.3.2.2.4.1. Skin cancer
6.3.2.2.4.1.1. Basal cell carcinoma
6.3.2.2.4.1.1.1. Basal cell carcinoma, reduced risk
6.3.2.2.4.1.2. Cutaneous melanoma
6.3.2.2.4.1.2.1. Cutaneous melanoma, reduced risk
6.3.2.2.5. Nervous system cancer
6.3.2.2.5.1. Central nervous system cancer
6.3.2.2.5.1.1. Glioma, reduced risk, association with
6.3.2.2.5.2. Peripheral nervous system neoplasm
6.3.2.2.5.2.1. Autonomic nervous system neoplasm
6.3.2.2.5.2.1.1. Neuroblastoma
6.3.2.2.5.2.1.1.1. Neuroblastoma, protection against
6.3.2.2.6. Reproductive organ cancer
6.3.2.2.6.1. Female reproductive organ cancer
6.3.2.2.6.1.1. Cervical cancer
6.3.2.2.6.1.1.1. Cervical cancer, decreased risk, association with
6.3.2.2.6.1.1.2. Cervical carcinoma
6.3.2.2.6.1.1.2.1. Cervical carcinoma survival, association with
6.3.2.2.6.1.1.2.2. Cervical carcinoma, decreased risk
6.3.2.2.6.1.2. Ovarian cancer
6.3.2.2.6.1.2.1. Epithelial ovarian cancer, reduced risk, association
6.3.2.2.6.1.2.2. Epithelial ovarian cancer, LMP serous, reduced risk
6.3.2.2.6.1.2.3. Epithelial ovarian cancer, serous type, protection, association
6.3.2.2.6.1.2.4. Ovarian cancer, delayed progression, association with
6.3.2.2.6.1.2.5. Ovarian cancer, epithelial, reduced risk
6.3.2.2.6.1.2.6. Ovarian cancer, reduced risk, association with
6.3.2.2.6.1.3. Uterine cancer
6.3.2.2.6.1.3.1. Endometrial cancer, reduced risk, association with
6.3.2.2.6.2. Male reproductive organ cancer
6.3.2.2.6.2.1. Prostate cancer
6.3.2.2.6.2.1.1. Prostate cancer, low aggressiveness, association with
6.3.2.2.6.2.1.2. Prostate cancer, reduced risk, association with
6.3.2.2.6.2.2. Testicular cancer
6.3.2.2.7. Respiratory system cancer
6.3.2.2.7.1. Lung cancer
6.3.2.2.7.1.1. Lung cancer and COPD, decreased risk
6.3.2.2.7.1.2. Lung cancer, decreased risk, association with
6.3.2.2.7.1.3. Lung cancer, lower risk, association with
6.3.2.2.7.1.4. Lung cancer, reduced risk, association with
6.3.2.2.7.1.5. Lung cancer, reduced risk
6.3.2.2.7.1.6. Lung cancer, reduced risk in Mexican Americans, association with
6.3.2.2.7.1.7. Lung cancer, survival, association with
6.3.2.2.7.1.8. Lung carcinoma
6.3.2.2.7.1.8.1. Lung adenocarcinoma, decreased risk, association with
6.3.2.2.7.1.8.2. Lung small cell carcinoma
6.3.2.2.7.1.8.2.1. Small-cell lung cancer survivial, association with
6.3.2.2.7.1.8.3. Non-small cell lung carcinoma
6.3.2.2.7.1.8.3.1. Non-small cell lung cancer survival, association with
6.3.2.2.7.1.8.3.2. Non-small-cell lung cancer survival, association with
6.3.2.2.8. Thoracic cancer
6.3.2.2.8.1. Breast cancer
6.3.2.2.8.1.1. Breast cancer in radiographers, decreased risk
6.3.2.2.8.1.2. Breast cancer, contralateral, reduced risk, association with
6.3.2.2.8.1.3. Breast cancer, decreased risk, association with
6.3.2.2.8.1.4. Breast cancer, descreased risk, association with
6.3.2.2.8.1.5. Breast cancer, hormone receptor-negative, reduced risk
6.3.2.2.8.1.6. Breast cancer, improved prognosis, association with
6.3.2.2.8.1.7. Breast cancer, protection against, association with
6.3.2.2.8.1.8. Breast cancer, reduced risk
6.3.2.2.8.1.9. Breast cancer, reduced risk in BRCA1 carriers
6.3.2.2.8.1.10. Breast cancer, reduced risk, association with
6.3.2.2.9. Urinary system cancer
6.3.2.2.9.1. Kidney cancer
6.3.2.2.9.1.1. Renal cell carcinoma, decreased risk
6.3.2.2.9.1.2. Renal cell carcinoma, reduced risk, association with
6.3.2.2.9.2. Urinary bladder cancer
6.3.2.2.9.2.1. Bladder cancer, decreased risk, association with
6.3.2.2.9.2.2. Bladder cancer, protection against, association with
6.3.2.2.9.2.3. Bladder cancer, reduced risk , association with
6.3.3. Pre-malignant neoplasm
6.3.4. Reduced cancer risk, association with
6.4. Disease of mental health
6.4.1. Cognitive disorder
6.4.1.1. Anxiety disorder
6.4.1.1.1. Panic disorder, reduced risk, association with
6.4.1.2. Mood disorder
6.4.1.2.1. Bipolar disorder
6.4.1.2.1.1. Bipolar disorder, reduced risk
6.4.1.2.2. Mental depression
6.4.1.2.2.1. Depressive disorder, protection against, association with
6.4.1.2.2.2. Major depressive disorder, reduced risk
6.4.1.2.2.3. Major depressive disorder, reduced rsik
6.4.1.2.3. Mood disorders, reduced risk of childhood-onset, association with
6.4.1.3. Psychotic disorder
6.4.1.3.1. Schizophrenia
6.4.1.3.1.1. Schizophrenia, decreased risk
6.4.1.3.1.2. Schizophrenia, protection, association with
6.4.1.3.1.3. Schizophrenia, reduced risk, association with
6.4.1.3.1.4. Schizophrenia, ultra-resistant, association with
6.4.1.3.1.5. 
6.4.2. Developmental disorder of mental health
6.4.2.1. Pervasive development disorder
6.4.2.1.1. Autism, reduced risk, association with
6.4.2.1.2. Autism spectrum disorder, reduced risk
6.4.3. Substance-related disorder
6.4.3.1. Substance dependence
6.4.3.1.1. Nicotine dependence, reduced risk
6.4.3.1.2. Opioid dependence, protection against, in African Americans, association with
6.5. Disease of metabolism
6.5.1. Acquired metabolic disease
6.5.1.1. Amyloidosis
6.5.1.2. Carbohydrate metabolism disease
6.5.1.2.1. Glucose metabolism disease
6.5.1.2.1.1. Diabetes mellitus
6.5.1.2.1.1.1. Diabetes mellitus, protection against
6.5.1.2.1.1.2. Diabetes, protection against, association with
6.5.1.2.1.1.3. Neonatal diabetes mellitus
6.5.1.2.1.1.4. Type 1 diabetes mellitus
6.5.1.2.1.1.4.1. Diabetes, type 1, protection against, association with
6.5.1.2.1.1.4.2. Diabetes, type 1, reduced risk
6.5.1.2.1.1.5. Type 2 diabetes mellitus
6.5.1.2.1.1.5.1. Diabetes mellitus 2, reduced risk, association with
6.5.1.2.1.1.5.2. Diabetes mellitus, type 2, reduced risk
6.5.1.2.1.1.5.3. Diabetes, type 2, lower risk, association with
6.5.1.2.1.1.5.4. Diabetes, type 2, protection, association
6.5.1.2.1.1.5.5. Diabetes, type 2, reduced risk
6.5.1.2.1.1.5.6. Diabetes, type 2, reduced risk, association with
6.5.1.2.1.2. Hyperglycemia
6.5.1.2.1.2.1. Hyperglycaemia in obese patients, reduced risk, association with
6.5.1.2.1.2.2. Hyperglycaemia, reduced risk, association with
6.5.1.3. Metabolic acidosis
6.5.1.4. Mineral metabolism disease
6.5.1.5. Nutrition disease
6.5.1.5.1. Overnutrition
6.5.1.5.1.1. Abdominal obesity-metabolic syndrome
6.5.1.5.1.1.1. Metabolic syndrome, reduced risk, association with
6.5.1.5.1.2. Obesity, decreased risk, association with
6.5.1.5.1.3. Obesity, delayed onset, association with
6.5.1.5.1.4. Obesity, reduced risk
6.5.1.5.1.5. Obesity, reduced risk in women, association with
6.5.1.5.1.6. Obesity, reduced risk, association with
6.5.2. Inherited metabolic disorder
6.5.2.1. Lipid metabolism disorder
6.5.2.1.1. Hyperlipidemia
6.5.2.1.1.1. Hypertriglyceridaemia, reduced risk, association with
6.5.3. Uncategorized/multiple categories
6.5.3.1. Enhanced metabolic efficiency
6.5.3.2. Insulin resistance, protection against, association
6.5.3.3. Obesity and diabetes, reduced risk, association
6.6. Genetic disease
6.7. Physical disorder
6.7.1. Idiopathic short stature, reduced risk
6.7.2. Liver transplant, reduced risk of acute rejection
6.7.3. Orofacial cleft
6.7.3.1. Oral clefts, non-syndromic, reduced risk
6.8. Syndrome
